/Semi-annual Report for 2026

NEWS

Semi-annual Report for 2026

Shanghai Stock Exchange

2026/08/28

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Company code: 603301 Company abbreviation: Zhende Medical Zhende Medical Supplies Co., Ltd. 2026 Semi-Annual Report

1/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Important tips

The company’s board of directors, directors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

2. All directors of the company shall attend the board meeting.

3. This semi-annual report has not been audited.

The person in charge of the company, Lu Jianguo, the person in charge of accounting work, Shen Hong, and the person in charge of the accounting department (accounting officer) Ma Shuyan declare that they guarantee the authenticity, accuracy and completeness of the financial report in the semi-annual report.
The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors

The company will not distribute profits or convert capital reserves into share capital in the mid-term of 2026.

6. Risk Statement for Forward-Looking Statements

√Applicable □Not applicable

The forward-looking descriptions of future plans and development strategies involved in this report do not constitute the company's substantive commitment to investors. Investors are advised to pay attention to investment risks.

7. Whether there is any non-operating use of funds by controlling shareholders and other related parties

8. Whether there is any violation of the prescribed decision-making procedures in providing external guarantees

Whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the semi-annual report disclosed by the company

10. Major Risk Warning

The Company has described in detail the possible relevant risks in this report. For details, please refer to "V. Other Disclosure Matters (1) Possible Risks" in "Section 3 Management Discussion and Analysis" of this report.

11. Others

□Applicable √Not applicable

2/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 1 Interpretation......................................................................................................................................................4

Section 2 Company Profile and Main Financial Indicators......................................................................................................4

Section 3 Management Discussion and Analysis................................................................................................................7

Section 4 Corporate Governance, Environment and Society......................................................................................................31

Section 5 Important Matters......................................................................................................................................33

Section 6 Changes in Shares and Status of Shareholders................................................................................................45

Section 7 Bond-related situations......................................................................................................................49

Section 8 Financial Report......................................................................................................................................50

The original 2026 semi-annual report signed and stamped by the chairman of the board.

Financial statements signed and stamped by the person in charge of the company, the person in charge of accounting work, and the person in charge of the accounting department (the person in charge of accounting documents for reference).

The original copies of all company documents and announcements publicly disclosed on the website designated by the China Securities Regulatory Commission during the reporting period.

3/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 1 Interpretation

In this report, unless the context otherwise requires, the following words have the following meanings:

Commonly used word definitions

The Company, the Company, Zhende Medical, and the issuer refer to Zhende Medical Products Co., Ltd. Reporting period refers to January 1 to June 30, 2026 China Securities Regulatory Commission refers to China Securities Regulatory Commission

Exchange refers to Shanghai Stock Exchange

Zhejiang Zhende refers to Zhejiang Zhende Holdings Co., Ltd.

Ningbo Shengyurui refers to Ningbo Shengyurui Medical Equipment Co., Ltd.

Section 2 Company Profile and Main Financial Indicators

1. Company information

The Chinese name of the company: Zhende Medical Products Co., Ltd.

The company’s Chinese abbreviation: Zhende Medical

The company's foreign name ZHENDEMEDICALCO.,LTD. The company's foreign name abbreviation ZHENDEMEDICAL

The legal representative of the company Lu Jianguo

2. Contact person and contact information

Secretary of the Board of Directors Name of Securities Affairs Representative Ji Baohai Yu Ping

Contact address: Gaobu Street, Yuecheng District, Shaoxing City, Zhejiang Province Gaobu Street, Yuecheng District, Shaoxing City, Zhejiang Province

No. 55, Xiangji Road No. 55, Xiangji Road Tel: 0575-88751963 0575-88751963 Fax: 0575-88751963 0575-88751963 Email: [email protected] [email protected]

3. Introduction to changes in basic situation

The company's registered address is No. 55, Xiangji Road, Gaobu Street, Yuecheng District, Shaoxing City, Zhejiang Province. Historical changes in the company's registered address. On January 6, 2026, the company's registered address was changed from "Gaobei Industrial Zone, Gaobu Town, Yuecheng District, Shaoxing City, Zhejiang Province" to "55 Xiangji Road, Gaobu Street, Yuecheng District, Shaoxing City, Zhejiang Province".

No."

Company office address No. 55, Xiangji Road, Gaobu Street, Yuecheng District, Shaoxing City, Zhejiang Province Postal code of the company office address 312035

Company website www.zhende.com

Email [email protected]

Query index for changes during the reporting period. For details, please refer to the "Zhende Zhende" disclosed by the company on the Shanghai Stock Exchange website www.sse.com.cn

Medical Announcement on Completion of Industrial and Commercial Change Registration (Announcement Number: 2026-003)

4. Brief introduction to changes in information disclosure and storage location

The names of the newspapers selected by the company for information disclosure: "China Securities Journal", "Shanghai Securities News", "Securities Daily", "Securities Times"

4/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

The website address for publishing the semi-annual report is www.sse.com.cn

The company's semi-annual report is prepared at the company's board of directors office

Query index for changes during the reporting period No changes during the reporting period

5. Brief introduction of company stocks

Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change

A shares Shanghai Stock Exchange Zhende Medical 603301 —

6. Other relevant information

□Applicable √Not applicable

7. The company’s main accounting data and financial indicators

(1) Main accounting data

Unit: Yuan Currency: RMB This reporting period Main accounting data for this reporting period compared with the same period last year

(January to June) Increase/decrease in the same period (%) Operating income 2,224,060,634.54 2,100,197,326.31 5.90Total profit 172,697,912.07 157,058,931.15 9.96Net profit attributable to shareholders of listed companies 143,778,780.32 127,764,203.45 12.53 Net profit attributable to shareholders of listed companies after deducting non-recurring 119,050,538.29 117,983,456.29 0.90 Profit and loss

Net cash flow generated from operating activities 44,897,555.43 160,708,480.57 -72.06 The end of this reporting period compared to the end of this reporting period The end of the previous year

Year-end increase or decrease (%) Net assets attributable to shareholders of listed companies 5,676,320,067.27 5,686,734,447.20 -0.18 Total assets 8,341,544,024.99 8,400,887,772.66 -0.71

(2) Main financial indicators

Main financial indicators of this reporting period This reporting period compared with the same period of the previous year

(January to June) Increase/decrease in the same period (%) Basic earnings per share (yuan/share) 0.54 0.48 12.50 Diluted earnings per share (yuan/share) 0.54 0.48 12.50Basic earnings per share after deducting non-recurring gains and losses 0.45 0.44 2.27 earnings (yuan/share)

Weighted average return on assets (%) 2.51 2.24 Increased by 0.27 percentage points Weighted average net return on assets after deducting non-recurring gains and losses 2.08 2.07 Increased by 0.01 percentage points (%)

Description of the company’s main accounting data and financial indicators

√Applicable □Not applicable

The net cash flow generated from operating activities during the reporting period decreased compared with the same period last year, mainly due to the increase in cash paid for purchasing raw materials for storage during the reporting period.

8. Differences in accounting data under domestic and foreign accounting standards

□Applicable √Not applicable

5/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

9. Non-recurring profit and loss items and amounts

√Applicable □Not applicable

Unit: Yuan Currency: RMB Notes (such as the amount of non-recurring profit and loss items

Applicable) Profit and loss from the disposal of non-current assets, including the write-off part of the asset impairment provision 6,477,666.99 Government subsidies included in the current profit and loss, but are closely related to the company's normal operating business and consistent with the company's normal operating business

Except for government subsidies that comply with national policies and regulations, are enjoyed according to determined standards, and have a continuous impact on the company’s profits and losses 4,085,969.96

In addition to effective hedging business related to the company's normal business operations, non-financial enterprises

Gains and losses from changes in fair value arising from holding financial assets and financial liabilities and gains and losses arising from disposal of financial assets and financial liabilities 18,058,940.86

Fund occupation fees charged to non-financial enterprises included in current profits and losses 1,396,226.42 Gains and losses from entrusting others to invest or manage assets

Profit and loss from external entrusted loans

Loss of various assets due to force majeure factors, such as natural disasters

Reversal of impairment provision for accounts receivable that has been individually tested for impairment

The investment cost for an enterprise to acquire subsidiaries, associates and joint ventures is less than the investment cost

shall enjoy the income generated from the fair value of the identifiable net assets of the investee

Net profit and loss for the current period from the beginning of the period to the date of merger of subsidiaries resulting from business combinations under common control

Gains and losses on non-monetary asset exchanges

Debt restructuring gains and losses

One-time expenses incurred by the enterprise due to the discontinuation of relevant business activities, such as placement of employees

expenses, etc.

One-time impact on current profits and losses due to adjustments to tax, accounting and other laws and regulations

One-time confirmation of share-based payment expenses due to cancellation or modification of equity incentive plan

For cash-settled share-based payment, after the vesting date, the amount of employee compensation payable shall be

Gains and losses arising from changes in fair value

Changes in the fair value of investment properties using the fair value model for subsequent measurement

profit and loss

Gains from transactions where the transaction price appears to be unfair

Profit and loss arising from contingencies unrelated to the company's normal business operations

Custody fee income from entrusted operations

Other non-operating income and expenses other than the above items -2,499,482.66 Other profit and loss items that meet the definition of non-recurring gains and losses

Less: Impact on income tax 2,781,372.29 Impact on minority shareholders’ equity (after tax) 9,707.25

Total 24,728,242.03

If a company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable

Companies with equity incentives and employee stock ownership plans may choose to disclose net profits after deducting the impact of share-based payments □ Applicable √ Not applicable

11. Others

□Applicable √Not applicable

6/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 3 Management Discussion and Analysis

1. Description of the company’s industry and main business during the reporting period

(1) The main business and main products of the company during the reporting period

Zhende Medical was established in 1994. It is an enterprise integrating R&D, production and sales for the coordinated development of the medical and health industry.

In the medical field, the company's main product lines include ostomy and modern wound care products, surgical infection control products, infection control protection products, basic care products, pressure treatment and fixation products, and respiratory anesthesia consumables. After years of accumulation, the company has become one of the domestic manufacturers of medical dressings and infection control protection products with a relatively complete product range and leading scale. After years of development, the company has built a marketing network covering major markets around the world. In the international market, the company has established an efficient business cooperation system with many well-known foreign medical device brands. The company has gained recognition from overseas customers with its high-quality products and excellent services; the company's products cover more than 70 countries and regions in Europe, North America, Asia, South America, Africa and Oceania. In the domestic market, the company sells its products under its own brand. The product sales terminals are mainly hospitals and patients. It has covered nearly 9,400 hospitals in various provinces, municipalities and autonomous regions across the country, including more than 1,300 tertiary hospitals and 99% of the top 100 hospitals, forming a stable market system.

In the field of health, the company advocates the brand proposition of "making healthy life within reach" and focuses on medical-grade personal care and home health care products. Its main product lines cover health protection, wound care, home cleaning, adult care, protective gear, physiotherapy patches, personal beauty care, mouth and nose care and other products, which are sold through offline chain pharmacies, supermarkets and convenience stores and online channels. The company has established a good reputation among consumers by virtue of Zhende's professional clinical academic background and excellent product design and quality. In terms of offline retail lines, the company's products have reached 99% coverage among the top 100 chain drugstores in the country, covering a total of more than 210,000 drugstore stores across the country. In terms of online retail, the company has opened a total of 17 stores on e-commerce platforms such as Tmall, JD.com, and Pinduoduo. As of the end of the reporting period, the company had approximately 9.8 million members worldwide.

In recent years, the company has won honors such as the Gold Medal of the Western Conference, China's Medical Health Growth List - Top 100 Listed Medical Devices, EcoVadis Rating Gold Certification, and China's Procurement Innovation Practice Pioneer in 2025.

The company's main products and their uses are as follows:

Products in the medical field:

Medical field products Main uses Specific products Main product pictures

Domain Product Category

2. Discussion and analysis of operating conditions

In the first half of 2026, the international situation remains complex and changeable, global economic growth generally slows down, and risks of uncertainty in the overall external environment continue to exist. The domestic economic operation is generally stable and steadily accelerating towards new and better conditions. The global medical device industry has maintained steady growth in recent years with the aging of the population, the expansion of chronic disease groups and the continued release of health needs. During the reporting period, the company anchored its development strategy and business goals, continued to adhere to the two-wheel drive of the international and domestic markets, solidly promoted various business management tasks, and successfully completed the goals set at the beginning of the year.

During the reporting period, the company achieved operating income of 2.224 billion yuan, an increase of 5.90% over the same period last year; net profit attributable to shareholders of listed companies was 144 million yuan, an increase of 12.53% over the same period last year; net profit attributable to shareholders of listed companies excluding non-recurring gains and losses was 119 million yuan, an increase of 0.90% over the same period last year.

The company’s operating income by product sales during the reporting period is as follows:

Unit: 10,000 yuan First half of 2026 Second quarter of 2026

The first half of 2026 is the same as the previous year. First in 2026. Second in 2026. Compared with the first product in 2026.

Annual income period-to-period increase and decrease ratio Quarterly income Quarterly income Quarter-on-quarter increase and decrease

(%) Proportion (%) Basic care 44,431.03 3.41 19,362.46 25,068.57 29.47 Surgical infection control 99,388.87 9.95 43,874.50 55,514.38 26.53 Pressure treatment and fixation 24,482.37 8.41 11,448.91 13,033.46 13.84

16/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Ostomy and modern wound care 35,962.43 -7.88 14,617.84 21,344.60 46.02 Infection control and protection 15,955.66 15.44 9,496.49 6,459.17 -31.98Others 2,185.70 80.47 1,241.22 944.48 -23.91 Total 222,406.06 5.90 100,041.42 122,364.65 22.31 During the reporting period, the company focused on the following work:

(1) Market development

Domestic market

(1) Domestic cinema market:

During the reporting period, the company's domestic theater chains continued to promote organizational transformation, focusing on product strategies to open up the entire chain from cost, access to services, deepening "value co-creation" channel partner partnerships, and continuously improving market coverage. The overall domestic theater chain business achieved rapid growth. The first is to promote the organizational transformation with "clinical scenarios" as the core. Each product line will fully open up the entire chain from cost, access to service through professional operations, effectively improving team efficiency. In the surgical sensory control and respiratory anesthesia product lines, we continue to optimize the product portfolio and upgrade our comprehensive solution capabilities in terms of safety and efficiency; in the basic care and rest therapy product lines, we help hospitals achieve standardized management and cost optimization of nursing consumables through product integration and economic value demonstration; in the pressure and wound ostomy product lines, we focus on the full-course management of patients and build full-course service capabilities covering hospitalization, discharge rehabilitation, and home care. The second is to implement a differentiated product strategy, promote the coordinated development of each product line, continue to deepen the market penetration of core products, expand the coverage of centralized purchasing products, improve the clinical evidence system, promote the full life cycle management of chronic diseases, and achieve cost reduction and efficiency increase through product portfolio, and overall promote the high-quality development of each product line. The third is to upgrade the channel collaboration model, deepen the cooperative relationship with channel partners, promote the shift from "traditional transaction-based cooperation" to "value co-creation strategic collaboration", unite high-quality channels to deepen the hospital scene, and build an embedded exclusive service system. It not only serves as a high-quality supplier to the hospital, but also strives to become a strategic collaboration partner for the hospital's "cost control" and "efficiency improvement" to achieve improved cooperation effectiveness.

As of the end of the reporting period, the company's products had covered nearly 9,400 hospitals in various provinces, municipalities and autonomous regions across the country, including more than 1,300 top tertiary hospitals and 99% of the top 100 hospitals.

(2) Domestic retail market

During the reporting period, the company anchored the professional brand positioning of "30 years of medical use, choose Zhende for nursing", firmly promoted the "721" product strategy, improved the global channel layout around the two strategic items of protective gear and varicose vein socks, continued to build three-dimensional competition barriers of "professional products + precision marketing + technological empowerment", and achieved steady development in various businesses in the domestic retail market.

In terms of channel operations, the company has promoted the integration of model store construction and O2O ecology in an orderly manner, and implemented innovative marketing projects such as Douyin Challenge, store experience activities, and chain in-store purchases, which have achieved good results. The company simultaneously carries out special product training for national chains to strengthen terminal professional promotion capabilities.

In terms of brand digital construction, we use AI to empower social communication, rely on neighborhood market live broadcasts to build a word-of-mouth communication matrix, and continue to output content related to product science popularization, festival promotion, and channel activities; we implement a standardized model display incentive mechanism to effectively improve the terminal brand display effect and terminal brand visibility. At the same time, the company continues to empower its teams through expert presentations, systematic business training and other measures to build a solid foundation for business development.

During the reporting period, the company achieved domestic main business income of 856 million yuan, an increase of 7.55% over the same period last year. Among them, the company achieved hospital line income in the domestic market of 598 million yuan, an increase of 12.23% over the same period last year; the company achieved online and offline retail line business income of 218 million yuan, an increase of 1.93% over the same period last year; the others are the company's direct sales business.

International market

During the reporting period, in the face of external factors such as the complex and ever-changing international situation, trade environment, and exchange rate fluctuations, the company's overseas business closely adhered to the goals of improving quality and efficiency, product optimization, and releasing production capacity set at the beginning of the year, and took multiple measures to cope with external uncertainties and achieve stable operation of overseas business.

First, in terms of supply chain, the company accelerated the release of production capacity in overseas production bases and continued to improve the efficiency of global operations. We will continue to promote the lean operation of the African production base and optimize the production technology and process. The per capita output of the factory, product quality control capabilities and operating results have all been significantly improved; we will accelerate the construction progress of the Mexican production base. After completion and commissioning, we will rely on localized delivery to reduce the risk of rising shipping costs and delivery delays, and enhance market competitiveness in the Americas; through the advantages of globalized industrial chain layout, we will deepen long-term strategic cooperation with international core major customers and cooperation stickiness with local customers, and lay a solid foundation for international business development. Second, in terms of market operations, the company continues to deeply explore the core markets of Europe and the United States, and accelerates penetration and coverage of emerging markets. In the European and American markets, the company continues to deeply cultivate core customers, optimize services from dimensions such as delivery, cost, and quality, and adapt to the upgrade needs of overseas operating rooms, optimize product structure, and improve profitability; in emerging markets, the company focuses on Southeast Asia, the Middle East, South America, and Africa and other markets to quickly conduct network layout, combining the advantages of a cost-effective product portfolio and a more flexible industrial chain layout to achieve rapid breakthroughs. The third is to persist in product innovation and iteration and continuously improve the product matrix.

17/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

In the field of surgical infection control, we closely follow the industry trend of popularization of minimally invasive surgery and robotic surgery, accelerate the research and development and registration of supporting infection control products, expand the series of infection control products, and officially launch a one-stop infection control overall procurement plan for operating rooms to better meet the procurement needs of overseas customers and consolidate and enhance the company's industry position; In the field of modern wound care, the company continues to improve market insight and research and judgment capabilities, increase investment in research and development, and further expand the product matrix of functional dressings and new wound care materials. At the same time, it firmly implements the operation strategy of "refined layout, deep penetration, strong products, and excellent services" to enhance the stickiness of cooperation with customers. At the same time, the company continues to practice the sustainable development business philosophy, continuously improves the ESG operation system, and relies on the Ecovadis gold certification endorsement to effectively enhance the company's industry influence and gain more customer resources and market opportunities.

During the reporting period, the company achieved overseas main business income of 1.346 billion yuan, an increase of 4.18% over the same period last year. The company's overseas business has steadily improved.

(2) Research and innovation

During the reporting period, the company focused on core technology areas and continued to increase investment in technological innovation to continuously improve its R&D innovation capabilities. Build a professional evaluation experimental platform for functional dressings to provide strong support for performance verification and effect evaluation in the development process of functional dressings; give full play to the innovative leadership of high-level talents, and arrange a number of key technology research topics around core directions such as wound antimicrobial technology, low-toxic physical antibacterial technology, wound microenvironment adjustment, wound exudate management, sensory control material technology, and adhesive technology; start planning experiments The database is established, and the model of AI-assisted experimental design based on the database is explored to continuously improve the digital level of the R&D system; research cooperation with universities is strengthened, and a comprehensive cooperation framework agreement is signed with Shaoxing University. The university's scientific research team, animal experiment platform and advanced testing equipment resources are used to carry out joint basic research, focusing on technical research on wound microenvironment regulation, low-toxicity and high-efficiency antibacterial materials, etc.

During the reporting period, the company obtained 5 new Class II medical device registration certificates and 1 invention patent. As of the end of this reporting period, the company had 128 invention patents, 165 national Class II medical device registration certificates and 12 Class III medical device registration certificates.

(3) Organization and talent building

During the reporting period, the company's organization and talent development closely followed its strategic positioning, and continued to promote the construction of a "talent supply chain based on business efficiency" system.

In terms of talent introduction, focusing on the global talent layout and core echelon construction, we will optimize and upgrade the "New Talent Plan", expand school recruitment channels to reserve young talents, match the overseas business layout to absorb international and local talents, and continue to optimize the global talent structure.

In terms of talent training, we will further promote the "Navigation" series of talent projects, use combat training to accelerate the ability transition of reserve talents, build a core talent management indicator system, use data to drive the digital construction of manpower, and continue to improve the "New Talent" training system for college students to smooth the development channels for young talents.

In terms of performance-based compensation, we promote the optimization of the organizational performance appraisal mechanism, improve the "strategic decoding-organizational performance-individual performance" full-chain management system, and add new performance empowerment measures to enhance organizational synergy and ensure performance implementation through process coaching, capability cultivation, cross-department collaboration, etc.

In terms of human resources informatization, we promote system upgrades and data interoperability of core modules such as recruitment, training, performance, and compensation, optimize employee shared service platforms and HR data integration cockpits, and use AI to empower talent portraits and data analysis to achieve full-process online collaboration in human resources business. We use data to support talent decision-making and organizational operations, and continuously build a solid foundation for talent competition.

(4) Digital construction

During the reporting period, the company's digital construction accelerated the transformation from "basic services" to "empowering business" and steadily advanced around the three main lines of system construction, technological innovation and talent management.

Many progresses have been made in system construction. The TMS was put into trial operation online, relying on intelligent order dispatch to help reduce logistics costs and increase efficiency; the CRM was continuously optimized to realize automatic analysis of customer information and improve the level of customer file management; the MES project was further promoted to achieve paperless production records, real-time and accurate transmission of information, and build a "one object, one code" full-process traceability system; with the help of large visual screens, online reporting of workshop output and abnormal situations, production transparency and problem response speed were improved. PDM completes the import of factory and sales view data and associated processing of frozen material drawings, optimizes the ECA function and promotes trial operation, connects OA and PDM engineering change process foolproof control, and strengthens data specification and change management capabilities.

The application of technology has achieved remarkable results. The implementation of AI and RPA has become a focus. The process digitalization team has set up a special AI promotion team to complete the localization deployment of the Alibaba Qianwen large model intranet. The scale of access to the "Dege" agent continues to increase, and significant progress has been made in scenarios such as intelligent quotation and knowledge base construction. VibeCoding tools have been introduced on the R&D side to effectively improve development efficiency.

Talent and process management continue to improve. The green belt and black belt systems have been optimized and upgraded, and the process framework has been officially finalized, providing solid support for subsequent management efficiency improvements.

(5) Lean manufacturing

18/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

During the reporting period, the company continued to improve the multi-level lean improvement matrix, coordinate and promote proposal improvement, micro-improvement, cross-domain collaboration and breakthrough improvement work, and completed a total of 9,441 proposal improvements, 457 micro-improvement projects, and 225 cross-domain breakthrough improvements, effectively achieving cost reduction and optimization of the manufacturing system. At the same time, special efforts were carried out to address pain points in the operation of production line equipment, and a total of 240 items were implemented to prevent mistakes and eliminate faults. The equipment failure rate dropped significantly year-on-year, and the mean time between failures was effectively improved, further laying the foundation for stable production operations. The company continues to build a lean management and equipment skills talent echelon, completing 393 people's lean knowledge ratings and 118 people's equipment skills ratings, consolidating the professional capabilities of front-line talents. The company continues to deepen the digital management of the entire life cycle of equipment, optimizes equipment performance management and control indicators, and ensures long-term and stable operation of the manufacturing system. At the same time, we are facing the transformation direction of intelligent manufacturing, actively exploring the application of artificial intelligence, and creating an interconnected production system with deep collaboration between artificial intelligence, industrial robots and digital execution systems.

(6) Brand building

During the reporting period, the company adhered to the core direction of "professional focus", steadily promoted the construction of the brand system, and achieved phased results in the two dimensions of professional leadership and consumer market. At the professional leadership level, the company's cooperation with Mölnlycke Health Care AB, the world's leading advanced wound care solution company (see "(7) BD Business Development" for details), will help further consolidate the company's professional clinical brand position in the field of advanced wound care; at the same time, it actively participates in various academic exchanges and international exhibitions, displays systematic clinical solutions in an all-round way, and continues to promote brand professionalization and international upgrading. At the consumer market level, the company continues to deepen cooperation with mainstream platforms, and continues to output brand value and product advantages and convey brand warmth through diversified new media forms such as professional popular science short videos and expert content planting. At the same time, relying on the exclusive naming of Zhejiang Men's Volleyball Sports IP, it empowers the brand with a positive sports spirit, promotes brand rejuvenation and scene-based upgrades, and effectively enhances brand awareness and penetration in the end market.

(7) BD business development

During the reporting period, the company signed a cooperation agreement with Mölnlycke Health Care AB (hereinafter referred to as "Mölnlycke"), the world's leading advanced wound care solutions company. The agreement stipulates that the two parties will establish a joint venture in Shanghai to accelerate the business layout of advanced wound care products in China. The joint venture after establishment will be controlled by Monique, integrating the domestic sales and business networks of both parties' advanced wound care products, focusing on the domestic marketing and promotion of both parties' advanced wound care products, providing more advanced treatment options for medical staff, patients and consumers, and improving the level of treatment and nursing services. This cooperation will give full play to the complementary advantages of both parties in terms of product portfolio, channel coverage and clinical expertise, and promote the business development of advanced wound care products in China.

Major changes in the company's operating conditions during the reporting period, as well as events that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future

□Applicable √Not applicable

3. Analysis of core competitiveness during the reporting period

√Applicable □Not applicable

(1) R&D advantages

The company has always adhered to the R&D concept of "from the market, to the market" and implemented the R&D strategy of "independent and in-depth R&D, extensive and in-depth cooperation, and possession of core technologies". It has provincial key enterprise research institutes and independent research teams, and has established postdoctoral mobile workstations with universities. It also carries out horizontal R&D cooperation with well-known domestic universities such as Zhejiang University, Hubei University, Shaoxing University, and medical institutions such as Beijing Hospital of Traditional Chinese Medicine, providing strong technical and clinical support for the company's R&D and innovation. At the same time, in the process of long-term in-depth cooperation with well-known foreign brands, the company has gradually developed an international perspective and can more accurately grasp the cutting-edge information of industry and technological development. The company has won a number of technology awards including provincial key enterprise research institute, provincial engineering technology research center, provincial high-tech enterprise research center, provincial enterprise technology center, provincial innovative pilot enterprise, and provincial patent demonstration enterprise, and has passed the national high-tech enterprise review.

During the reporting period, the company added 5 new Class II medical device product registration certificates and 1 invention patent. As of the end of this reporting period, the company had 128 invention patents, 165 national Class II medical device registration certificates and 12 Class III medical device registration certificates. The research and development of new products, new technologies and new processes expands the company's product line and technical reserves, helps build product differentiation, forms technical and competitive barriers, and better meets the needs of patients and consumers.

(2) Quality advantage

The company has always attached great importance to product quality management, and has continuously strengthened employee professional ethics education and quality awareness cultivation. In accordance with the requirements of international standards, it has formed a strict quality management system covering the entire process from research and development to after-sales, and continues to improve the system to ensure product quality is the cornerstone of the company's sustainable development. The company established a quality management system early in the industry and passed ISO13485 medical device quality management system certification, passed on-site inspections by the US FDA, and passed multiple quality system inspections organized and implemented by national and local drug regulatory authorities. During the reporting period, the company continued to strengthen the construction of quality management system, and through lean manufacturing by all employees,

19/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Continuously optimize the production process, improve automation level and equipment management capabilities, continue to promote the construction of lean production management system, continuously improve the quality management system, ensure product quality, enhance the company's market competitiveness, and lay a solid foundation for the company to continuously and rapidly expand domestic and overseas markets.

(3) Product category advantages

The company has been deeply involved in the medical and health field products for many years. At present, the company's medical field has covered products in many fields such as ostomy and modern wound care, surgical infection control products, infection control protection products, basic wound care products, pressure treatment and fixation products, respiratory anesthesia consumables, etc. The health field has covered It covers health protection, wound care, household cleaning, adult care, protective gear, physiotherapy patches, personal beauty care, mouth and nose care and other products, covering a wide range of categories. It continues to carry out product innovation iterations and horizontal and vertical expansion, forming a leading competitive product line portfolio in the segmented industries. For the company, a complete range of categories can bring about economies of scale and reduce the cost of selling single products. Moreover, the company can rely on a complete and competitive product range to meet the one-stop purchasing needs of customers and consumers, improve procurement and purchase efficiency, enhance the company's satisfaction among customers and consumers, and form a better competitive advantage in the fierce market competition.

(4) Customer and channel advantages

After years of business development, the company has accumulated rich customer and consumer resources at home and abroad. In the international market, the company has established good long-term strategic cooperative relationships with many well-known foreign medical device brands, including Lohmann & Rauscher, Cardinal Healthcare, Medline, Hartmann, Mckesson, Molnlycke, and Onemed. The company's products cover Europe, North America, South America, Asia, Africa, Oceania and other continents. In the domestic hospital line market, the company's products have covered nearly 9,400 hospitals in various provinces, municipalities and autonomous regions across the country, including more than 1,300 top tertiary hospitals and 99% of the top 100 hospitals, forming a stable market system; in the domestic offline retail line, the company's products have been sold nationwide The coverage rate of the top 100 chain drugstores has reached 99%, covering a total of more than 210,000 drugstore stores across the country; on the online retail line, the company has opened a total of 17 direct e-commerce stores on e-commerce platforms such as Taobao, JD.com, Pinduoduo, Douyin, Kuaishou, 1688 and Amazon. At the same time, through online and offline interactions, the user experience and purchase accessibility of customers and consumers are continuously improved.

(5) Brand advantages

With its excellent product quality, design and service, the company has been widely recognized by customers and consumers, and has formed good brand influence and popularity. In the retail line, Zhende Health has built the brand image of "professionalism and caring" through self-media and multiple offline and online platforms, deepening the communication of "30 years of medical use, choosing Zhende for nursing" to enhance consumer brand awareness; in the hospital line, the company deeply cultivates professionalism, adheres to academic leadership, and actively participates in various Through various academic activities and medical device exhibitions, we conduct brand promotion for the professional market, continue to build the brand image of Zhende Medical as "craftsmanship, warmth and responsibility", constantly consolidate its leading brand position in the fields of surgical infection control and pressure therapy, and continue to increase investment in brand promotion in the fields of stoma wounds and respiratory anesthesia.

(6) Supply chain advantages

After more than 30 years of dedicated operation and continuous innovation, the company has formed a global and full-industry chain supply chain advantage covering the raw material end, manufacturing end, and product delivery end. The company continues to deepen lean manufacturing, promote the construction of automated information-based smart factories, promote the digital transformation of business processes, optimize the business strategic structure, continue to optimize the entire process of production, supply and marketing, continuously improve the efficiency of the supply chain, and achieve the trinity of production, supply and sales to quickly respond to customer needs. The global industrial chain layout can better meet the diversified supply chain needs of international customers and enhance the company's market competitiveness. At the same time, as the company's business scale continues to grow, the company's production scale is at the leading level in the industry. The leading production scale has brought significant scale advantages to the company, further improving the company's ability to reduce costs and improve quality.

4. Main operating conditions during the reporting period

(1) Main business analysis

Analysis table of changes in relevant accounts of financial statements

Unit: Yuan Currency: RMB account Number for the current period Number for the same period last year Change ratio (%) Operating income 2,224,060,634.54 2,100,197,326.31 5.90 Operating costs 1,454,743,382.89 1,382,130,817.97 5.25 Sales expenses 185,477,351.18 178,392,032.41 3.97 Administrative expenses 304,963,031.93 287,009,742.65 6.26 Financial expenses 30,316,185.87 14,542,347.65 108.47 Research and development expenses 64,888,620.92 63,735,842.41 1.81

20/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Net cash flow from operating activities 44,897,555.43 160,708,480.57 -72.06 Net cash flow from investing activities -24,020,496.85 -573,919,044.79 - Net cash flow from financing activities -134,336,276.27 676,379,344.34 -119.86 Investment income 22,946,175.57 1,631,335.23 1,306.59 Income from changes in fair value 10,690,009.70 4,795,660.88 122.91 Asset impairment losses -21,588,938.29 -11,447,368.00 -Income from asset disposal -8,313,935.18 340,181.43 -2,543.97 Profit and loss of minority shareholders 7,271,971.21 2,889,473.05 151.67

Explanation of reasons for changes in operating income: Not applicable

Explanation of reasons for changes in operating costs: Not applicable

Explanation of reasons for changes in sales expenses: Not applicable

Explanation of reasons for changes in administrative expenses: Not applicable

Explanation of reasons for changes in financial expenses: It was due to the increase in exchange losses caused by fluctuations in foreign currency exchange rates during the reporting period.

Explanation of reasons for changes in R&D expenses: Not applicable

Explanation of reasons for changes in net cash flow generated from operating activities: due to the increase in cash paid for purchasing raw materials for inventory during the reporting period. Explanation of the reasons for changes in net cash flow generated from investing activities: The amount of cash management products purchased and the amount paid for fixed assets during the reporting period decreased compared with the same period last year, and the redemption amount received for cash management products increased compared with the same period last year. Explanation of reasons for changes in net cash flow generated from financing activities: due to the decrease in the amount of new bank borrowings received during the reporting period. Explanation of reasons for changes in investment income: During the reporting period, it was due to the combined impact of the recognition of income from the disposal of the equity of Baoma Medical Technology (Wuxi) Co., Ltd. held by the company and the increase in income from the disposal of commodity futures contracts.

Explanation on the reasons for the change in income from changes in fair value: The increase in income from changes in fair value of commodity futures contracts recognized during the reporting period. Explanation of reasons for changes in asset impairment losses: due to the increase in inventory depreciation losses accrued during the reporting period.

Explanation of reasons for changes in asset disposal income: due to losses from equipment disposal during the reporting period.

Explanation of reasons for changes in minority shareholders' profits and losses: This is due to the increase in net profit of non-wholly-owned subsidiaries during the reporting period compared with the same period last year.

Detailed description of major changes in the company’s business type, profit composition or profit sources during this period

□Applicable √Not applicable

(2) Explanation of significant changes in profits caused by non-main business

□Applicable √Not applicable

(3) Analysis of assets and liabilities

√Applicable □Not applicable

Assets and liabilities status

Unit: Yuan Currency: RMB Current Period

Current period Previous year period

The final amount is the final amount of the feeling. The final amount is the final amount.

Compared with the previous year, project name. Closing amount of the current period. Total assets. Closing amount of the previous year. Total assets.

The proportion of the change at the end of the period

Dynamic ratio (%) (%)

(%)

Monetary funds 693,990,042.23 8.32 825,308,081.42 9.82 -15.91Accounts receivable 765,525,742.66 9.18 703,054,733.84 8.37 8.89Inventory 898,504,640.45 10.77 754,130,482.20 8.98 19.14 Contract assets - - - - -Investment real estate - - - - -Long-term equity investment 117,676,001.90 1.41 118,455,594.32 1.41 -0.66

21/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Fixed assets 3,090,329,389.35 37.05 3,007,931,714.46 35.80 2.74 Construction in progress 338,964,255.07 4.06 468,589,159.87 5.58 -27.66Right-of-use assets 53,073,731.45 0.64 29,790,569.34 0.35 78.16 Short-term borrowings 906,451,862.12 10.87 767,002,817.30 9.13 18.18 Contract liabilities 28,823,533.49 0.35 21,597,685.23 0.26 33.46 Long-term borrowings 381,833,847.77 4.58 383,096,181.74 4.56 -0.33 Lease liabilities 30,460,385.77 0.37 8,796,917.26 0.10 246.26 Other non-current funds

16,252,163.09 0.19 71,927,026.58 0.86 -77.40Financial assets

Notes payable 10,381,930.51 0.12 16,450,317.87 0.20 -36.89 Due within one year

9,483,135.28 0.11 105,540,294.68 1.26 -91.01Non-current liabilities

Other current liabilities 14,123,270.15 0.17 26,603,512.85 0.32 -46.91Treasury shares - 0.00 46,543,090.89 0.55 -100.00Other comprehensive income -49,496,552.09 -0.59 -3,141,814.03 -0.04 -Other notes

Explanation of reasons for changes in currency funds: Not applicable
Explanation of reasons for changes in accounts receivable: Not applicable
Explanation of reasons for inventory changes: Not applicable
Explanation of reasons for changes in contract assets: Not applicable
Explanation of reasons for changes in investment real estate: Not applicable
Explanation of reasons for changes in long-term equity investment: Not applicable
Explanation of reasons for changes in fixed assets: Not applicable
Explanation of reasons for changes in projects under construction: Not applicable
Explanation of reasons for changes in right-of-use assets: This is due to the increase in leased assets recognized as right-of-use assets during the reporting period.
Explanation of reasons for changes in short-term borrowings: Not applicable
Explanation of reasons for changes in contract liabilities: Due to the increase in advance payments from customers during the reporting period.
Explanation of reasons for changes in long-term borrowings: Not applicable
Explanation of reasons for changes in lease liabilities: This is due to the increase in leased assets recognized as right-of-use assets during the reporting period.
Explanation of reasons for changes in other non-current financial assets: During the reporting period, it was due to the disposal of the company’s equity in Baoma Medical Technology (Wuxi) Co., Ltd. and the recovery of part of the investment funds from Shanghai Hongsheng Yide Private Investment Fund Partnership (Limited Partnership).
Explanation of reasons for changes in notes payable: due to the decrease in material purchase funds used for settlement of bank acceptance notes at the end of the reporting period.
Reasons for changes in non-current liabilities due within one year: This is due to the repayment of long-term borrowings due within one year during the reporting period.
Explanation of reasons for changes in other current liabilities: During the reporting period, the company disposed of the equity held by Baoma Medical Technology (Wuxi) Co., Ltd. to offset part of the equity transfer payment received in advance last year and the combined impact of part of the asset disposal payment received in advance in this period.
Explanation of reasons for changes in treasury shares: During the reporting period, it was confirmed that the second phase of the employee stock ownership plan had not unlocked some relevant repurchase obligations and canceled the repurchased unused shares in the repurchase account.
Explanation of reasons for changes in other comprehensive income: The fluctuation in foreign currency exchange rates during the reporting period resulted in an increase in the translation differences of foreign currency statements.
Overseas assets

√Applicable □Not applicable

(1) Asset scale

Among them: overseas assets 253,008.57 (unit: 10,000 yuan, currency: RMB), accounting for 30.33% of the total assets.

(2) Relevant explanations on the high proportion of overseas assets

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB This reporting period Name of overseas assets during this reporting period Reason for formation Operation model

Operating income Net profit

22/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Zhende Medical Supplies (Hong Kong) Co., Ltd. Investment and establishment Independent accounting 8,245.74 -1,020.72 Hong Kong New Starting Point Investment Co., Ltd. Investment and establishment Independent accounting 74,982.79 573.20

Other instructions

Note: The above financial data of Zhende Medical Supplies (Hong Kong) Co., Ltd. and Hong Kong New Starting Point Investment Co., Ltd. include their consolidated overseas subsidiaries.

Restrictions on major assets as of the end of the reporting period

√Applicable □Not applicable

Item Book value at the end of the period (yuan) Reason for restriction

Monetary funds 64,700,762.29 Guarantee deposit, letter of credit deposit interest, litigation-related frozen funds, third-party payment

Pay platform and e-commerce store deposits

Total 64,700,762.29 -

Other instructions

□Applicable √Not applicable

(4) Investment status analysis

Overall analysis of external equity investment

√Applicable □Not applicable

During the reporting period, the company's equity investment increased by 40.546 million yuan, and the amount of equity investment in the same period last year was 214.9452 million yuan, a year-on-year decrease of 81.14%.

23/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(1)Significant equity investment

□Applicable √Not applicable

(2) Significant non-equity investment

√Applicable □Not applicable

The 15th meeting of the company's second board of directors was held on February 9, 2021, and the "Proposal on Investment in New Protective Equipment, Surgical Access Medical Device Production Bases and Medical Bio-New Materials Research Institute Construction Projects" was reviewed and approved. The board of directors agreed that the company would obtain the right to use state-owned construction land through public bidding in Binhai New District, Shaoxing, Zhejiang Province, and invest in the construction of new protective equipment, surgical access medical device production bases and medical bio-new materials research institute construction projects. The total investment in the project is expected to be approximately 650 million yuan. The construction land for this project (land area: 66,852 square meters) has been obtained through public bidding, and the land price is 45.13 million yuan. During the reporting period, the project was completed and put into use.

(3) Financial assets measured at fair value

√Applicable □Not applicable

Unit: Yuan Currency: RMB included in equity

Fair value in this period Sale/redemption in this period

Asset category Beginning balance Cumulative fair price less Purchase amount in the current period Other changes Closing balance Profit and loss amount

value change value

Others 25,709,568.07 -6,602,402.06 19,107,166.01 Others 71,927,026.58 55,409,090.91 -265,772.58 16,252,163.09 Others 280,286,160.14 2,096,326.76 200,370,000.00 216,000,000.00 266,752,486.90 Others 3,035,157.06 -35,157.06 40,000,000.00 43,000,000.00 -Derivatives 8,628,840.00 -8,593,340.00 35,500.00

Total 380,957,911.85 10,690,009.70 - - 240,370,000.00 314,409,090.91 -15,461,514.64 302,147,316.00

Securities investment situation

□Applicable √Not applicable

Explanation of securities investment situation

□Applicable √Not applicable

Private equity fund investment status

24/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

√Applicable □Not applicable

On September 6, 2021, the company and relevant partners signed the "Shanghai Hongsheng Yide Private Equity Investment Fund Partnership (Limited Partnership) Partnership Agreement", which stipulates that all parties will jointly invest 400 million yuan to establish Shanghai Hongsheng Yide Private Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "Hongsheng Yide"), mainly engaged in equity investment, investment management, asset management and other activities. Among them, the company, as a limited partner of Hongsheng Yide, subscribed to invest 20 million yuan, accounting for 5.00% of the total capital contribution of the fund. As of the end of this reporting period, the company had actually invested RMB 20 million. Hongsheng Yide has withdrawn from some investment projects and distributed a total of RMB 4.451 million to the company. The company has conducted accounting treatment in accordance with relevant accounting standards after receiving the allocated funds.

Derivatives investment situation

√Applicable □Not applicable

(1) Derivative investments for hedging purposes during the reporting period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Closing book price included in equity

Value accounts for the company's reported initial investment. The opening book value of the period. The cumulative fair value of the current period. The reporting period. The closing book value during the reporting period.

Derivatives investment type Net capital amount at the end of the reporting period Value Change in profit and loss Change in fair value Purchase amount Amount sold Value

production ratio

(%)

Derivative financial assets - options foreign exchange contracts

Derivative financial assets-forward foreign exchange contract 83,000.00

Derivative financial instruments - commodity futures contracts 8,545,840.00 35,500.00 0.0006 Total 8,628,840.00 35,500.00 0.0006 Accounting policies and accounting calculations for hedging business during the reporting period

Please refer to Note 5, Important Accounting Policies and Specific Principles of Section 8 of this report for details of the accounting policies and specific accounting principles for hedging business during the reporting period, as well as whether any significant changes have occurred compared with the previous reporting period.

Accounting estimates 11. Financial instruments have not changed significantly compared with the previous reporting period.

Description of big changes

During the reporting period, derivative financial assets - options and foreign exchange contracts realized gains and losses of RMB 0 from changes in fair value and investment income of RMB 185,000.00; explanation of actual gains and losses during the derivative reporting period. Financial assets - forward foreign exchange contracts realized gains and losses from changes in fair value of RMB 83,000 and investment income of RMB 1,667,595.05; derivative financial assets

Profit and loss from changes in fair value of commodity futures contracts was RMB 8,545,840.00, and investment income was RMB 2,414,208.42.

Explanation of the hedging effect: The company's hedging business has effectively reduced the impact of exchange rate fluctuations and raw material price fluctuations on the company's operating performance.

Source of funds for derivatives investment: Company’s own funds

Risk analysis and control measures for derivatives positions during the reporting period 1. In order to establish a complete risk management and internal control system for forward foreign exchange trading business and hedging business, the "Financial Derivatives

25/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(Including but not limited to market risks, liquidity risks, and credit risks. "Product Trading Management System" clarifies business approval authority, operating procedures and risk control standards, and comprehensively regulates various derivatives business operations. 2. Risks, operational risks, legal risks, etc.) All forward foreign exchange transactions and hedging businesses are based on real transactions. Hedging businesses are implemented strictly in accordance with the company's predicted foreign currency receipts (payments) amounts, business conditions and time. We adhere to the hedging principle, resolutely eliminate speculative transactions, and ensure that transaction amounts and terms are strictly controlled within the approved limits. 3. The company only chooses to conduct forward foreign exchange transactions and hedging business with operating institutions with legal business qualifications to control transaction risks. 4. The company's internal audit institution, the audit committee of the board of directors, and the independent directors will regularly and irregularly review the actual forward foreign exchange transaction business and hedging business. 5. The company establishes an abnormality reporting system in strict accordance with relevant regulations, reasonably arranges the use of professionals, strengthens business training for relevant personnel, improves overall quality, and forms

Effective risk handling procedures effectively control transaction risks.

The market price or fair price of the products during the reporting period of the invested derivatives

In case of changes in value, the analysis of the fair value of derivatives should be based on the price in the valuation notice/transaction settlement statement of each financial institution as the fair value of the contract.

Disclose the specific methods used and related assumptions and parameter settings.

Involvement in litigation (if applicable) None

Disclosure date of announcement by the board of directors for approval of derivatives investment (if any) November 21, 2025, April 24, 2026

Announcement and disclosure date of shareholders’ meeting for approval of derivatives investment (if any) May 23, 2026

(2) Derivative investments for speculative purposes during the reporting period

□Applicable √Not applicable

Other instructions

The company held the fourth meeting of the fourth board of directors on November 20, 2025, and reviewed and approved the "Proposal on Carrying out Hedging Business". In order to effectively control the risk of raw material price fluctuations and ensure the relative stability of product costs, the board of directors agreed that the company will develop polyethylene, polypropylene and rubber and other raw materials. For material-related financial derivatives hedging business, the guarantee amount at any time within the authorization period (within 12 months from the date of approval by the board of directors) shall not exceed RMB 30 million, and this amount can be recycled; the maximum contract value held at any time shall not exceed RMB 200 million. The board of directors authorizes the legal representative or the authorized agent designated by the legal representative to handle specific matters of the company's hedging business within the scope of the above authorization.

The company held the seventh meeting of the fourth board of directors and the 2025 annual shareholders' meeting on April 22, 2026 and May 22, 2026, and reviewed and approved the "Proposal on the Company's Forward Foreign Exchange Transaction Business", agreeing that the company will carry out forward foreign exchange transaction business, with the total annual amount not exceeding US$350 million (including US dollars, euros, pounds and other related settlement currencies involved in the company's normal operations), and the above quota can be used on a rolling basis. The shareholders' meeting authorizes the legal representative or the authorized agent designated by the legal representative to handle the specific matters of the company's daily forward foreign exchange transactions within the scope of the above authorization.

During the reporting period, the company strictly followed relevant systems such as the "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 5 - Transactions and Related Transactions" and carried out forward foreign exchange business and hedging business legally and prudently within the limits approved by the shareholders' meeting and the board of directors. In accordance with the requirements of accounting standards, the company and its subsidiaries conduct corresponding accounting and presentation of forward foreign exchange business and hedging business in accordance with relevant regulations and guidelines such as "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", "Accounting Standards No. 37 - Presentation of Financial Instruments", "Accounting Standards No. 39 - Fair Value Measurement", and reflect them in relevant items of the company's balance sheet and profit and loss statement.

26/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(5) Major assets and equity sales

□Applicable √Not applicable

(6) Analysis of major holding and participating companies

√Applicable □Not applicable

Information about major subsidiaries and joint-stock companies that affect the company's net profit by more than 10%

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit Shaoxing Zhende Medical Use

Subsidiaries Sales of medical supplies 15,413.53 65,145.56 20,594.56 58,917.44 408.23 289.38 Products Co., Ltd.

Xuchang Zhende Medical Compression Medical supplies production and

Subsidiaries 33,000 145,646.86 70,287.15 42,995.88 4,249.29 3,867.47 Materials Co., Ltd. Sales

Xuchang Zhengde Medical Medical Supplies Production and

Subsidiary 16,000.00 101,203.38 75,155.54 47,161.25 2,654.32 2,475.26 Products Co., Ltd. Sales

Shanghai Yaao Medical Insurance Medical supplies production and

Subsidiaries 2,319.2988 29,968.02 23,726.84 23,024.48 4,166.94 3,694.22 Jianpin Co., Ltd. Sales

New Beginning (Singapore

Subsidiary Sales of medical supplies USD 1 million 132,965.28 2,610.62 48,406.09 1,603.35 1,454.63) Private Limited

Acquisition and disposal of subsidiaries during the reporting period

□Applicable √Not applicable

Other instructions

√Applicable □Not applicable

During the reporting period, the company transferred 10% of the equity held by minority shareholders of Ningbo Shengyurui Medical Equipment Co., Ltd. and completed the relevant industrial and commercial change procedures on June 25, 2026. After the completion of this acquisition, Ningbo Shengyurui became a wholly-owned subsidiary of the company.

27/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(7) Structured entities controlled by the company

□Applicable √Not applicable

5. Other disclosure matters

(1) Possible risks

√Applicable □Not applicable

Risks of industrial policy adjustment

The company belongs to the medical and health industry, and its products are closely related to human health. Therefore, it is an industry that is deeply affected by national policies. In recent years, with the continuous deepening of the reform of the national medical and health system, policies such as hierarchical diagnosis and treatment, encouragement of innovation, and import substitution have been continuously introduced, and supervision has become increasingly strict. The industry is undergoing major changes and the competitive landscape continues to be renovated. If the company cannot adapt to profound changes in industry policies in a timely manner, its production and operations may be adversely affected.

The company will pay close attention to and analyze national and industry policies, track and grasp the development trend of the industry, and continue to increase market investment and brand building efforts by continuously improving its operation and management level, team professional service capabilities, and R&D innovation capabilities, continuously increasing market coverage and share, and reducing possible operating risks caused by policy adjustments.

Product quality risks

The company's main products are medical supplies that come into direct contact with wounds or are used for infection protection. Their quality, safety and stability are crucial to the lives and health of patients and medical staff. The company has established and continuously improved its quality management system, and formulated and implemented strict quality control measures. However, we still face risks caused by unforeseen factors (such as product quality disputes, litigation, administrative penalties, etc.), which will have an adverse impact on the company's operating capabilities and reputation.

The company will conscientiously implement relevant quality management specifications, continue to strengthen quality control, promote the optimization of the supply chain system and quality management system through lean management, automation, informatization, digitalization, intelligence, etc., adhere to product life cycle quality control, improve the company's quality control capabilities, and continue to provide high-quality products.

Market risk

From the perspective of the international market, in recent years, affected by factors such as the uncertainty of the global political and economic environment, trade frictions, exchange rate fluctuations, adjustments to various countries' medical insurance policies, and rising domestic labor costs, market demand has been weak in recovery, uncertainty has increased, and competition among export companies has intensified. In addition, my country's medical consumables export companies also face competition from countries with lower labor costs in Southeast Asia and other regions.

In the domestic market, the production of my country's medical device industry still lacks scale and intensification, the market concentration is relatively low, the quality of products of the same variety is uneven, low-level duplication of production is serious, and market competition is fierce. But at the same time, as the country pays more and more attention to the medical industry, and favorable policies such as encouraging innovation, accelerating approval, and import substitution are continuously introduced, coupled with residents' health awareness and consumption upgrade needs, the upgrading of the medical product industry is also imperative. The industry is expected to gradually shift to the high-end links of the value chain and achieve import substitution in the high-end product market; with the promotion of national medical reform Advances and supervision are becoming increasingly strict, industry standards and regulatory systems are constantly refined and improved, and higher requirements are put forward for product quality, cost and innovation. The industry will face major changes and concentration will increase rapidly; as medical resources sink and the medical and health infrastructure strengthening project continues to be implemented, and the level of grassroots diagnosis and treatment is promoted, the overall demand for the medical device industry will be further released.

In recent years, the company has gained in-depth insights into customer needs. With its excellent supply chain capabilities, healthy and orderly price management system, stable and reliable product quality, and continuously enriched product portfolio, it has been recognized by customers and consumers. The company's sales channels, brand influence and market coverage have been greatly improved. At the same time, the company continues to improve its supply chain capabilities and R&D innovation capabilities, continuously improves its ability to export competitive product line portfolios, actively explores the "going global" model, and accelerates the international layout of the supply chain. The African production base has been successfully completed and put into operation, and the Mexican production base is accelerating construction. A more flexible global supply chain layout will help the company cope with the complex and ever-changing international environment and provide a strong guarantee for the company's subsequent business growth.

Risks of exchange rate fluctuations and raw material price fluctuations

28/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

As the company's internationalization strategy continues to advance, the overall international business scale will continue to grow, and the company's assets and sales scale settled in foreign currencies such as US dollars will continue to increase. In recent years, uncertainties in the international political and economic situation have increased, the country's market-oriented exchange rate reform has deepened, and the RMB exchange rate has fluctuated greatly. The company will face the risk of exchange rate fluctuations during the foreign exchange settlement process. At the same time, exchange rate fluctuations will also affect the value of the company's assets and liabilities denominated in foreign currencies. The company will continue to pay attention to the dynamics of the foreign exchange market, understand market trends and potential risks, continuously optimize the domestic and overseas asset structure, and control risks caused by exchange rate fluctuations. In addition, on the one hand, the company has developed a reasonable price adjustment mechanism with long-term and stable cooperative customers. When key factors affecting prices, such as exchange rates and raw materials, fluctuate significantly, all parties will make price adjustments in accordance with the agreed mechanism. On the other hand, the company actively responds. In recent years, based on actual business, it has chosen opportunities to carry out forward foreign exchange settlement and sales business to avoid and reduce the risk of exchange rate fluctuations on the company's operating results.

In addition, due to geopolitical and other factors, commodity price fluctuations have intensified, which may pose certain challenges to the company's raw material procurement and cost control. The company will strengthen the collection and analysis of information on macroeconomics, policies and regulations, industrial supply and demand, market transactions, etc., and effectively control raw material price fluctuations and supply risks through measures such as improving production and marketing coordination, strengthening sales forecasts and strategic reserves, and hedging to achieve stable operations.

(2) Other disclosure matters

√Applicable □Not applicable

The 2026 semi-annual evaluation report of the “Improving Quality, Increasing Efficiency and Focusing on Returns” action plan is as follows:

In order to thoroughly implement the spirit of the Central Economic Work Conference and the Central Financial Work Conference, conscientiously implement the requirements of the State Council's "Opinions on Further Improving the Quality of Listed Companies", actively respond to the Shanghai Stock Exchange's "Initiative on Carrying out the Special Action of "Improving Quality, Increasing Efficiency and Focusing on Returns" of Shanghai Stock Exchange Companies, practice the concept of "investor-oriented", and promote The company's high-quality development and improvement of investment value protect the legitimate rights and interests of investors, especially small and medium-sized investors. The company combined its own development strategy and actual operating conditions to formulate the 2026 "Improving Quality, Increasing Efficiency and Focusing on Returns" action plan, which was reviewed and approved at the seventh meeting of the company's fourth board of directors held on April 22, 2026. In the first half of 2026, the company actively carried out and implemented various tasks according to the action plan. The main work results are now reported as follows

Focus on the main business and achieve sustainable development

During the reporting period, in the face of the complex and ever-changing external environment, the company adhered to the core of "deeply cultivating the main business, improving quality and efficiency", and took product focus, internationalization, cost reduction and efficiency, innovation leadership, organization and talent development as the core strategic measures. It firmly adhered to the two-wheel drive of domestic market and international business, promoted various operation and management tasks in an orderly manner, and the overall operating situation was stable and positive, laying a solid foundation for the company to move towards high-quality development.

In the first half of 2026, the company achieved operating income of 2.224 billion yuan, an increase of 5.90% over the same period last year; net profit attributable to shareholders of listed companies was 144 million yuan, an increase of 12.53% over the same period last year; net profit attributable to shareholders of listed companies excluding non-recurring gains and losses was 119 million yuan, an increase of 0.90% over the same period last year.

Pay attention to investor returns

The company continues to strengthen the awareness of returning shareholders, improves the shareholder return mechanism, and strictly implements the requirements of "enhancing the stability and sustainability of dividends". In the first half of 2026, after fully considering the current and future profit scale, cash flow status, development stage, the company's development capital needs and other factors, and after review and approval by the board of directors and the annual shareholders' meeting, the company implemented the 2025 profit distribution plan. The company carried out the 2025 profit distribution based on the total share capital registered on the equity registration date for the implementation of equity distribution: 10% of the total share capital was distributed to all shareholders for every 10 years. The company distributed a cash dividend of RMB 3.00 (tax included), and the total cash dividend distributed was RMB 79,162,867.50, accounting for 30.35% of the company’s 2025 net profit attributable to shareholders of listed companies of RMB 260,817,281.43. This cash bonus will be distributed on June 18, 2026.

The company will continue to attach importance to investor returns, continuously improve and improve the shareholder return mechanism, strive to improve the quality and investment value of listed companies, and create better returns for investors.

Pay attention to the quality of information disclosure and investor relations management

During the reporting period, the company strictly followed the basic principles of true, accurate, complete, timely and fair information disclosure and effectively fulfilled its information disclosure obligations. At the same time, the company is guided by investor needs and continues to improve the readability and effectiveness of information disclosure content. During the preparation and disclosure of periodic reports, the company analyzes and elaborates on industry development trends, operating conditions of each business segment, and future development plans, providing effective information support for investors to make investment value judgments.

29/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

In the first half of 2026, the company actively organized and held a performance briefing for 2025 and the first quarter of 2026, introducing to investors the company's operating results and financial indicators for 2025 and the first quarter of 2026, and answering questions that investors were concerned about.

The company attaches great importance to investor relations management and has built a three-dimensional communication matrix of "online interaction + offline communication". It will continue to actively communicate the company's value through diversified channels such as information disclosure, performance briefings, shareholders' meetings, Shanghai Stock Exchange interactive platform, investor calls, research and exchanges, shareholder receptions and brokerage strategy meetings, serve as an effective communication bridge between listed companies and investors, and effectively protect the legitimate rights and interests of investors, especially small and medium-sized investors.

Improve corporate governance

In the first half of 2026, the company will adhere to standardizing operations and improving efficiency as the core, and will continue to improve the governance system to ensure the company's compliant and efficient operations. During the reporting period, the company revised the "Remuneration Management System for Directors and Senior Management Personnel" in accordance with relevant regulations and combined with the company's actual operating conditions. This revision further improved the long-term incentive and restraint mechanism for directors and senior management personnel and strengthened the duty performance responsibilities of the "key minority".

In terms of ESG, the company disclosed the "2025 Sustainability Report and ESG (Environmental, Social and Governance) Report" on April 24, 2026. The company deeply integrates ESG concepts with the company's business strategies, continues to promote and deepen sustainable development management and practices, and further enhances the long-term value and social responsibility of the company.

Strengthen the responsibilities of "key minorities" and improve their performance level

The company continues to consolidate the main responsibilities of the "key minority" such as controlling shareholders, actual controllers, directors, and senior managers, strictly implements the requirements of the Shanghai Stock Exchange's "Supervision Reminder for Controlling Shareholders and Actual Controllers of Listed Companies", establishes a normalized policy transmission mechanism, and pushes the latest regulatory developments and key regulatory matters to the "key minority" as soon as possible , strengthen their awareness of compliance operations and awareness of standardized operations; systematically organize directors and senior executives to participate in special compliance training sponsored by the Shanghai Stock Exchange, Zhejiang Listed Companies Association, etc., using a combination of legal thinking and case warnings to comprehensively enhance the legal awareness, compliance literacy and performance capabilities of the "key minority", and effectively build a firm risk prevention and control line for the company.

Risk warning

In the second half of 2026, the company will continue to promote and evaluate the implementation of the "Improving Quality, Efficiency and Focusing on Returns" action plan, focusing on its main business, improving corporate governance, promoting the company's sustained, healthy and high-quality development, and better returning investors.

This action plan is a plan made by the company based on the current operating conditions and external environment. It does not constitute a substantial commitment by the company to investors. In the future, it may be affected by macro policy adjustments, industry competition, changes in domestic and foreign market environments and other factors. There is a certain degree of uncertainty. Investors are advised to pay attention to related risks.

30/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 4 Corporate Governance, Environment and Society

1. Changes in directors and senior managers of the company

√Applicable □Not applicable

Name Position held Change situation Reason for change Reason for change Shen Hong Chief Financial Officer Appointment Work transfer Work adjustment

Jin Haiping, head of finance, resigned, job transfer, job adjustment

Description of changes in directors and senior managers of the company

√Applicable □Not applicable

Due to work adjustment, Ms. Jin Haiping applied to resign from the position of financial director of the company during the reporting period. After resigning as financial director, she still held other positions in the company. The company held the eighth meeting of the fourth session of the Board of Directors on May 22, 2026. After nomination by the company's general manager and review by the Nomination Committee and Audit Committee of the Board of Directors, Ms. Shen Hong was appointed as the company's financial controller, with a term until the expiration of the company's fourth session of the Board of Directors.

2. Profit distribution or capital reserve conversion plan

The profit distribution plan and the plan for converting public reserve funds into share capital prepared in the semi-annual period

Whether to allocate or convert to increase No Number of bonus shares for every 10 shares (shares) 0 Number of dividends for every 10 shares (yuan) (tax included) 0 Number of convertible shares for every 10 shares (shares) 0 Description of the profit distribution or capital reserve conversion plan

Not applicable

3. The situation and impact of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

(1) Relevant equity incentive matters have been disclosed in temporary announcements and there is no progress or change in subsequent implementation

□Applicable √Not applicable

(2) Incentives not disclosed in temporary announcements or with subsequent progress

Equity incentives

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Employee stock ownership plan status

√Applicable □Not applicable

The company held the sixth meeting of the fourth board of directors and the second extraordinary shareholders' meeting in 2026 on January 23 and February 9, 2026 respectively, and reviewed and approved the "Proposal on the Company's Second Employee Stock Ownership Plan (Revised Draft) and its Summary", the "Proposal on the Management Measures for the Company's Second Employee Stock Ownership Plan (Revised Draft)", and " "Proposal on Repurchasing Unlocked Shares of the Company's Second Phase Employee Stock Ownership Plan", "Proposal on Changing the Use of Repurchased Shares and Cancellation" and "Proposal on Changing the Company's Registered Capital, Amending the Articles of Association and Handling Industrial and Commercial Change Registration", it was agreed to repurchase and cancel 1,829,868 company shares that were not unlocked in the second phase of the employee stock ownership plan. For details, please refer to the company’s announcements disclosed on the Shanghai Stock Exchange website (www.sse.com.cn) on January 24, 2026, February 10, 2026, and April 2, 2026.

During the reporting period, the company repurchased and canceled 1,829,868 company shares that were not unlocked under the second phase of the employee stock ownership plan. The cancellation date is April 7, 2026. The company has completed the liquidation and distribution of assets related to the second phase of the employee stock ownership plan in accordance with regulations, and has closed securities, bank and other accounts.

31/169

Zhende Medical Supplies Co., Ltd. 2026 Semi-Annual Report Other Incentive Measures

□Applicable √Not applicable

Environmental information of listed companies and their major subsidiaries included in the list of companies that disclose environmental information in accordance with the law □Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Consolidate and expand the results of poverty alleviation, rural revitalization and other work □Applicable √Not applicable

32/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 5 Important Matters

1. Fulfillment of commitments

(1) Commitments made by the company’s actual controller, shareholders, related parties, acquirers and the company and other relevant parties during the reporting period or continuing into the reporting period

√Applicable □Not applicable

If not, if it is not possible, if it is not possible, if it is timely, whether it is timely, it is timely.

Yes, it should be said that the commitment is back. Commitment. Commitment. Commitment. Promise. Commitment time. Performance. Clarify the unfinished situation. Type. Content. Period.

Planning and first time shares

After the expiration of the sales restriction period, the directors and supervisors of the company shall not transfer more shares than they own directly or indirectly during their term of office.

Public release, limited sale, May 2017, discomfort

25% of the total shares of Zhende Medical held by officers and senior management will not be transferred within six months after resignation No Long-term Yes Not applicable Bank-related Used on the 11th of the month

Personnel Let me directly or indirectly hold the shares of Zhende Medical.

commitment

Others If I/our company/enterprise violates the above commitment by directly or indirectly reducing the issuer's shares, it shall be in violation of the above commitments.

The income from the shareholding reduction in response to the above commitments belongs to the issuer, and will be collected within five working days of receiving the income.

The aforementioned income will be paid to the issuer's designated account within the business day. I/our company/enterprise will be

Publicly explain failure to fulfill commitments at the general meeting of shareholders of the initial issuer and in newspapers designated by the China Securities Regulatory Commission.

Publicly disclose the specific reasons before the issuance and listing, and apologize to other shareholders of the issuer and public investors. At the same time I / 2017 5 discomfort

No Long-term Yes Not applicable Bank-related entity shareholders The lock-in period of the issuer's stocks held by the company/enterprise is automatically extended for six months. If the commitment used on the 11th of the month causes losses to the issuer or its investors due to failure to perform the above commitments, I/this person shall

The company/enterprise will bear compensation liability to the issuer or other investors in accordance with the law. At the same time this

The person/company/enterprise voluntarily accepts the terms and conditions of the China Securities Regulatory Commission and the Shanghai Stock Exchange that are valid at that time.

Regulatory documents impose penalties on the company.

Other company directors and supervisors

For the first time, I shall not abandon the performance of relevant commitments due to changes in positions, resignations, etc. in the issuer. May 2017 Unsuitable

Executive, senior management No Long-term Yes Not applicable to public commitments. January 11th Staff

33/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If not, if it is not possible, if it is not possible, if it is timely, whether it is timely, it is timely

Yes, it should be said that the commitment is back. Commitment. Commitment. Commitment. Promise. Commitment time. Performance. Clarify the unfinished situation. Type. Content. Period.

Rowing related

commitment

After the lock-up period expires, the company/I will prudently formulate a reduction plan for the issuer’s shares.

Sales restrictions: Gradually reduce holdings according to relevant plans, and the number of reductions each year shall not exceed the total shares of the issuer at the end of the previous year.

5% of the capital. Within two years after the expiration of the lock-in period, if the issuer stocks held by the company/I

The reduction of holdings will be carried out through legal methods such as bidding transactions, block transactions, and agreement transfers.

For the first time, the company/I will notify the issuer at least three trading days in advance to announce the reduction.

Disclose the quantity of Zhejiang Zhende and Shen holdings, the price range of holdings reduction, the time range of holdings reduction, etc. If the company/I violate the above regulations on May 2017, I will not be able to

No Long-term Yes Not applicable Line-related Zhenfang Statement: The company/I will publicly explain the specific reasons for non-fulfillment and apologize to shareholders and public investors, and will publicly explain the specific reasons for non-fulfillment of the commitments made at the issuer's general meeting of shareholders and the newspapers designated by the China Securities Regulatory Commission on November 11th, and will

Repurchase illegal transactions within 10 trading days in compliance with laws, regulations and normative documents.

The stocks are sold according to regulations, and the lock-up period of the shares held is automatically extended from the date of completion of the repurchase3

months; if any income is obtained due to failure to perform the above public declaration matters, the income obtained

owned by the issuer.

Others 1. I promise not to transfer benefits to other units or individuals for free or on unfair terms.

interests, and shall not harm the interests of the company in other ways. 2. I promise to fulfill my duties

constrain consumption behavior. 3. I promise not to use the company’s assets to engage in any performance related to my performance.

with first time

Investment and consumption activities unrelated to responsibilities. 4. I promise to fully support the board of directors or remuneration and

Publicly issued company director, Gao 2017 May 5, unwell

When the appraisal committee formulates the remuneration system, it should be consistent with the implementation of the company's compensation return measures. No Long-term Yes Not applicable Bank-related level managers Used on 11th of March

and vote in favor (if you have the right to vote) when considering relevant motions. 5. My commitment

commitment

Fully support the implementation of the company’s equity incentive exercise conditions and the company’s supplementary return measures to be announced

and be willing to vote in favor of the resolutions of the board of directors and general meeting of shareholders related to the performance of the business (if

have the right to vote) on such motions. 6. I promise to earnestly implement the relevant supplementary returns formulated by the company.

34/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If not, if it is not possible, if it is not possible, if it is timely, whether it is timely, it is timely

If there is a commitment, the commitment should be made in a timely manner by the commitment party. Commitment time, performance, unfinished situation, type, content, deadline, strict explanation of the specific steps, time limits, reasons, planning measures and any commitments made by me regarding repayment measures for the next period. If I

If I violate these commitments and cause losses to the company or investors, I am willing to bear the responsibility according to law.

Compensation liability to the company or investors. As one of the responsible entities responsible for filling the return measures

If I violate the above commitments or refuse to perform the above commitments, I agree to follow the Chinese

Relevant regulations formulated or issued by securities regulatory agencies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange,

According to the rules, penalties will be imposed on the individual or relevant management measures will be taken.

Others After listing, the company will strictly fulfill all the commitments made before listing. If the company

If the commitments made cannot be fulfilled or are indeed unable to be fulfilled or cannot be fulfilled on time, the company will take

The following measures: 1. Disclose information at the general meeting of shareholders and the information disclosure media designated by the China Securities Regulatory Commission and

timely and fully disclose the specific reasons why the company failed to fulfill its commitments, was unable to perform, or was unable to perform as scheduled.

with first time

personal reasons, and apologize to shareholders and public investors; 2. Provide additional commitments to investors

Published on May 2017 Illness

The company promises or replaces commitments to protect the rights and interests of investors as much as possible; 3. If it fails to fulfill its commitments No Long-term Yes Not applicable

If any matter causes investors to suffer losses in securities transactions, the company will provide legal advice to the investors in accordance with the law.

commitment

Compensation for related losses. The China Securities Regulatory Commission determined that the company’s prospectus contained false records.

Within 5 trading days after the disclosure, misleading statement or major omission, the company will initiate compensation investment.

Work related to investor losses. The investor's losses are based on the amount determined through negotiation with the investor,

Or based on the method or amount determined by the China Securities Regulatory Commission.

Others After the company is listed, I/the company will strictly fulfill all the commitments made before the company was listed.

with the first actual controller Lu Nuo, and voluntarily accept the following restraint measures: 1. If the commitments are not fulfilled, I/this person

Public disclosure Jianguo, Shen Zhen The company will promptly and fully disclose information at the general meeting of shareholders and the information disclosure media designated by the China Securities Regulatory Commission. May 2017 Inappropriate

No Long-term Yes Not applicable Bank-related; Controlling shareholder Disclose the specific reasons why the company failed to fulfill its commitments, was unable to fulfill them, or was unable to perform them on time. Zhejiang Zhende’s commitments on May 11 and apologized to shareholders and public investors; 2. If any proceeds are obtained due to failure to fulfill commitments

Beneficial, the income earned by me/the company belongs to Zhende Medical, and within 5 days of receiving the income

35/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If not, if not

Can it be fulfilled in a timely manner?

Whether the performance is timely, the performance should be stated as the promise, the commitment, the commitment, the commitment, the commitment, the commitment time, the performance, the unfinished situation, type, content, deadline, strict description

Fulfill the details of the next issue

Pedometer limit reason

Pay the proceeds to the designated account of Zhende Medical within the scheduled working days; 3. If the commitment is not fulfilled,

If the incident causes losses to Zhende Medical or other investors, I/the company will pay the damages to

The loser shall be liable for compensation in accordance with the law; 4. If the promised matters are not fulfilled, the aforementioned

Before liability for compensation, I/the company shall not transfer Zhende Medical shares (due to inheritance, rape

Situations where stock transfer is necessary for implementation of corporate governance, company reorganization, and fulfillment of commitments to protect the interests of investors, etc.

Except); during the period when the commitments are not performed, the Zhende of the current year that belongs to me/the company

Medical cash dividend income belongs to Zhende Medical, and I/the company shall not veto this period.

As the actual controller/controller of myself/the company,

During the period of being a shareholder, if Zhende Medical fails to fulfill its commitments and causes losses to investors, it shall

The directors and senior managers of Zhende Medical failed to fulfill their commitments, causing losses to investors.

, I/our company promise to assume joint and several liability for compensation in accordance with the law.

Others I promise to strictly fulfill the commitments made by the company before listing, and at the same time promise to accept

The binding measures when the commitments are not fulfilled are as follows: 1. If the commitments are not fulfilled,

I will promptly and fully disclose information at the general meeting of shareholders and the information disclosure media designated by the China Securities Regulatory Commission.

Disclose the specific reasons why I fail to fulfill my commitments, cannot perform them, or cannot perform them on time, and

For the first time, I apologize to shareholders and public investors; 2. If I fail to fulfill my commitments, I will

company director, supervisor

Publicly issued Within 10 trading days from the date of the occurrence of the above-mentioned events, stop receiving remuneration. At the same time, I hold the company's shares (if any) related to the company's shares (if any) that I hold in May 2017. Incompetent, senior management No Long-term Yes Not applicable

commitments (except for situations where equity transfer is necessary to fulfill the commitment to protect the interests of investors), the returns will be returned during this period.

The company's cash dividend income (if any) belonging to me for the year belongs to the company until I

Fulfill and complete relevant commitments; 3. The income earned by me due to failure to fulfill commitments shall belong to the company

All the proceeds will be paid to the company's designated account within 5 working days of receipt of the proceeds.

If I cause losses to the company or investors due to my failure to fulfill my commitments,

36/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If not, if it is not possible, if it is not possible, if it is timely, whether it is timely, it is timely

If there is a commitment, the commitment should be made in a timely manner by the commitment party. Commitment time, performance, unfinished situation, type, content, deadline, strict explanation, specific steps and time limit for the next period, and the reason for the completion of the plan. I will bear compensation liability to the company or investors in accordance with the law; 5. The above commitments will not be due to me.

Changes due to job adjustment or resignation at Zhende Medical.

Others If the company (including its predecessor) and its holding subsidiaries and branches have

There are any missed, unpaid or late payments of social insurance premiums and housing provident funds during the period of existence.

Any expenses, economic compensation or other economic losses caused by the first-time actual controller Lu’s defective payment behavior shall be

Publicly issued Jianguo, Shen Zhen The company/I will unconditionally bear full liability for compensation, or the company and its controlling subsidiaries 2017 5 Not suitable

No Long-term Yes Not applicable Bank-related commitments Zhejiang Zhende Zhejiang Zhende Zhejiang Zhende subsidiaries and branches will be fully compensated in a timely manner if the controlling shareholder must pay such expenses in advance.

The defective payment of provident funds caused the company and its holding subsidiaries, branches and companies to go public

Any loss suffered by subsequent public shareholders.

Solution 1. There is currently no company or other organization under my control that is engaged in the issuance of

There is no horizontal competition among peers and holding subsidiaries in the same or similar business. 2. Our company/

Competition The companies or other organizations controlled by me will not engage in any form of competition or development within or outside China.

The pedestrian and its holding subsidiaries currently have the same or similar businesses, including no investment in or outside China.

Capital investments, acquisitions, and mergers that directly compete with the existing main businesses of the issuer and its holding subsidiaries

For the first time, the actual controller Lu

company or other economic organization. 3. If the issuer and its holding subsidiaries engage in new businesses in the future,

Publicly released by Jianguo and Shen Zhen on May 2017. Unwell

If the company/company or other organization controlled by me will not be in or outside China, the company/company or other organization controlled by me will not be related to the industry.

Engage in any form of business that directly competes with the new business areas of the issuer and its holding subsidiaries

Commitment Zhejiang Zhende

business activities, including investments, acquisitions, mergers and issuers and controlling subsidiaries in and outside China.

Companies or other economic organizations that directly compete with the new business that the company will engage in in the future. 4. If

The company/legal person controlled by me has direct competition with the issuer and its holding subsidiaries.

When the business situation is changing, the issuer and its holding subsidiaries have the right to preferentially acquire or entrust operations.

This method concentrates competing businesses on the issuer and its holding subsidiaries. 5. Our company/

37/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If not, if not

Can it be fulfilled in a timely manner?

Fulfill the details of the next issue

Pedometer limit reason

I promise not to seek illegitimate interests as a controlling shareholder/actual controller of the issuer.

This will in turn harm the rights and interests of the issuer and other shareholders of its holding subsidiaries. If the company/person and the controller

The breach of the above commitments by a controlled company or other organization has resulted in the issuer and its controlling subsidiaries suffering losses

If the rights and interests are damaged, the company/I agree to bear relevant liabilities to the issuer and its holding subsidiaries.

liability for damages.

Solution (1) The company/I will try my best to avoid and reduce the risk of the company/I or others under my control.

Related party transactions between enterprises and joint-stock companies. (2) For unavoidable or reasonable reasons

Transactions: For related transactions that occur as a result, the company/I and other companies under my control will handle the related transactions in accordance with relevant laws.

The actual controller shall comply with the laws, regulations and normative documents as well as the Articles of Association of the joint-stock company, and shall abide by the principles of equality, freedom and autonomy.

Jianguo and Shen Zhenyuan followed the general commercial principles of equal value and compensation, and performed legal procedures to sign a contract with the joint-stock company.

with first time

Fang; the controlling shareholder shall enter into the joint transaction agreement and ensure that the prices of the related transactions are fair to protect the joint-stock company and its shares.

The public issuance in May 2017 is not suitable for the interests of Zhejiang Zhende; public shareholders (especially small and medium shareholders). (3) The company/I promise not to use the position and influence in the company as a director or supervisor to harm the interests of the company and other shareholders through related transactions. No Long-term Yes Not applicable.

commitment

affairs, senior management and legitimate rights and interests. This company/I or other companies controlled by me guarantee that I will not take advantage of the

Personnel’s status and influence in the joint-stock company, illegal occupation or transfer of the company’s funds, assets and their

other resources, or require the joint-stock company to provide guarantees in violation of regulations. (4) If the company/person violates

If you promise to conduct related transactions with a joint-stock company, the proceeds from the transaction will belong to the joint-stock company;

If a subsidiary company causes losses, the company/himself or other companies under his control shall compensate.

Others (1) Do not interfere with the company’s business management activities beyond their authority, do not encroach on the company’s interests, and earnestly perform their duties

Controlling shareholder Zhejiang

Measures related to refinancing the company's returns. (2) As the responsible party responsible for filling the return measures

Zhende and actual control 2019 May 2019 Unsuitable investment related 1. If the company/I violate the above commitments or refuse to perform the above commitments, the company/I No Long-term Yes Not applicable

Shen Zhenfang and his wife

The relevant provisions and rules of the Company shall be punished or relevant supervisory measures shall be taken against the Company/I.

38/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If not, if not

Can it be fulfilled in a timely manner?

It should be said whether or not you have performed your duty well.

Promise Back Commitment Commitment Commitment Promise Promise Timely Fulfillment Promised Party Time Commitment Performance Not Completed

Scenario Type Content Deadline Strict Explanation Complete Fulfillment

Fulfill the details of the next issue

Pedometer limit reason

Others (1) I promise not to transfer benefits to other units or individuals for free or on unfair terms.

interests, and shall not harm the interests of the company in other ways. (2) I promise to be responsible for my duties

constrain service consumption behavior. (3) I promise not to use company assets to engage in any business related to myself.

Investment and consumption activities unrelated to the performance of duties. (4) I promise to fully support the board of directors or

When the remuneration and assessment committee formulates the remuneration system, it should complement the implementation of return measures with the company.

be linked to the relevant circumstances and vote in favor (if you have the right to vote) when considering relevant proposals. (5)

and refinancing. I promise to fully support the proposed exercise conditions of the company's equity incentives and the company's top-up returns.

Director of the company, Senior Director of the Board of Directors and General Meeting of Shareholders in May 2019 and willing to vote No Long-term Yes Not applicable

Level management personnel pledged to support (if they have the right to vote) such motions on 20 May. (6) I promise to earnestly implement the policies formulated by the company

Relevant supplementary return measures and any commitment I have made in relation to the supplementary return measures

If I violate these commitments and cause losses to the company or investors, I am willing to

We intend to assume the liability for compensation to the company or investors in accordance with the law. Relevant as a fill return measure

As one of the responsible parties, if I violate the above commitments or refuse to perform the above commitments, I agree with

It is intended that securities regulatory authorities such as the China Securities Regulatory Commission and the Shanghai Stock Exchange shall comply with the regulations formulated or issued by them.

Relevant regulations and rules will impose penalties on individuals or take relevant supervisory measures.

Other commitments Other Sun Jimu Not to reduce the holdings within 12 months from the date of completion of the transfer of this agreement (October 16, 2025) 9 2025 Yes 12 Yes Not applicable Not committed The shares of the company transferred under this agreement. Month 10th Month Used

2. Non-operating capital occupation by controlling shareholders and other related parties during the reporting period

□Applicable √Not applicable

3. Illegal guarantee situation

□Applicable √Not applicable

39/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

4. Audit status of semi-annual report

□Applicable √Not applicable

5. Changes and handling of matters involved in non-standard audit opinions in last year’s annual report

□Applicable √Not applicable

6. Matters related to bankruptcy and reorganization

□Applicable √Not applicable

7. Major litigation and arbitration matters

□The company has major litigation and arbitration matters during this reporting period √The company has no major litigation and arbitration matters during this reporting period

Listed companies and their directors, senior managers, controlling shareholders, and actual controllers are suspected of violating laws and regulations, and have been punished and reorganized.

Change the situation

□Applicable √Not applicable

9. Explanation of the integrity status of the company, its controlling shareholders and actual controllers during the reporting period

√Applicable □Not applicable

During the reporting period, the company, its controlling shareholders, and actual controllers did not fail to fulfill the effective court judgments or have large amounts of debts that were due and unpaid.

10. Major related transactions

(1) Related transactions related to daily operations

Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation

□Applicable √Not applicable

Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation

√Applicable □Not applicable

On April 22, 2026, the company held the seventh meeting of the fourth board of directors and reviewed and approved the "Proposal on the Confirmation of Daily Related Transactions in 2025 and the Estimation of Daily Related Transactions in 2026" (for details, please see the company's announcement disclosed on the Shanghai Stock Exchange website (www.sse.com.cn) on April 24, 2026). During the reporting period, the company strictly followed the authorization and approval process of the board of directors. See the table below for details:

Related party transactions for the first half of 2026 Related party transactions Within Related party transactions Estimated funds for 2026

Related transaction parties Actual amount type Volume-price principle Amount (10,000 yuan)

(Ten thousand yuan) Yanling Zhende Biomass Energy to related parties

Steam and electricity market price 6,000 2,297.21Yuan Thermal Power Co., Ltd. Purchase goods

Yanling Xiangfa Packaging and Printing to related parties

Purchase goods Market price 2,500 846.73 Co., Ltd. Purchase goods

Shaoxing Yuantong Information Technology to related parties

Procurement Services Market Price 2 1.78 Co., Ltd. Procurement Services

Total 8,502 3,145.72

40/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Matters not disclosed in temporary announcements

□Applicable √Not applicable

(2) Related transactions arising from asset acquisition or equity acquisition or sale

Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable
Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable
Matters not disclosed in temporary announcements

□Applicable √Not applicable

If a performance agreement is involved, the performance achievement during the reporting period should be disclosed □Applicable √Not applicable

(3) Major related transactions of joint external investments

Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable
Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable
Matters not disclosed in temporary announcements

□Applicable √Not applicable

(4) Related credit and debt transactions

Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable
Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable
Matters not disclosed in temporary announcements

□Applicable √Not applicable

(5) Financial business between the company and related financial companies, company-controlled financial companies and related parties □ Applicable √ Not applicable

(6) Other major related transactions

□Applicable √Not applicable

41/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(7) Others

□Applicable √Not applicable

Major contracts and their performance

(1) Custody, contracting and leasing matters □Applicable √Not applicable

42/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Major guarantees performed and not yet completed during the reporting period

√Applicable □Not applicable

Unit: 10,000 yuan Currency: US dollars Company’s external guarantees (excluding guarantees to subsidiaries)

Guarantor Guarantee Issuer Guarantee is

Is the collateral

Listed Guaranteed Date of Birth Guarantee Guarantee Main Debt No Already Guaranteed Yes Guarantee Overdue Counter Guarantee Related Guarantor Guarantee Amount Guarantee Type (such as Related Party

Party of the company (agreement signed, starting date, expiry date, situation, performance completed, overdue, amount, situation, relationship) Guarantee

Relationship (Date of Department) Completed

Total amount of guarantees incurred during the reporting period (excluding guarantees for subsidiaries)

Total guarantee balance at the end of the reporting period (A) (excluding guarantees to subsidiaries)

insurance)

The company’s guarantees for subsidiaries

The total amount of guarantees issued to subsidiaries during the reporting period

Total guarantee balance for subsidiaries at the end of the reporting period (B) 3,000

Total amount of company guarantees (including guarantees to subsidiaries)

Total guarantee (A+B) 3,000 Ratio of total guarantee to the company’s net assets (%) 3.60 Among them:

Amount of guarantee provided to shareholders, actual controllers and their related parties (C)

Provided directly or indirectly to guaranteed objects whose asset-liability ratio exceeds 70%

3,000 debt guarantee amount (D)

The amount of the total guarantee exceeding 50% of the net assets (E)

The total amount of the above three guarantees (C+D+E) 3,000 The unexpired guarantee may bear joint and several liability for repayment. For details, please refer to the guarantee description.

As approved by the company's 2024 Annual General Meeting of Shareholders, the company's wholly-owned subsidiary New Starting Point (Singapore) Pte. Ltd. (hereinafter referred to as "Guarantee Statement" "Singapore New Starting Point") signed a "Loan Agreement" (hereinafter referred to as the "Loan Agreement") with INTERNATIONAL FINANCE CORPORATION (hereinafter referred to as "IFC") in May 2025 due to business development needs. It plans to provide IFC with

43/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Apply for a loan with a total principal amount not exceeding US$30 million equivalent in RMB. The principal repayment date of such loans is June 15 of each year from 2029 to 2033. At the same time, the company and its wholly-owned subsidiaries Hong Kong New Starting Point Investment Co., Ltd. and Zhende Medical Supplies (Hong Kong) Co., Ltd. signed the "Guarantee" (hereinafter referred to as the "Guarantee Agreement") with IFC to provide a joint liability guarantee for the above-mentioned loans applied by Singapore New Starting Point from IFC. The guarantee period shall be from this Guarantee From the date when the Agreement is signed and becomes effective until the date when the loan principal, interest and other payable fees that Singapore New Starting Point shall repay/pay to IFC under the "Loan Agreement" are fully paid, the scope of the guarantee includes the loan principal, interest and other payable fees that Singapore New Starting Point shall repay/pay to IFC under the "Loan Agreement". As of the end of this reporting period, the balance of the above guarantees was US$30 million equivalent in RMB.

44/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(3) Other major contracts

□Applicable √Not applicable

12. Instructions on the use of raised funds

□Applicable √Not applicable

13. Description of other major matters

□Applicable √Not applicable

Section 6 Changes in Shares and Shareholders

1. Changes in share capital

(1) Statement of changes in shares

Statement of changes in shares

Unit: Share capital before this change Increase or decrease (+, -) After this change

send

Compare the product, compare the value, and give away

Quantity Example Gold Other Subtotal Quantity Example Share

(%) to (%) shares

State shareholding
Shareholding by state-owned legal persons
Other domestic shareholdings

Among them: domestic non-state-owned legal persons

shareholding

Domestic natural person shareholding

Foreign shareholding

Including: shares held by overseas legal persons

Shareholding by foreign natural persons

Circulating shares without selling restrictions 265,835,535 100 -1,959,310 -1,959,310 263,876,225 100 shares
RMB ordinary shares 265,835,535 100 -1,959,310 -1,959,310 263,876,225 100
Domestic-listed foreign shares
Foreign-invested stocks listed overseas
Others
Total number of shares 265,835,535 100 -1,959,310 -1,959,310 263,876,225 100
Description of changes in shares

√Applicable □Not applicable

The company's total share capital at the beginning of the reporting period was 265,835,535 shares, all of which were tradable shares without selling restrictions. The company held the sixth meeting of the fourth board of directors and the second extraordinary shareholders' meeting in 2026 on January 23 and February 9, 2026, respectively, and reviewed and approved the "Proposal on the Company's Second Employee Stock Ownership Plan (Revised Draft) and its Summary", the "Proposal on the Management Measures for the Company's Second Employee Stock Ownership Plan (Revised Draft)", and the "Repurchase of the Company's Second Employee Stock Ownership Plan"

45/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Proposal on Unlocked Shares", "Proposal on Changing the Use of Partial Repurchased Shares and Cancellation" and "Proposal on Changing the Company's Registered Capital, Amending the Articles of Association and Handling Industrial and Commercial Change Registration", it was agreed to cancel the unused 129,442 company shares in the special securities account for repurchase and the 1,829,868 unlocked company shares in the second phase of the employee stock ownership plan repurchased by the company, for a total of 1,959,310 company shares. The above-mentioned shares have been canceled on April 7, 2026 and April 10, 2026 respectively.

As of the end of this reporting period, the company's total share capital was 263,876,225 shares, all of which are tradable shares without selling restrictions.

The impact of changes in shares between the reporting period and the disclosure date of the semi-annual report on financial indicators such as earnings per share and net assets per share (if any)

□Applicable √Not applicable

Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable √Not applicable

(2) Changes in restricted shares

□Applicable √Not applicable

2. Shareholder situation

(1) Total number of shareholders:

Total number of common shareholders (households) as of the end of the reporting period 8,152 Total number of preference shareholders (households) with restored voting rights as of the end of the reporting period 0

(2) Shareholding status of the top ten shareholders and top ten tradable shareholders (or shareholders without selling restrictions) as of the end of the reporting period

Unit: Shareholding status of the top ten shareholders (excluding shares lent through refinancing)

Held with pledged, marked or frozen

Name of shareholder Increase in number of shares held during the reporting period Ratio of shares held at the end of the period Sales restriction conditions

Nature of shareholder (full name) Reduction (%) Shares Shares

Quantity

Quantity Status

Zhejiang Zhende Holdings has domestic non-state-owned

0 131,190,860 49.72 0 Pledge 21,999,260

Co., Ltd. Legal person Sun Jimu 0 13,322,560 5.05 0 None 0 Domestic natural person Shen Zhenfang 0 9,310,000 3.53 0 None 0 Domestic natural person Bank of China Co., Ltd.

Co., Ltd. - Huabaozhong

Securities medical trading type 4,395,643 4,395,643 1.67 0 None 0 Other open index securities investments

capital fund

Lu Jianguo 0 3,924,646 1.49 0 None 0 Domestic natural person Wang Yang 757,680 3,895,339 1.48 0 None 0 Domestic natural person Wang Minzhou 1,345,674 3,880,000 1.47 0 None 0 Domestic natural person Qi Baigang 346,042 3,833,242 1.45 0 None 0 Domestic natural person Wang Quanchang 590,555 3,470,786 1.32 0 None 0 Domestic natural person Cong Mengran 48,962 3,429,743 1.30 0 None 0 Shareholding status of the top ten domestic natural persons shareholders without selling restrictions (excluding shares lent through refinancing)

Type and number of shares held without selling restrictions

Shareholder name

Number of shares Type Quantity

46/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Zhejiang Zhende Holdings Co., Ltd. 131,190,860 RMB ordinary shares 131,190,860 Sun Jimu 13,322,560 RMB ordinary shares 13,322,560 Shen Zhenfang 9,310,000 RMB ordinary shares 9,310,000 Bank of China Co., Ltd. - Huabao

CSI Healthcare Traded Open Index Securities 4,395,643 RMB ordinary shares 4,395,643 Bond Investment Fund

Lu Jianguo 3,924,646 RMB ordinary shares 3,924,646 Wang Yang 3,895,339 RMB ordinary shares 3,895,339 Wang Minzhou 3,880,000 RMB ordinary shares 3,880,000 Qi Baigang 3,833,242 RMB ordinary shares 3,833,242 Wang Quanchang 3,470,786 RMB ordinary shares 3,470,786 Cong Mengran 3,429,743 RMB ordinary shares 3,429,743 The situation of special repurchase accounts among the top ten shareholders

Not applicable

Ming

The voting rights and trusteeship forms of the above-mentioned shareholders

Not applicable

Explanation of voting rights and waiver of voting rights

Among the above shareholders, Zhejiang Zhende is the company’s controlling shareholder, and Lu Jianguo holds 87.16% of Zhejiang Zhende

of the equity, Shen Zhenfang holds 2% of the equity of Zhejiang Zhende, Lu Jianguo and Shen Zhenfang are husband and wife, the above-mentioned shareholders are related or acting in concert

They are the actual controllers of the company. Except for the above-mentioned relationships, the Company is not aware of any description of the above-mentioned shareholders.

Whether there is a related relationship or a consistent practice stipulated in the "Administrative Measures for the Acquisition of Listed Companies"

Touching relationship.

Preference shareholders and shareholders whose voting rights have been restored

Not applicable

Description of number of shares

The situation of shareholders holding more than 5% of the shares, the top ten shareholders and the top ten shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable √Not applicable

The top ten shareholders and the top ten shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable √Not applicable

Number of shares held by the top ten shareholders subject to selling restrictions and conditions for selling restrictions

□Applicable √Not applicable

(3) Strategic investors or general legal persons become the top ten shareholders due to the placement of new shares

□Applicable √Not applicable

3. Directors and senior managers

(1) Changes in shareholdings of current and departing directors and senior managers during the reporting period

□Applicable √Not applicable

Other situation description

□Applicable √Not applicable

(2) Equity incentives granted to directors and senior managers during the reporting period

□Applicable √Not applicable

47/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(3) Other instructions

□Applicable √Not applicable

Changes in controlling shareholders or actual controllers □Applicable √Not applicable

5. Relevant information on preference shares

□Applicable √Not applicable

48/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 7 Bond-Related Information

Corporate bonds (including corporate bonds) and non-financial corporate debt financing instruments □ Applicable √ Not applicable

2. Convertible corporate bonds

□Applicable √Not applicable

49/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Section 8 Financial Report

1. Audit report

□Applicable √Not applicable

2. Financial statements

Consolidated Balance Sheet

June 30, 2026

Prepared by: Zhende Medical Products Co., Ltd.

Unit: Yuan Currency: RMB

Item Notes June 30, 2026 Current assets as of December 31, 2025:

Monetary funds 7. 1 693,990,042.23 825,308,081.42 Settlement reserve fund

Loan funds

Trading financial assets 7.2 266,752,486.90 283,321,317.20 Derivative financial assets 7.3 249,500.00

Notes receivable

Accounts receivable 7. 5 765,525,742.66 703,054,733.84 Accounts receivable financing 7. 7 19,107,166.01 25,709,568.07 Prepayments 7. 8 90,853,660.93 73,121,155.91 Premium receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 7.9 37,881,221.47 44,813,852.61 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 7.10 898,504,640.45 754,130,482.20 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 7.13 131,771,734.77 149,589,115.95

Total current assets 2,904,636,195.42 2,859,048,307.20 Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment VII. 17 117,676,001.90 118,455,594.32 Other equity instrument investments

Other non-current financial assets VII. 19 16,252,163.09 71,927,026.58 Investment real estate

Fixed assets 7. 21 3,090,329,389.35 3,007,931,714.46 Construction in progress 7. 22 338,964,255.07 468,589,159.87 Productive biological assets

50/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

oil and gas assets

Right-of-use assets 7. 25 53,073,731.45 29,790,569.34 Intangible assets 7. 26 703,642,025.21 722,679,300.13 Including: data resources

Development expenditure 8.2 18,326,243.19 14,629,804.61 Including: data resources

Goodwill VII. 27 1,026,387,403.88 1,036,722,214.96 Long-term deferred expenses VII. 28 8,689,802.85 5,403,960.09 Deferred income tax assets VII. 29 63,566,813.58 65,710,121.10 Other non-current assets

Total non-current assets 5,436,907,829.57 5,541,839,465.46

Total assets 8,341,544,024.99 8,400,887,772.66 Current liabilities:

Short-term borrowings 7. 32 906,451,862.12 767,002,817.30 Borrowings from the Central Bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities 7.34 214,000.00

Notes payable VII. 35 10,381,930.51 16,450,317.87 Accounts payable VII. 36 476,523,744.29 556,582,886.75 Advance payments VII. 37 3,458,689.43 191,276.41 Contract liabilities VII. 38 28,823,533.49 21,597,685.23 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable VII. 39 108,980,289.20 123,059,599.37 Taxes payable VII. 40 39,569,814.77 41,611,578.16 Other payables VII. 41 152,991,601.22 149,514,610.48 including: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 7. 43 9,483,135.28 105,540,294.68 Other current liabilities 7. 44 14,123,270.15 26,603,512.85

Total current liabilities 1,751,001,870.46 1,808,154,579.10 Non-current liabilities:

insurance contract reserves

Long-term borrowings VII. 45 381,833,847.77 383,096,181.74 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 7. 47 30,460,385.77 8,796,917.26 Long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 7.51 215,190,710.81 215,236,541.61

51/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Deferred income tax liabilities 7. 29 22,616,958.19 23,342,042.39 Other non-current liabilities

Total non-current liabilities 650,101,902.54 630,471,683.00

Total liabilities 2,401,103,773.00 2,438,626,262.10 Owners’ equity (or shareholders’ equity):

Paid-in capital (or equity) 7. 53 263,876,225.00 265,835,535.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve VII. 55 1,698,831,567.37 1,772,090,902.96 Less: treasury shares VII. 56 46,543,090.89 Other comprehensive income VII. 57 -49,496,552.09 -3,141,814.03 Special reserves

Surplus reserve VII. 59 239,372,019.36 239,372,019.36 General risk reserve

Undistributed profits 7. 60 3,523,736,807.63 3,459,120,894.80 Attributable to the owners’ equity of the parent company

5,676,320,067.27 5,686,734,447.20 (or shareholders’ equity) total

Minority shareholders’ equity 264,120,184.72 275,527,063.36 Owner’s equity (or shareholder’s rights

5,940,440,251.99 5,962,261,510.56 profit) total

Liabilities and Owner's Equity

8,341,544,024.99 8,400,887,772.66 (or shareholders’ equity) total

Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

Parent company balance sheet

June 30, 2026

Prepared by: Zhende Medical Products Co., Ltd.

Unit: Yuan Currency: RMB

Item Notes June 30, 2026 Current assets as of December 31, 2025:

Monetary funds 229,492,639.76 215,521,540.52 Trading financial assets 266,752,486.90 280,286,160.14 Derivative financial assets

Notes receivable

Accounts receivable 19.1 283,137,908.71 386,544,533.19 Accounts receivable financing 13,903,787.96 20,718,604.55 Prepayments 607,014,587.13 465,575,866.24 Other receivables 19.2 676,412,787.79 930,300,832.94 Including: interest receivable

Dividends receivable

Inventory 195,170,260.33 177,455,977.66 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 49,359,542.84 43,067,815.89 Total current assets 2,321,244,001.42 2,519,471,331.13

52/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 19.3 1,775,695,063.44 1,739,574,655.86 Other equity instrument investments

Other non-current financial assets 14,090,909.09 69,500,000.00 Investment real estate

Fixed assets 714,481,670.76 697,452,457.68 Construction in progress 19,466,970.34 45,131,808.76 Productive biological assets

oil and gas assets

Right-of-use assets 689,512.87 1,138,379.05 Intangible assets 117,593,151.95 119,242,122.51 Including: data resources

Development expenditure 13,993,229.36 10,725,407.75 Including: data resources

goodwill

Long-term deferred expenses

Deferred income tax assets 8,598,569.88 12,460,218.77 Other non-current assets

Total non-current assets 2,664,609,077.69 2,695,225,050.38

Total assets 4,985,853,079.11 5,214,696,381.51 Current liabilities:

Short-term borrowings 1,000,468.61 610,393,280.56 Trading financial liabilities

Derivative financial liabilities

Notes payable 500,000,000.00

Accounts payable 134,379,827.92 211,156,777.07 Advance payments 1,448,333.10

Contract liabilities 9,214,048.26 9,488,720.77 Employee benefits payable 37,566,344.88 42,813,405.75 Taxes payable 653,660.33 3,932,089.07 Other payables 158,042,670.30 159,802,958.47 of which: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year 2,571,105.17 1,619,174.76 Other current liabilities 1,063,474.14 26,186,910.04

Total current liabilities 845,939,932.71 1,065,393,316.49 Non-current liabilities:

Long-term borrowings 381,833,847.77 383,096,181.74 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 131,879.07

long-term payables

Long-term employee benefits payable

53/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Estimated liabilities

Deferred income 23,007,991.70 24,972,472.70 Deferred income tax liabilities

Other non-current liabilities

Total non-current liabilities 404,973,718.54 408,068,654.44 Total liabilities 1,250,913,651.25 1,473,461,970.93 Owners’ equity (or shareholders’ equity):

Paid-in capital (or equity) 263,876,225.00 265,835,535.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 1,791,483,949.71 1,836,033,496.23 Less: treasury shares 46,543,090.89 Other comprehensive income

special reserve

Surplus reserve 239,372,019.36 239,372,019.36 Undistributed profits 1,440,207,233.79 1,446,536,450.88 Owners’ equity (or shareholders’ rights

3,734,939,427.86 3,741,234,410.58 profit) total

Liabilities and Owner's Equity

4,985,853,079.11 5,214,696,381.51 (or shareholders’ equity) total

Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

consolidated income statement

January-June 2026

Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

Total operating income 2,224,060,634.54 2,100,197,326.31 Including: operating income 7. 61 2,224,060,634.54 2,100,197,326.31 Interest income

Premiums earned

Fee and commission income

Total operating costs 2,067,911,454.10 1,952,592,060.03 Including: operating costs 7. 61 1,454,743,382.89 1,382,130,817.97 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges VII. 62 27,522,881.31 26,781,276.94 Sales expenses VII. 63 185,477,351.18 178,392,032.41 Administrative expenses VII. 64 304,963,031.93 287,009,742.65 R&D expenses VII. 65 64,888,620.92 63,735,842.41 Financial expenses VII. 66 30,316,185.87 14,542,347.65 Including: interest expense 15,709,188.11 13,228,489.81 Interest income 2,539,094.22 4,765,356.05

54/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Add: Other income 7. 67 18,318,613.35 18,991,712.00 Investment income (losses are listed with "-") 7. 68 22,946,175.57 1,631,335.23 Including: losses to associates and joint ventures

-779,592.42 -1,542,790.73Investment income

Financial assets measured at amortized cost

Derecognition of income (losses are listed with "-")

Exchange gains (losses are listed with "-")

Net exposure hedging income (losses are filled in with "-"

column)

Gains from changes in fair value (losses indicated by “-”

70 10,690,009.70 4,795,660.88 (please fill in the list)

Credit impairment losses (losses are filled in with "-"

71 -2,834,702.62 -4,024,468.39 columns)

Asset impairment losses (losses are filled in with "-"

Column 72 -21,588,938.29 -11,447,368.00)

Asset disposal income (losses are filled in with "-"

73 -8,313,935.18 340,181.43 columns)
Operating profit (losses are listed with "-") 175,366,402.97 157,892,319.43 Add: non-operating income 7. 74 75,216.88 652,775.07

Less: Non-operating expenses 7.75 2,743,707.78 1,486,163.35

Total profits (total losses are listed with "-") 172,697,912.07 157,058,931.15

Less: Income tax expenses 7.76 21,647,160.54 26,405,254.65

Net profit (net loss is listed with "-") 151,050,751.53 130,653,676.50

(1) Classification by business continuity

Net profit from continuing operations (net loss is marked with "-"

151,050,751.53 130,653,676.50 fill in the column)

Net profit from discontinued operations (net loss is marked with "-"

Fill in the column)

(2) Classification according to ownership ownership

Net profit (net loss) attributable to shareholders of the parent company

143,778,780.32 127,764,203.45 (please use "-")

Profit and loss of minority shareholders (net loss is filled in with "-"

7,271,971.21 2,889,473.05 columns)

Net after-tax amount of other comprehensive income -57,189,920.69 55,099,633.19

(1) Other comprehensive assets attributable to the owners of the parent company

-46,354,738.06 34,066,102.61 Net after-tax income

Other comprehensive income that cannot be reclassified into profit or loss

(1) Remeasurement of changes in defined benefit plan

(2) Other comprehensive income that cannot be transferred to profit or loss under the equity method

benefit

(3) Changes in fair value of other equity instrument investments

(4) Changes in the fair value of the company’s own credit risk

Other comprehensive income that will be reclassified into profit and loss -46,354,738.06 34,066,102.61 (1) Other comprehensive income that can be converted into profit and loss under the equity method

(2) Changes in fair value of other debt investments

(3) Financial assets are reclassified and included in other comprehensive income

amount of

(4) Credit impairment provisions for other debt investments

(5) Cash flow hedging reserve

55/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(6) Translation difference of foreign currency financial statements -46,354,738.06 34,066,102.61 (7) Others

(2) Other comprehensive income attributable to minority shareholders

-10,835,182.63 21,033,530.58 net profit after tax

Total comprehensive income 93,860,830.84 185,753,309.69

(1) Comprehensive income attributable to owners of the parent company

97,424,042.26 161,830,306.06 Total profit

(2) Total comprehensive income attributable to minority shareholders

-3,563,211.42 23,923,003.63 amount

8. Earnings per share:

(1) Basic earnings per share (yuan/share) 0.54 0.48

(2) Diluted earnings per share (yuan/share) 0.54 0.48 If a business merger under common control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.

Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

Parent company income statement

January-June 2026

Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

Operating income 19.4 931,472,782.04 903,507,451.31 Less: Operating costs 664,593,027.44 668,848,326.31 Taxes and surcharges 9,765,190.81 10,082,747.17 Sales expenses 94,491,769.59 95,081,132.72 Administrative expenses 89,230,119.08 100,971,973.67 Research and development expenses 29,009,810.50 29,100,619.46 Financial expenses 17,719,897.55 5,673,859.15 Including: interest expense 10,621,686.69 9,943,964.65

Interest income 741,311.14 1,938,675.46 plus: other income 6,138,895.03 6,379,258.11 Investment income (losses are listed with "-") 19.5 49,556,794.51 9,533,328.78 Including: investment income from associates and joint ventures

-779,592.42 -1,542,790.73 profit

Financial assets measured at amortized cost are derecognised

Recognized gains (losses are listed with "-")

Net exposure hedging income (losses are listed with a “-” sign)

Gains from changes in fair value (losses are filled in with a “-” sign

2,096,326.76 1,023,316.84 columns)

Credit impairment loss (losses are listed with "-") 2,090,706.21 -3,443,496.26 Asset impairment losses (losses are listed with "-") -8,879,254.06 -2,082,821.38 Asset disposal income (losses are listed with "-") 1,356.40 201,642.52

Operating profit (losses are listed with "-") 77,667,791.92 5,360,021.44 Plus: non-operating income 22,527.75 168,853.06 Less: non-operating expenses 995,020.38 279,190.15
Total profits (total losses are listed with "-") 76,695,299.29 5,249,684.35 Less: income tax expenses 3,861,648.89 1,287,655.84
Net profit (net loss is listed with "-") 72,833,650.40 3,962,028.51

56/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(1) Net profit from continuing operations (net loss is filled in with "-"

72,833,650.40 3,962,028.51 columns)

(2) Net profit from discontinued operations (net loss is filled in with "-"

column)

5. Net amount of other comprehensive income after tax

(1) Other comprehensive income that cannot be reclassified into profit or loss

Remeasure the changes in defined benefit plan
Other comprehensive income that cannot be transferred to profit or loss under the equity method
Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk

(2) Other comprehensive income that will be reclassified into profit and loss

Other comprehensive income that can be converted to profit or loss under the equity method
Changes in fair value of other debt investments
Financial assets are reclassified and included in other comprehensive income.

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements

7.Others

Total comprehensive income 72,833,650.40 3,962,028.51

7. Earnings per share:

(1) Basic earnings per share (yuan/share)

(2) Diluted earnings per share (yuan/share)

Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

Consolidated cash flow statement from January to June 2026 Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 2,328,761,588.73 2,327,975,913.23 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 118,313,157.71 100,156,924.91 Other cash received related to operating activities 7.78 38,003,063.72 19,134,730.20

Subtotal of cash inflows from operating activities 2,485,077,810.16 2,447,267,568.34 Cash paid for purchasing goods and receiving services 1,606,069,178.37 1,366,574,378.67 Net increase in customer loans and advances

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

57/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 531,118,206.21 502,248,827.32 Various taxes paid 160,754,786.17 200,257,035.63 Other cash paid related to operating activities 7.78 142,238,083.98 217,478,846.15 Subtotal of cash outflows from operating activities 2,440,180,254.73 2,286,559,087.77

Net cash flow generated from operating activities 44,897,555.43 160,708,480.57

2. Cash flow generated from investing activities:

Cash received from recovery of investment 329,329,338.92 170,247,865.38 Cash received from investment income 420,449.32

Disposal of fixed assets, intangible assets and other long-term

42,618,012.20 393,716.81 Net cash amount from asset recovery

Received from disposal of subsidiaries and other business units

net cash

Received other cash related to investing activities VII. 78 1,396,226.42

Subtotal of cash inflows from investing activities 373,764,026.86 170,641,582.19 Purchase and construction of fixed assets, intangible assets and other long-term assets

146,351,156.11 310,651,368.58 Cash paid for assets

Cash paid for investment VII. 78 251,433,367.60 433,909,258.40 Net increase in pledged loans

Obtain payment from subsidiaries and other business units

net cash

Payment of other cash related to investment activities 7.78

Subtotal of cash outflows from investing activities 397,784,523.71 744,560,626.98

Net cash flow generated from investing activities -24,020,496.85 -573,919,044.79

3. Cash flow generated from financing activities:

Cash received from investment 2,750,325.00

Among them: subsidiaries absorb investment income from minority shareholders

2,750,325.00

Cash arrived

Cash received from borrowings 886,000,000.00 1,500,000,000.00 Cash received from other financing activities

Subtotal of cash inflows from financing activities 888,750,325.00 1,500,000,000.00 Cash paid to repay debts 845,800,000.00 630,191,361.11 Cash paid to distribute dividends, profits or repay interest

97,427,455.87 183,009,815.61 cash

Including: shares paid by subsidiaries to minority shareholders

2,200,000.00

Profit, profit

Payment of other cash related to financing activities 7.78 79,859,145.40 10,419,478.94 Subtotal of cash outflows from financing activities 1,023,086,601.27 823,620,655.66

Net cash flow generated from financing activities -134,336,276.27 676,379,344.34

4. The impact of exchange rate changes on cash and cash equivalents

-18,241,185.56 4,631,576.53 impact

Net increase in cash and cash equivalents -131,700,403.25 267,800,356.65 Plus: opening balance of cash and cash equivalents 760,989,683.19 589,333,115.00
Balance of cash and cash equivalents at the end of the period 629,289,279.94 857,133,471.65 Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

Parent company cash flow statement

January-June 2026

58/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 1,788,562,915.73 1,630,762,211.90 Tax refunds received 24,524,908.95 19,812,634.75 Cash received from other operating activities 114,469,836.62 129,428,551.23

Subtotal of cash inflows from operating activities 1,927,557,661.30 1,780,003,397.88 Cash paid for purchasing goods and receiving services 838,312,696.17 1,281,648,513.09 Cash paid to and for employees 116,480,564.54 125,350,057.10 Various taxes paid 52,018,222.23 63,664,168.68 Other cash paid related to operating activities 252,959,767.34 612,786,820.19

Subtotal of cash outflows from operating activities 1,259,771,250.28 2,083,449,559.06 Net cash flow from operating activities 667,786,411.02 -303,446,161.18

2. Cash flow generated from investing activities:

Cash received from recovery of investment 264,128,802.10 145,954,319.51 Cash received from investment income 31,220,449.32 10,000,000.00 Disposal of fixed assets, intangible assets and other long-term assets

29,788,588.20 213,628.32 Net cash recovered from property

Cash received from disposal of subsidiaries and other business units

net amount

Other cash received related to investing activities 1,396,226.42 1,438,340.00

Subtotal of cash inflows from investing activities 326,534,066.04 157,606,287.83 Purchase and construction of fixed assets, intangible assets and other long-term assets

23,063,477.51 51,804,738.52 Cash paid for property

Cash paid for investment 200,370,000.00 300,000,000.00 Cash paid for acquisition of subsidiaries and other business units

net amount

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 223,433,477.51 351,804,738.52

Net cash flow generated from investing activities 103,100,588.53 -194,198,450.69

3. Cash flow generated from financing activities:

Cash received from investment 1,270,000,000.00 Cash received from borrowing 1,000,000.00

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 1,000,000.00 1,270,000,000.00 Cash paid to repay debts 611,000,000.00 400,091,361.11 Cash paid to distribute dividends, profits or pay interest 89,635,489.43 179,739,991.45 Cash payments related to other financing activities 55,919,206.10 1,810,007.67 Subtotal of cash outflows from financing activities 756,554,695.53 581,641,360.23

Net cash flow generated from financing activities -755,554,695.53 688,358,639.77

Impact of exchange rate changes on cash and cash equivalents -1,388,057.04 -264,699.62
Net increase in cash and cash equivalents 13,944,246.98 190,449,328.28 Plus: opening balance of cash and cash equivalents 211,996,563.86 65,147,001.52
Balance of cash and cash equivalents at the end of the period 225,940,810.84 255,596,329.80 Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

59/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Consolidated Statement of Changes in Owner's Equity

January-June 2026

Unit: Yuan Currency: RMB 2026 Half Year

Owner's equity attributable to parent company

Other equity interests - capital reserve

Item Specific minority shareholders' equity Owner's equity Total paid-in capital (or item risk) Other comprehensive income Surplus reserves Undistributed profits Subtotal equity) Other savings insurance Others continued

He prepares stocks and bonds

Prepare

1. Previous year period

265,835,535.00 1,772,090,902.96 46,543,090.89 -3,141,814.03 239,372,019.36 3,459,120,894.80 5,686,734,447.20 275,527,063.36 5,962,261,510.56 Ending balance

Add: Accounting

policy change

upfront difference

Error correction

Others

2. Current year

265,835,535.00 1,772,090,902.96 46,543,090.89 -3,141,814.03 239,372,019.36 3,459,120,894.80 5,686,734,447.20 275,527,063.36 5,962,261,510.56 Initial balance

3. Added in this issue

Less change amount

-1,959,310.00 -73,259,335.59 -46,543,090.89 -46,354,738.06 64,615,912.83 -10,414,379.93 -11,406,878.64 -21,821,258.57 (reduced by "-"

(Fill in the number)

(1) Comprehensive

-46,354,738.06 143,778,780.32 97,424,042.26 -3,549,079.10 93,874,963.16 Total income

(2) All

Investor investment and reduction -1,959,310.00 -44,549,546.52 -46,543,090.89 34,234.36 -5,657,799.53 -5,623,565.18 Less capital

1． owner

Common shares invested -5,657,799.53 -5,657,799.53

60/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other equity instrument holders - invested capital 3. Share-based payments are included in all

-1,959,310.00 -44,549,546.52 -46,543,090.89 34,234.36 34,234.36 Amount of shareholders’ equity

4． Others

(3) Profit

-79,162,867.49 -79,162,867.49 -2,200,000.00 -81,362,867.49Distribution

1． Withdraw profit

-Excess reserve

Extract one

-General risk preparation 3. Distribution to owners (or shareholders) 4. Others

(4) Internal carryover of owners’ equity

1． Convert capital reserve to capital (or share capital) 2. Convert surplus reserves to capital (or share capital) 3. Surplus reserve to make up for losses 4. Changes in defined benefit plans are carried forward to retained earnings

Other comprehensive income carried forward to retained earnings

61/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Others

(5) Special projects

reserve

1． This issue mentions

take

This issue makes

use

(6) Others -28,709,789.07 -28,709,789.07 -28,709,789.07

4. This issue

263,876,225.00 1,698,831,567.37 -49,496,552.09 239,372,019.36 3,523,736,807.63 5,676,320,067.27 264,120,184.72 Ending balance of 5,940,440,251.99

2025 half year

Owner's equity attributable to parent company

Other equity work 1

capital reserve

Project Specification

Minority shareholders’ equity Total paid-in capital (or other comprehensive income items) Owner’s equity Risks Permanently reduced: treasury shares Surplus reserves Undistributed profits Subtotal equity) Other savings Insurance Others Continued

He prepares stocks and bonds

Prepare

1. Previous year period

266,451,202.00 1,786,968,328.68 21,494,683.09 8,945,477.00 224,565,433.41 3,377,815,618.11 5,643,251,376.11 253,146,545.23 5,896,397,921.34 Ending balance

Add: Accounting

policy change

upfront difference

Error correction

Others

2. Current year

266,451,202.00 1,786,968,328.68 21,494,683.09 8,945,477.00 224,565,433.41 3,377,815,618.11 5,643,251,376.11 253,146,545.23 5,896,397,921.34 Initial balance

3. Added in this issue

Less change amount

34,066,102.61 -45,344,940.55 -11,278,837.94 23,923,003.63 12,644,165.69 (reduced by "-"

(Fill in the number)

(1) Comprehensive

34,066,102.61 127,764,203.45 161,830,306.06 23,923,003.63 185,753,309.69 Total income

62/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Owner’s investment and capital reduction

1． Common stock invested by owners

Capital invested by other equity instrument holders 3. The amount of share-based payment included in owners’ equity

4． Others

(3) Profit

-173,109,144.00 -173,109,144.00 -173,109,144.00 allocation

1． Withdrawal from surplus reserve

Extract general risk reserves 3. Distribution to owners (or shareholders) 4. Others

(4) Internal carryover of owners’ equity

1． Convert capital reserve to capital (or share capital) 2. Convert surplus reserves to capital (or share capital) 3. Surplus reserve to cover losses

63/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

Other comprehensive

Consolidated income carried forward

retained earnings

Others

(5) Special projects

reserve

1． This issue mentions

take

This issue makes

use

(6) Others

4. This issue

266,451,202.00 1,786,968,328.68 21,494,683.09 43,011,579.61 224,565,433.41 3,332,470,677.56 5,631,972,538.17 277,069,548.86 5,909,042,087.03 Ending balance

Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of the accounting department: Ma Shuyan

Statement of changes in owner's equity of the parent company

January-June 2026

Unit: Yuan Currency: RMB Other equity work for the first half of 2026

Tools Other items Paid-in capital (or shares Special preference Permanent capital reserve less: treasury shares Comprehensive surplus reserve Undistributed profits Total owners’ equity) Other reserves Continued Income Others

stocks bonds

Closing balance of the previous year 265,835,535.00 1,836,033,496.23 46,543,090.89 239,372,019.36 1,446,536,450.88 3,741,234,410.58 Add: changes in accounting policies

Early error correction

Others

Balance at the beginning of the year 265,835,535.00 1,836,033,496.23 46,543,090.89 239,372,019.36 1,446,536,450.88 3,741,234,410.58

3. Increase or decrease of change funds in this period

-1,959,310.00 -44,549,546.52 -46,543,090.89 -6,329,217.09 -6,294,982.72 (reductions are filled in with "-"

64/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

column)

(1) Total comprehensive income 72,833,650.40 72,833,650.40

(2) Owner’s investment and

-1,959,310.00 -44,549,546.52 -46,543,090.89 34,234.37 Capital reduction

1． Common stock invested by owners

Capital invested by other equity instrument holders

3． Share-based payments are included in all

-1,959,310.00 -44,549,546.52 -46,543,090.89 34,234.37 Amount of shareholders’ equity

4． Others

(3) Profit distribution -79,162,867.49 -79,162,867.49 1. Withdrawal from surplus reserve - 2. to the owner (or stock

-79,162,867.49 -79,162,867.49 East) distribution

3． Others

(4) Internal carryover of owners’ equity

1． Conversion of capital reserves to capital (or share capital)

Conversion of surplus reserves to capital (or share capital)

3． Surplus reserve to make up for losses 4. Changes in defined benefit plans are carried forward to retained earnings

Other comprehensive income carried forward to retained earnings
Others

(5) Special reserves

1． Extract this period

Used in this issue

(6) Others

Ending balance of the current period 263,876,225.00 1,791,483,949.71 239,372,019.36 1,440,207,233.79 3,734,939,427.86

65/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other equity instruments for the first half of 2025, other items, paid-in capital (or equity capital reserves, less: treasury shares, comprehensive surplus reserves, undistributed profits, total owners’ equity), first continued, other income

Stock Debt Reserve

Closing balance of the previous year 266,451,202.00 1,850,910,921.95 21,494,683.09 224,565,433.41 1,477,982,596.17 3,798,415,470.44 Add: changes in accounting policies

Early error correction

Others

Opening balance of the year 266,451,202.00 1,850,910,921.95 21,494,683.09 224,565,433.41 1,477,982,596.17 3,798,415,470.44

3. Increases and decreases in this period

Amount (reduced by "-" -169,147,115.49 -169,147,115.49)

(1) Total comprehensive income

3,962,028.51 3,962,028.51 amount

(2) Owner’s investment

and reduce capital

1． invested by the owner

common stock

Other equity instruments

holders invest capital

3． Share-based payment included

Amount of Owner's Equity

4． Others

(3) Profit distribution -173,109,144.00 -173,109,144.00 1. Withdrawal from surplus reserve

to the owner (or

-173,109,144.00 -173,109,144.00 distribution to shareholders)

3． Others

(4) Owner’s equity

internal carry forward

1． Capital reserve transfer to increase

capital (or equity)

Transfer of surplus reserve to increase

capital (or equity)

66/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

3． Surplus reserve to cover losses

4． Changes in defined benefit plans are carried forward to retained earnings

Other comprehensive income carried forward to retained earnings
Others

(5) Special reserves 1. Extract this period

Used in this issue

(6) Others

Ending balance of the current period 266,451,202.00 1,850,910,921.95 21,494,683.09 224,565,433.41 1,308,835,480.68 3,629,268,354.95 Person in charge of the company: Lu Jianguo Person in charge of accounting work: Shen Hong Person in charge of accounting department: Ma Shuyan

67/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

3. Basic situation of the company

Company profile

√Applicable □Not applicable

Zhende Medical Products Co., Ltd. (hereinafter referred to as the company or the company) was formerly Shaoxing Zhende Medical Dressing Co., Ltd. (hereinafter referred to as Shaoxing Zhende Company). Shaoxing Zhende Company was jointly funded by Shaoxing County Yuexia Lianying Medical and Health Products Factory and Jin Xiaode. It was registered with the Shaoxing Administration for Industry and Commerce on August 18, 1994, and obtained an enterprise legal person business license with the registration number Qihe Zheshaozongzi No. 000920. Shaoxing Zhende Company was established with a registered capital of US$200,000. Shaoxing Zhende Company was changed into a joint-stock company with March 31, 2016 as the base date. It was registered with the Shaoxing Market Supervision Administration on July 15, 2016 and is headquartered in Shaoxing City, Zhejiang Province. The company currently holds a business license with a unified social credit code of 91330600609661634M, a registered capital of 263,876,225.00 yuan, and a total of 263,876,225 shares (face value 1 yuan per share), all of which are tradable shares without sale conditions. The company's shares were listed for trading on the Shanghai Stock Exchange on April 12, 2018.

The company belongs to the medical device industry. The main business activities are the research and development, production and sales of medical dressings. The main products include: basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control and protection.

This financial statement has been approved for external reporting by the ninth meeting of the company's fourth board of directors on August 27, 2026.

4. Basis for preparation of financial statements

Basics of preparation

The company's financial statements are prepared on a going concern basis.

Continuous operation

√Applicable □Not applicable

The Company has no events or circumstances that would cause significant doubts about its ability to continue operating within 12 months from the end of the reporting period.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

√Applicable □Not applicable

Important note: The Company has formulated specific accounting policies and accounting estimates based on the actual production and operation characteristics for transactions or matters such as impairment of financial instruments, inventory, depreciation of fixed assets, construction in progress, intangible assets, revenue recognition, etc.

Statement on compliance with corporate accounting standards

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, changes in shareholders' equity, cash flow and other relevant information.

Accounting period

The company's fiscal year begins on January 1 and ends on December 31 of the Gregorian calendar.

Business cycle

√Applicable □Not applicable

The company's operating business has a short operating cycle, and 12 months is used as the liquidity classification standard for assets and liabilities.

Accounting standard currency

The company and its domestic subsidiaries use RMB as the accounting standard currency. Zhende Medical Supplies (Hong Kong) Co., Ltd., Hong Kong New Starting Point Investment Co., Ltd., ROCIALLE HEALTHCARE LIMITED, ZHENDE ETHIOPIA MEDICAL PLC, MIDMEDS LIMITED, NEW BEGINNINGS (SINGAPORE) PTE LTD, FULLCARE (KENYA) MEDICAL TECHNOLOGY EPZ LIMITED, BOSTON BGECARE INC、DENE HEALTHCARE LIMITED、FULLCARE(KENYA)MEDICALSEZLIMITED、MEDTECHMEDICALMEXICO,S.DE

68/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Overseas subsidiaries such as R.L.DE C.V., MEDTECH MEXICO HEALTH, S.DE R.L.DE C.V., Zhende Medical Japan Co., Ltd., PT INDONESIA FULLCARE MEDICAL and ZHENDE MIDDLE EAST COMPANY are engaged in overseas operations and choose the currency in the main economic environment in which they operate as the accounting standard currency.

Determination method and selection basis of materiality criteria

√Applicable □Not applicable

Project Materiality Criteria

Important individual prepayments for bad debt provision: The individual amount exceeds 0.5% of total assets

Important individual accounts receivable with provision for bad debts: The individual amount exceeds 0.5% of total assets

The bad debt provision for important accounts receivable is recovered or reversed. The individual amount exceeds 0.5% of total assets.

Important write-off accounts receivable, individual amount exceeds 0.5% of total assets

Important other receivables for which bad debt provisions are individually provided The individual amount exceeds 0.5% of total assets

Important write-off of other receivables, the individual amount exceeds 0.5% of the total assets

Important construction projects under construction The total investment in a single project exceeds 0.5% of the total assets

Important other payables aged more than 1 year. The individual amount exceeds 0.5% of the total assets.

Important cash flows from investing activities: the amount of a single item exceeds 5% of total assets

Important overseas operating entities whose total assets/total revenue/total profits exceed the group’s total assets/

15% of total revenue/profit

Important capitalized R&D projects with a single amount exceeding 0.5% of total assets

Important subsidiaries, non-wholly owned subsidiaries, total assets/total revenue/total profits exceed the group’s total assets/

15% of total revenue/profit

Important associates: The book value of a single long-term equity investment exceeds 15% of the group's net assets/the investment income calculated by the equity method exceeds the group's

15% of total profit

Important commitments Commitments or other commitments with a single amount exceeding 3% of total assets

Matters that have an important impact on investor decision-making

Important contingencies: Commitments or other matters with a single amount exceeding 3% of total assets

Matters that have an important impact on investor decision-making

Important post-balance sheet events: profit distribution and other investments after the balance sheet date

matters that have an important impact on the decision-making process

Accounting treatment methods for business combinations under the same control and those not under the same control

√Applicable □Not applicable

Accounting treatment for business combinations under common control

The assets and liabilities acquired by the company in a business merger are measured according to the book value of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date. The company adjusts the capital reserve based on the difference between the book value share of the owner's equity of the merged party in the final controlling party's consolidated financial statements and the book value of the merger consideration paid or the total face value of the shares issued; if the capital reserve is insufficient for offset, the company adjusts the retained earnings.

Accounting treatment for business combinations not under common control

On the acquisition date, the company recognizes the difference between the merger cost and the fair value share of the acquiree's identifiable net assets acquired in the merger as goodwill; if the merger cost is less than the fair value share of the acquiree's identifiable net assets acquired in the merger, the difference is first recognized as goodwill. The fair value of the acquiree's identifiable assets, liabilities and contingent liabilities and the measurement of merger costs are reviewed. After review, if the merger cost is still less than the fair value share of the acquiree's identifiable net assets obtained in the merger, the difference is included in the current profit and loss.

Judgment standards for control and preparation methods of consolidated financial statements

√Applicable □Not applicable

Judgment of control

If it has power over the investee, enjoys variable returns by participating in the relevant activities of the investee, and has the ability to use its power over the investee to affect the amount of its variable returns, it is deemed to be control.

69/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Preparation method of consolidated financial statements

The parent company includes all subsidiaries it controls in the consolidated financial statements. The consolidated financial statements are based on the financial statements of the parent company and its subsidiaries, and based on other relevant information, are prepared by the parent company in accordance with the "Accounting Standards for Business Enterprises No. 33 - Consolidated Financial Statements".

Classification of joint arrangements and accounting treatment of joint operations

√Applicable □Not applicable

Joint arrangements are divided into joint operations and joint ventures.
When the company is a joint venture party, the following items related to the interest share in the joint operation are recognized:

(1) Recognize assets held individually, and recognize assets held jointly based on holding shares;

(2) Recognize liabilities borne individually and liabilities borne jointly based on holding shares;

(3) Recognize the income generated from the sale of the company’s share of joint operating output;

(4) The income generated by the joint operation from the sale of assets is recognized based on the company’s share;

(5) Recognize the expenses incurred individually, and recognize the expenses incurred by joint operations based on the company’s holding share.

Determination standards for cash and cash equivalents

Cash equivalents refer to investments held by an enterprise that have a short term (generally due within three months from the date of purchase), are highly liquid, are easily convertible into known amounts of cash, and have little risk of value changes.

Foreign currency business and foreign currency statement conversion

√Applicable □Not applicable

Foreign currency business conversion

When foreign currency transactions are initially recognized, they are converted into RMB amounts using the approximate spot exchange rate on the date of the transaction. On the balance sheet date, foreign currency monetary items are translated using the spot exchange rate on the balance sheet date. The exchange differences arising from different exchange rates, except for the exchange differences on the principal and interest of special foreign currency borrowings related to the acquisition and construction of assets that qualify for capitalization, are included in the current profit and loss; calculated at historical cost. Non-monetary items in foreign currencies are still translated at the approximate exchange rate of the spot exchange rate on the date of the transaction, without changing their RMB amounts; non-monetary items in foreign currencies measured at fair value are translated at the spot exchange rate on the date when the fair value is determined, and the difference is included in the current profit or loss or other comprehensive income.

Translation of foreign currency financial statements

Assets and liability items in the balance sheet are translated using the spot exchange rate on the balance sheet date; owners' equity items, except for "undistributed profits" items, are translated using the spot exchange rate on the date of the transaction; income and expense items in the income statement are translated using the approximate exchange rate of the spot exchange rate on the date of the transaction. The translation difference of foreign currency financial statements arising from the above translation shall be included in other comprehensive income.

Financial instruments

√Applicable □Not applicable

Classification of financial assets and financial liabilities

Financial assets are divided into the following three categories upon initial recognition: (1) Financial assets measured at amortized cost; (2) Financial assets measured at fair value with changes included in other comprehensive income; (3) Financial assets measured at fair value with changes included in current profits and losses.

Financial liabilities are divided into the following four categories upon initial recognition: (1) Financial liabilities measured at fair value and whose changes are included in current profits and losses; (2) Financial liabilities formed when the transfer of financial assets does not meet the conditions for derecognition or continued involvement in the transferred financial assets; (3) Financial guarantee contracts that do not belong to the above (1) or (2), and loan commitments that do not belong to the above (1) and provide loans at lower than market interest rates; (4) Financial liabilities measured at amortized cost.

Recognition basis, measurement method and derecognition conditions of financial assets and financial liabilities

(1) Recognition basis and initial measurement method of financial assets and financial liabilities

When a company becomes a party to a financial instrument contract, it recognizes a financial asset or financial liability. When a financial asset or financial liability is initially recognized, it is measured at fair value; for financial assets and financial liabilities measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss; for other types of financial assets or financial liabilities, the relevant transaction costs are included in the initial

70/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Confirm the amount. However, if the company's initial recognition of accounts receivable does not contain a significant financing component or the company does not consider the financing component in a contract that does not exceed one year, the initial amount shall be based on the transaction price defined in "Accounting Standards for Business Enterprises No. 14 - Revenue".

(2) Subsequent measurement method of financial assets

Financial assets measured at amortized cost

The actual interest rate method is adopted and subsequent measurement is carried out based on amortized cost. Gains or losses arising from financial assets that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when derecognized, reclassified, amortized according to the effective interest method, or impairment is recognized.

Debt instrument investments measured at fair value and changes included in other comprehensive income

Fair value is used for subsequent measurement. Interest, impairment losses or gains and exchange gains and losses calculated using the effective interest rate method are included in the current profit and loss, and other gains or losses are included in other comprehensive income. When derecognition is terminated, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in the current profit and loss.

Equity instrument investments measured at fair value and changes included in other comprehensive income

Fair value is used for subsequent measurement. Dividends received (except for the recovery part of investment costs) are included in the current profits and losses, and other gains or losses are included in other comprehensive income. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

Financial assets measured at fair value and changes included in current profits and losses

Fair value is used for subsequent measurement, and the resulting gains or losses (including interest and dividend income) are included in the current profit or loss, unless the financial asset is part of a hedging relationship.

(3) Subsequent measurement method of financial liabilities

Financial liabilities measured at fair value and changes included in current profits and losses

Such financial liabilities include trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated as measured at fair value with changes included in current profits and losses. Such financial liabilities are subsequently measured at fair value. The amount of changes in the fair value of financial liabilities designated as at fair value through profit or loss due to changes in the company's own credit risk is included in other comprehensive income, unless such treatment would cause or expand accounting mismatches in profit or loss. Other gains or losses arising from such financial liabilities (including interest expenses, excluding changes in fair value caused by changes in the company's own credit risk) are included in the current profits and losses, unless the financial liabilities are part of a hedging relationship. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

Financial liabilities arising from the transfer of financial assets that do not meet the conditions for derecognition or continued involvement in the transferred financial assets

Measurement shall be carried out in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets".

Financial guarantee contracts that do not fall under 1) or 2) above, and loan commitments that do not fall under 1) above and provide loans at lower than market interest rates

After initial recognition, subsequent measurement shall be based on the higher of the following two amounts: ① The amount of loss provision determined in accordance with the impairment regulations of financial instruments; ② The balance after the initial recognition amount deducts the accumulated amortization amount determined in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 14 - Revenue".

Financial liabilities measured at amortized cost

Measured at amortized cost using the effective interest method. Gains or losses arising from financial liabilities that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when they are derecognized and amortized according to the effective interest method.

(4) Derecognition of financial assets and financial liabilities

Financial assets are derecognised when one of the following conditions is met:

① The contractual right to receive cash flows from financial assets has terminated;

② The financial assets have been transferred, and the transfer meets the provisions of "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets" regarding the derecognition of financial assets.

When the current obligation of a financial liability (or part thereof) has been discharged, the financial liability (or part thereof) shall be derecognised accordingly.

Recognition basis and measurement method of financial asset transfer

If the company transfers almost all the risks and rewards of the ownership of the financial asset, it shall terminate the recognition of the financial asset, and separately recognize the rights and obligations arising or retained in the transfer as assets or liabilities; if it retains almost all the risks and rewards of the ownership of the financial asset, it shall continue to recognize the transferred financial asset. If the company neither transfers nor retains substantially all the risks and rewards of ownership of the financial assets, the following situations will be dealt with: (1) If the company does not retain control of the financial assets, the financial assets will be derecognised and transferred.

71/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

The rights and obligations arising or retained in the transfer are separately recognized as assets or liabilities; (2) If control of the financial assets is retained, the relevant financial assets are recognized to the extent of continued involvement in the transferred financial assets, and the relevant liabilities are recognized accordingly.

If the overall transfer of a financial asset meets the conditions for derecognition, the difference between the following two amounts will be included in the current profit and loss: (1) The book value of the transferred financial asset on the date of derecognition; (2) The sum of the consideration received for the transfer of the financial asset and the amount corresponding to the derecognition part of the cumulative amount of changes in fair value that was originally directly included in other comprehensive income (the financial assets involved are debt instrument investments measured at fair value and their changes are included in other comprehensive income). If a part of a financial asset is transferred, and the transferred part as a whole meets the conditions for derecognition, the entire book value of the financial asset before transfer will be apportioned between the derecognized part and the continued recognition part according to their respective relative fair values on the date of transfer, and the difference between the following two amounts shall be included in the current profit and loss: (1) The book value of the derecognized part; (2) The consideration for the derecognition part is the sum of the amount corresponding to the derecognition part of the cumulative amount of changes in fair value that was originally directly included in other comprehensive income (the financial assets involved in the transfer are debt instrument investments that are measured at fair value and their changes are included in other comprehensive income).

Determination method of fair value of financial assets and financial liabilities

The company determines the fair value of relevant financial assets and financial liabilities using valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information. The company divides the input values used in the valuation technology into the following levels and uses them in sequence:

(1) The first level input value is the unadjusted quoted price in an active market for the same asset or liability that can be obtained on the measurement date;

(2) The second level input value is the directly or indirectly observable input value of the relevant assets or liabilities in addition to the first level input value, including: quotations of similar assets or liabilities in active markets; quotations of the same or similar assets or liabilities in inactive markets; other observable input values other than quotations, such as interest rates and yield curves that are observable during normal quotation intervals; market verification input values, etc.;

(3) The third level input value is the unobservable input value of the relevant assets or liabilities, including interest rates that cannot be directly observed or cannot be verified by observable market data, stock volatility, future cash flows of abandonment obligations assumed in business combinations, financial forecasts made using its own data, etc.

Impairment of financial instruments

Based on expected credit losses, the company calculates financial assets measured at amortized cost, debt instrument investments measured at fair value with changes included in other comprehensive income, contract assets, lease receivables, and financial liabilities classified as measured at fair value with changes included in current profits and losses. Other than loan commitments, financial liabilities that are not measured at fair value through profit or loss, or financial guarantee contracts that are not financial liabilities arising from the transfer of financial assets that do not meet the conditions for derecognition or that continue to be involved in the transferred financial assets are subject to impairment treatment and loss provisions are recognized.

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original effective interest rate, that is, the present value of all cash shortfalls. Among them, credit-impaired financial assets purchased or originated by the company are discounted according to the credit-adjusted actual interest rate of the financial assets.

For purchased or originated financial assets that have suffered credit impairment, the company will only recognize the cumulative change in expected credit losses during the entire duration since initial recognition as loss provisions on the balance sheet date.

For lease receivables, receivables and contract assets formed from transactions regulated by "Accounting Standards for Business Enterprises No. 14 - Revenue" and do not contain significant financing components or the company does not consider financing components in contracts that do not exceed one year, the company uses simplified measurement methods and measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

For financial assets other than the above measurement methods, the company evaluates at each balance sheet date whether its credit risk has increased significantly since initial recognition. If the credit risk has increased significantly since the initial recognition, the company will measure the loss provision based on the amount of expected credit losses during the entire duration; if the credit risk has not increased significantly since the initial recognition, the company will measure the loss provisions based on the amount of expected credit losses of the financial instrument in the next 12 months.

The Company uses reasonable and evidence-based information available, including forward-looking information, to determine whether the credit risk of a financial instrument has increased significantly since initial recognition by comparing the risk of default on the financial instrument on the balance sheet date with the risk of default on the initial recognition date.

On the balance sheet date, if the company determines that a financial instrument has only low credit risk, it is assumed that the credit risk of the financial instrument has not increased significantly since initial recognition.

The company assesses expected credit risk and measures expected credit losses on the basis of a single financial instrument or a combination of financial instruments. When based on a portfolio of financial instruments, the company divides financial instruments into different portfolios based on common risk characteristics.

The company remeasures expected credit losses on each balance sheet date, and the resulting increase or reversal of loss provisions is included in the current profit and loss as impairment losses or gains. For financial assets measured at amortized cost, the loss allowance is reduced by the financial asset

72/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

The book value listed in the balance sheet; for debt investments measured at fair value and whose changes are included in other comprehensive income, the company recognizes its loss provision in other comprehensive income and does not deduct the book value of the financial asset.

Offset of financial assets and financial liabilities

Financial assets and financial liabilities are presented separately in the balance sheet and do not offset each other. However, if the following conditions are met at the same time, the company will present the net amount after offsetting each other in the balance sheet: (1) The company has the legal right to offset the recognized amount, and the legal right is currently enforceable; (2) The company plans to settle on a net basis, or realize the financial assets and pay off the financial liabilities at the same time. For transfers of financial assets that do not meet the conditions for derecognition, the company will not offset the transferred financial assets and related liabilities.

(12) Recognition standards and accrual methods for expected credit losses on accounts receivable and contract assets

Accounts receivable and contract assets with expected credit losses based on combinations of credit risk characteristics

Determine the combination

Portfolio Category Method of Measuring Expected Credit Loss

basis

Bank acceptance bills receivable: With reference to historical credit loss experience, combined with current conditions and predictions of future economic conditions, the expected credit losses are calculated through the default risk exposure and the expected credit loss throughout the duration of the commercial acceptance bill receivable rate.

Refer to historical credit loss experience, combine current conditions and future economic conditions for accounts receivable - aging group

Forecast the aging of accounts receivable and prepare a comparison table between the aging of accounts receivable and the expected credit loss rate.

Calculate expected credit losses

Consolidation Scope Referring to historical credit loss experience, combined with the current situation and future economic conditions, accounts receivable - Consolidation Scope

Forecasting the situation of related parties within the scope of default risk exposure and expected credit losses throughout the duration of the portfolio

[Note] rate to calculate expected credit losses

Refer to historical credit loss experience, combined with current conditions and future economic conditions and other receivables - value-added

Forecast of the nature of payments, through default risk exposure and the next 12 months or the entire deposit tax refund portfolio

Renewal expected credit loss rate, calculate expected credit loss

Refer to historical credit loss experience, combined with current conditions and future economic conditions and other receivables - aging

Forecast the aging of accounts and prepare a comparison combination of the aging of other receivables and the expected credit loss rate

Table, Calculation of Expected Credit Loss

The scope of consolidation refers to historical credit loss experience, combined with the current situation and future economic conditions other receivables - consolidation

Forecast of internal related party conditions, through default risk exposure and related party transaction portfolio within the next 12 months or within the entire deposit scope

[Note] Renewal expected credit loss rate, calculation of expected credit losses

Refer to historical credit loss experience, combined with current conditions and future economic conditions and other receivables - futures

Forecast of the nature of deposits, through default risk exposure and the next 12 months or the entire deposit portfolio

Renewal expected credit loss rate, calculate expected credit loss

[Note] It is a company within the scope of the consolidated financial statements of Zhende Medical Products Co., Ltd.

Comparison table of aging and expected credit loss rate of aging portfolio

Expected credit loss rate of other receivables Aging Expected credit loss rate of accounts receivable (%)

(%)

Within 1 year (inclusive, the same below) 5.00 5.00

1-2 years 10.00 10.00

2-3 years 30.00 30.00

More than 3 years 100.00 100.00

The aging of accounts receivable/other receivables is calculated from the date of initial recognition.

Recognition standards for accounts receivable and contract assets for which expected credit losses are to be calculated individually

For receivables and contract assets whose credit risk is significantly different from the combined credit risk, the company accrues expected credit losses on an individual basis.

73/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Notes receivable

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Account aging calculation method based on aging confirmation credit risk characteristics combination

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Judgment criteria for individual provision of bad debt provisions based on individual provision

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Accounts receivable

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Account aging calculation method based on aging confirmation credit risk characteristics combination

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Judgment criteria for single provision based on the determination of individual provision for bad debts

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Receivables Financing

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Account aging calculation method based on aging confirmation credit risk characteristics combination

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Judgment criteria for individual provision of bad debt provisions based on individual provision

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Other receivables

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Account aging calculation method based on aging confirmation credit risk characteristics combination

√Applicable □Not applicable

74/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Judgment criteria for individual provision of bad debt provisions based on individual provision

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Inventory

√Applicable □Not applicable

Inventory categories, issue pricing methods, inventory systems, amortization methods for low-value consumables and packaging √ Applicable □ Not applicable

Classification of inventory

Inventories include finished products or commodities held for sale in daily activities, work-in-progress in the production process, materials and supplies consumed in the production process or in the process of providing services, etc.

Valuation method for issued inventory

Inventories are issued using the weighted average method at the end of the month.

Inventory inventory system

The inventory system of inventories is the perpetual inventory system.

Amortization method for low-value consumables and packaging materials

(1) Low value consumables

Amortization is carried out according to the one-time write-off method based on the number of uses.

(2) Packaging

Amortization is carried out according to the one-time write-off method based on the number of uses.

Recognition standards and accrual methods for inventory depreciation provisions

√Applicable □Not applicable

On the balance sheet date, inventories are measured at the lower of cost and net realizable value, and inventory depreciation provisions are made based on the difference between cost and net realizable value. For inventories that are directly used for sale, the net realizable value is determined by the estimated selling price of the inventory minus the estimated sales expenses and related taxes in the normal production and operation process; for inventories that need to be processed, the estimated selling price of the finished products produced during the normal production and operation process is deducted by the estimated costs to be incurred upon completion. The amount after the estimated sales expenses and related taxes is determined to determine its net realizable value; on the balance sheet date, if part of the same inventory has a contract price and other parts do not have a contract price, its net realizable value is determined separately and compared with its corresponding cost to determine the amount of provision or reversal of inventory depreciation provisions.

The combination categories and basis for determining inventory depreciation reserves according to the combination, and the basis for determining the net realizable value of different types of inventories □ Applicable √ Not applicable

Calculation method and basis for determining the net realizable value of each warehouse age combination based on the inventory age confirmation of the net realizable value □Applicable √Not applicable

Contract assets

□Applicable √Not applicable

Non-current assets or disposal groups held for sale

□Applicable √Not applicable

Recognition standards and accounting treatment methods for non-current assets or disposal groups classified as held for sale √ Applicable □ Not applicable

Classification of non-current assets or disposal groups held for sale

75/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

The company classifies non-current assets or disposal groups that meet the following conditions into the category held for sale: (1) According to the practice of selling such assets or disposal groups in similar transactions, they can be sold immediately under the current conditions; (2) The sale is very likely to occur, that is, the company has made a resolution on the sale plan and obtained a firm purchase commitment, and the sale is expected to be completed within one year.

If the non-current assets or disposal groups acquired by the company specifically for resale meet the condition of "the sale is expected to be completed within one year" on the acquisition date, and are likely to meet other classification conditions for the held-for-sale category in the short term (usually 3 months), they will be classified as held-for-sale category on the acquisition date.

If a transaction between unrelated parties fails to be completed within one year due to one of the following reasons beyond the control of the company, and the company is still committed to selling non-current assets or disposal groups, the non-current assets or disposal groups will continue to be classified as held for sale: (1) The buyer or other party unexpectedly sets conditions that lead to the postponement of the sale, and the company has taken timely action on these conditions, and is expected to be able to successfully resolve the delay factors within one year from the setting of the conditions that lead to the postponement of the sale; (2) Due to rare circumstances, the sale of non-current assets or disposal groups held for sale failed to be completed within one year. The company has taken necessary measures in response to these new circumstances within the first year and has re-satisfied the conditions for classification into the held-for-sale category.

Accounting treatment of non-current assets or disposal groups held for sale

(1) Initial measurement and subsequent measurement

During initial measurement and re-measurement on the balance sheet date of non-current assets or disposal groups held for sale, if their book value is higher than the net amount of fair value minus selling expenses, the book value will be written down to the net amount of fair value minus selling expenses. The amount of the write-down is recognized as an asset impairment loss and included in the current profit and loss, and an impairment provision for assets held for sale is made at the same time.

For non-current assets or disposal groups that are classified as held for sale on the acquisition date, at the time of initial measurement, the initial measurement amount and the net amount of fair value minus selling expenses are compared assuming that they are not classified as held for sale, and the lower of the two is measured. Except for non-current assets or disposal groups acquired in business combinations, the difference arising from the initial measurement amount of non-current assets or disposal groups based on their fair value minus selling expenses shall be included in the current profit and loss.

For the amount of asset impairment loss recognized by a disposal group held for sale, the book value of the goodwill in the disposal group is first deducted, and then the book value is deducted proportionally based on the proportion of the book value of each non-current asset in the disposal group.

No depreciation or amortization is provided for non-current assets held for sale or non-current assets in the disposal group, and interest and other expenses on liabilities in the disposal group held for sale continue to be recognized.

(2) Accounting treatment for reversal of asset impairment losses

If the net amount of the fair value of non-current assets held for sale less selling expenses increases on subsequent balance sheet dates, the previously written-down amount will be restored and reversed within the amount of asset impairment losses recognized after being classified as held-for-sale, and the reversed amount will be included in the current profit and loss. Impairment losses on assets recognized before being classified as held for sale are not reversed.

If the net amount of the fair value of the disposal group held for sale less selling expenses increases on the subsequent balance sheet date, the previously written-down amount will be restored and reversed within the amount of asset impairment losses recognized after the non-current assets were classified as held-for-sale, and the reversed amount will be included in the current profit and loss. The book value of goodwill that has been deducted and the asset impairment losses recognized before non-current assets are classified as held for sale are not reversed.

The subsequent reversal amount of asset impairment losses recognized by the disposal group held for sale will increase its book value in proportion based on the proportion of the book value of various non-current assets in the disposal group except goodwill.

(3) Accounting treatment for no longer being classified as held for sale and derecognition

When a non-current asset or disposal group is no longer classified as a held-for-sale category because it no longer meets the conditions for classification into a held-for-sale category or when a non-current asset is removed from a held-for-sale disposal group, it is measured according to the lower of the following two: 1) The book value before being classified as a held-for-sale category, adjusted for the depreciation, amortization or impairment that would have been recognized if it was not classified as a held-for-sale category; 2) The recoverable amount.

When non-current assets or disposal groups held for sale are derecognised, the unrecognized gains or losses will be included in the current profits and losses.

Determination standards and presentation methods for discontinued operations

√Applicable □Not applicable

The company separately lists profits and losses from continuing operations and profits and losses from discontinued operations in the income statement. Impairment losses and reversal amounts from discontinued operations and other operating profits and losses as well as disposal gains and losses are presented as profits and losses from discontinued operations. For discontinued operations reported in the current period, the information originally presented as profits and losses from continuing operations will be re-presented as profits and losses from discontinued operations in the comparable period in the financial statements for the current period. If the discontinued operations no longer meet the conditions for classification into the held-for-sale category, the information originally presented as profits and losses from discontinued operations will be re-presented as profits and losses from continuing operations for the comparable period in the current financial statements.

76/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Long-term equity investment

√Applicable □Not applicable

Judgment of joint control and significant influence

If there is shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the parties sharing control rights, it is deemed to be joint control. Having the power to participate in decision-making on the financial and operating policies of the investee, but not being able to control or jointly control the formulation of these policies with other parties, is deemed to have significant influence.

Determination of investment costs

(1) Formed through a merger of enterprises under common control, if the merging party pays cash, transfers non-cash assets, assumes debts or issues equity securities as the merger consideration, the initial investment cost shall be the share of the book value of the owner's equity of the merged party in the consolidated financial statements of the ultimate controlling party on the date of merger. The difference between the initial investment cost of the long-term equity investment and the book value of the merger consideration paid or the total face value of the shares issued is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

The company realizes the long-term equity investment formed by the merger of enterprises under the same control step by step through multiple transactions to determine whether it is a "package transaction". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package deal", on the merger date, the initial investment cost will be determined based on the share of the book value of the combined party's net assets in the ultimate controlling party's consolidated financial statements that should be enjoyed after the merger. The difference between the initial investment cost of the long-term equity investment on the merger date and the book value of the long-term equity investment before the merger plus the book value of the new payment for further shares acquired on the merger date is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

(2) If it is formed by a business combination not under the same control, the fair value of the merger consideration paid on the purchase date shall be regarded as its initial investment cost.

The company realizes the long-term equity investment formed by the merger of enterprises not under common control step by step through multiple transactions, and distinguishes individual financial statements and consolidated financial statements for relevant accounting treatment:

In individual financial statements, the sum of the book value of the original equity investment plus the new investment cost is regarded as the initial investment cost that is calculated according to the cost method.
In the consolidated financial statements, determine whether it is a "package deal". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package transaction", the equity of the purchased party held before the purchase date will be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value will be included in the investment income of the current period; if the equity of the purchased party held before the purchase date involves other comprehensive income under equity method accounting, the other comprehensive income related to it will be converted into the current period income on the purchase date. However, other comprehensive income arising from changes in the net liabilities or net assets of the defined benefit plan due to the remeasurement of the investee is excluded.

(3) Except for business mergers: if it is obtained by paying cash, the actual purchase price paid will be used as its initial investment cost; if it is obtained by issuing equity securities, its initial investment cost will be based on the fair value of the equity securities issued; if it is obtained by debt restructuring, its initial investment cost will be determined according to "Accounting Standards for Business Enterprises No. 12 - Debt Reorganization"; if it is obtained by exchanging non-monetary assets, its initial investment cost will be determined according to "Accounting Standards for Business Enterprises No. 7 - Exchange of Non-monetary Assets".

Subsequent measurement and profit and loss recognition methods

Long-term equity investments that control the invested unit are accounted for using the cost method; long-term equity investments in associates and joint ventures are accounted for using the equity method.

Methods for disposing of investments in subsidiaries step by step through multiple transactions until loss of control

(1) Principles for judging whether it is a “package deal”

If the equity investment in a subsidiary is disposed of in stages through multiple transactions until it loses control, the company shall determine whether the step-by-step transaction is a "package transaction" based on the transaction agreement terms of each step of the step-by-step transaction, the disposal consideration obtained respectively, the object of the equity sale, the disposal method, the time of disposal, and other information. If the terms, conditions and economic impact of each transaction meet one or more of the following conditions, it usually indicates that multiple transactions are a "package deal":

These transactions are entered into at the same time or with consideration of mutual effects;
These transactions as a whole can achieve a complete business result;
The occurrence of one transaction depends on the occurrence of at least one other transaction;
A transaction is uneconomical on its own but is economical when considered together with other transactions.

(2) Accounting treatment that does not belong to “package deal”

Individual financial statements

For the equity disposed of, the difference between its book value and the actual price obtained shall be included in the current profit and loss. For the remaining equity, if it still has a significant influence on the invested unit or exercises joint control with other parties, it will be converted to equity method accounting; the invested unit can no longer be accounted for.

77/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If an investment unit exercises control, joint control or significant influence, accounting shall be carried out in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments".

Consolidated financial statements

Before the loss of control, the difference between the disposal price and the share of the subsidiary's net assets corresponding to the disposal of the long-term equity investment continuously calculated from the date of purchase or merger will be adjusted to the capital reserve (capital premium). If the capital premium is insufficient to offset, the retained earnings will be offset.

When control over the atomic company is lost, the remaining equity will be remeasured according to its fair value on the date of loss of control. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income for the period when control is lost, and goodwill shall be offset at the same time. Other comprehensive income related to the equity investment in the original subsidiary shall be converted into investment income for the current period when control is lost.

(3) Accounting treatment for “package transactions”

Individual financial statements

Each transaction is accounted for as a transaction in which a subsidiary is disposed of and control is lost. However, the difference between the price of each disposal before the loss of control and the book value of the long-term equity investment corresponding to the disposal investment is recognized as other comprehensive income in individual financial statements, and is transferred to the profit and loss of the current period when control is lost.

Consolidated financial statements

Each transaction is accounted for as a transaction in which a subsidiary is disposed of and control is lost. However, before the loss of control, the difference between the price of each disposal and the share of the subsidiary's net assets corresponding to the disposal investment is recognized as other comprehensive income in the consolidated financial statements, and is transferred to the profits and losses of the current period when the control is lost.

Investment real estate

Not applicable

Fixed assets

(1) Confirmation conditions

√Applicable □Not applicable

Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a useful life of more than one accounting year. Fixed assets are recognized when it is likely that economic benefits will flow in and the cost can be measured reliably.

(2) Depreciation method

√Applicable □Not applicable

Category Depreciation method Depreciation period (years) Residual value rate Annual depreciation rate Houses and buildings Year-averaged method 20 5% 4.75%

Machinery and equipment Straight-line method 3-10 5% 31.67%-9.50% Machinery and equipment Double-declining balance method 10 5% 9.50%

Means of transportation Average age method 3-5 5% 31.67-19.00% Other equipment Average age method 3-10 5% 31.67-9.50%

land ownership [note]

[Note] The land ownership of the Mexican subsidiary is permanent property and no depreciation is required.

Projects under construction

√Applicable □Not applicable

Construction in progress is recognized when it is likely that economic benefits will flow in and the cost can be measured reliably. Construction in progress is measured based on the actual costs incurred before the asset reaches its intended usable condition.
When the project under construction reaches the intended usable state, it will be transferred to fixed assets according to the actual cost of the project. If the asset has reached the intended usable state but has not yet completed the final settlement, the estimated value will be transferred to fixed assets first. After the final settlement is completed, the original temporary estimated value will be adjusted according to the actual cost, but the originally accrued depreciation will not be adjusted.

78/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Category Standards and timing for transferring construction in progress to fixed assets

Houses and buildings pass the preliminary acceptance and reach the intended usable state or the standards specified in the contract

After installation and commissioning, the machinery and equipment meet the design requirements or standards stipulated in the contract.

Other equipment shall meet the design requirements or standards stipulated in the contract after installation and commissioning.

Borrowing costs

√Applicable □Not applicable

Recognition principles for capitalization of borrowing costs

If the borrowing costs incurred by the company can be directly attributed to the purchase, construction or production of assets that meet the capitalization conditions, they shall be capitalized and included in the cost of the relevant assets; other borrowing costs shall be recognized as expenses when incurred and included in the current profits and losses.

Borrowing cost capitalization period

(1) Capitalization begins when borrowing costs meet the following conditions at the same time: 1) Asset expenditures have occurred; 2) Borrowing costs have been incurred; 3) The purchase, construction or production activities necessary to bring the asset to its intended usable or salable state have begun.

(2) If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs is suspended; the borrowing costs incurred during the interruption are recognized as current expenses until the acquisition, construction or production activities of the asset are restarted.

(3) When the assets purchased, constructed or produced that meet the capitalization conditions reach the intended usable or salable state, the capitalization of borrowing costs ceases.

Capitalization rate and capitalization amount of borrowing costs

If a special loan is borrowed for the purpose of purchasing, constructing or producing assets that meet the capitalization conditions, the interest expense actually incurred on the special loan in the current period (including the amortization of the discount or premium determined according to the actual interest rate method) shall be deducted from the interest income obtained from depositing the unused borrowed funds in the bank or the investment income obtained from temporary investment. The amount of interest that should be capitalized is determined based on the amount after profit; if general borrowings are occupied for the purchase, construction or production of assets that meet the capitalization conditions, the amount of interest that should be capitalized on the general borrowings is calculated and determined based on the weighted average of the cumulative asset expenditures exceeding the special borrowings multiplied by the capitalization rate of the general borrowings occupied.

Biological assets

□Applicable √Not applicable

Oil and gas assets

□Applicable √Not applicable

Intangible assets

(1) Useful life and its basis for determination, estimation, amortization method or review procedure

√Applicable □Not applicable

Intangible assets include land use rights, information systems, management software, franchise rights, patent rights and non-patented technologies, pollution discharge rights, etc., and are initially measured at cost.
Intangible assets with limited service life shall be amortized systematically and reasonably within the service life according to the expected realization method of the economic benefits related to the intangible asset. If the expected realization method cannot be reliably determined, the straight-line method shall be used for amortization. The details are as follows:

Item Service life Basis for determination of service life Amortization method

Land use rights 50 years, 99 years Property rights registration period Straight-line method

Information system 10 years Estimated economic useful life Straight-line method

Management software 5-10 years Estimated economic useful life Straight-line method

Franchise 3-10 years Estimated economic useful life Straight-line method

79/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Item Service life Basis for determination of service life Amortization method

Patents and non-patented technologies 5-10 years Estimated economic useful life Straight-line method

Emission rights 5 years Warrant registration period Straight-line method

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

√Applicable □Not applicable

(1) Personnel labor costs

Personnel labor expenses include the wages and salaries of the company's R&D personnel, basic pension insurance premiums, basic medical insurance premiums, unemployment insurance premiums, work-related injury insurance premiums, maternity insurance premiums and housing provident funds, as well as labor costs for external R&D personnel.

If R&D personnel serve multiple R&D projects at the same time, labor costs will be recognized based on the working hours records of R&D personnel for each R&D project provided by the company's management department, and will be allocated proportionally among different R&D projects.

For those who are directly engaged in R&D activities or external R&D personnel who are also engaged in non-R&D activities, the company will allocate the actual labor costs incurred by the R&D personnel between R&D expenses and production and operating expenses based on reasonable methods such as the proportion of actual working hours based on the R&D personnel’s working time records in different positions.

(2) Direct investment costs

Direct investment expenses refer to the actual expenditures incurred by the company to implement research and development activities. Including: 1) Direct consumption of materials, fuel and power costs; 2) Development and manufacturing costs of molds and process equipment used for intermediate testing and product trial production, purchase costs for samples, prototypes and general testing methods that do not constitute fixed assets, and inspection fees for trial products; 3) Operation and maintenance, adjustment, inspection, detection, repair and other costs of instruments and equipment used for research and development activities.

(3) Depreciation expenses and long-term prepaid expenses

Depreciation expenses refer to the depreciation expenses of instruments, equipment and buildings in use used for research and development activities.

If instruments, equipment, and buildings in use are used for R&D activities and are also used for non-R&D activities, necessary records shall be made of the use of such instruments, equipment, and buildings in use, and the actual depreciation expenses incurred shall be allocated between R&D expenses and production and operating expenses in a reasonable manner based on factors such as actual working hours and usage area.

Long-term deferred expenses refer to the long-term deferred expenses incurred during the reconstruction, modification, decoration and repair of R&D facilities. They are collected based on actual expenditures and amortized evenly in installments within the specified period.

(4) Amortization expense of intangible assets

Amortization expenses of intangible assets refer to the amortization expenses of software, intellectual property, non-patented technology (proprietary technology, licenses, design and calculation methods, etc.) used in research and development activities.

(5) Design fees

Design expenses refer to the expenses incurred in conceiving, developing and manufacturing new products and new processes, and designing processes, technical specifications, procedures, operating characteristics, etc., including expenses related to creative design activities to obtain innovative, creative, and breakthrough products.

(6) Commissioned external research and development expenses

Entrusted external research and development expenses refer to the expenses incurred by the company entrusting other institutions or individuals at home and abroad to conduct research and development activities (the results of research and development activities are owned by the company and are closely related to the company's main business).

(7) Other expenses

Other expenses refer to other expenses directly related to research and development activities in addition to the above expenses, including technical book materials fees, data translation fees, expert consultation fees, high-tech R&D insurance fees, retrieval, demonstration, review, identification, and acceptance fees for R&D results, application fees, registration fees, agency fees for intellectual property rights, conference fees, travel expenses, communication fees, etc.

Expenditures in the research phase of internal research and development projects are included in the current profits and losses when incurred. Expenditures in the development phase of internal research and development projects are recognized as intangible assets if they meet the following conditions: (1) It is technically feasible to complete the intangible asset so that it can be used or sold; (2) There is the intention to complete the intangible asset and use or sell it; (3) The way in which the intangible asset generates economic benefits includes being able to prove that there is a market for the products produced using the intangible asset or that the intangible asset itself has a market. If the intangible asset will be used internally, its usefulness can be proven; (4) It has sufficient technical, financial and other resource support to complete the development of the intangible asset and has the ability to use or sell the intangible asset; (5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.
The company’s specific standards for dividing the research phase expenditures and development phase expenditures of internal research and development projects:

80/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Research stage: The company's project feasibility investigation, project establishment and preliminary research and development are considered as the research stage. The starting point of the research phase is when the project team submits the project approval materials to the company, and the end point is when the project passes the review of design and development. Expenditures in the research phase of internal research and development projects are included in the current profits and losses when incurred.

Development stage: The development stage is from the time the company's project passes the review of design and development to the stage when the project applies for a medical device registration certificate or filing certificate. The starting point of the development stage is when the project passes the review of design and development, and the end point is when the project obtains a medical device registration certificate or filing certificate. When a company enters the development stage, its project expenditures are first accounted for in detail in the "Development Expenditure" account. If the capitalization conditions are met, they will be transferred to the "Intangible Assets" account for detailed accounting when the project obtains a medical device registration certificate or filing certificate and forms an intangible asset.

Impairment of long-term assets

√Applicable □Not applicable

For long-term assets such as long-term equity investments, fixed assets, projects under construction, right-of-use assets, and intangible assets with limited useful lives, if there are signs of impairment on the balance sheet date, the recoverable amount is estimated. Goodwill and intangible assets with indefinite useful lives formed due to business combinations are subject to impairment testing every year regardless of whether there are signs of impairment. Goodwill is tested for impairment in combination with its related asset groups or combinations of asset groups.

If the recoverable amount of the above-mentioned long-term assets is lower than its book value, the asset impairment provision shall be recognized based on the difference and included in the current profit and loss.

Long-term deferred expenses

√Applicable □Not applicable

Long-term deferred expenses are calculated as expenses that have been spent and have an amortization period of more than 1 year (excluding 1 year). Long-term deferred expenses are recorded according to the actual amount incurred, and are amortized evenly over the benefit period or a specified period. If a long-term deferred expense item cannot benefit future accounting periods, all the amortized value of the item that has not been amortized will be transferred to the current profit and loss.

Contract liabilities

√Applicable □Not applicable

Companies present contract assets or contract liabilities on their balance sheets based on the relationship between the fulfillment of performance obligations and payments from customers. The company will present the net amount after offsetting contract assets and contract liabilities under the same contract.

The Company presents the right to receive consideration from customers that is unconditional (i.e., dependent only on the passage of time) as receivables and the right to receive consideration for goods transferred to the customer (that right is dependent on factors other than the passage of time) as a contract asset.

The Company presents obligations to transfer goods to customers for consideration received or receivable from customers as contract liabilities.

Employee compensation

(1) Accounting treatment of short-term compensation

√Applicable □Not applicable

During the accounting period when employees provide services to the company, the actual short-term compensation is recognized as a liability and included in the current profit and loss or related asset costs.

(2) Accounting treatment of post-employment benefits

√Applicable □Not applicable

Post-employment benefits are divided into defined contribution plans and defined benefit plans.

(1) During the accounting period when employees provide services to the company, the deposit amount payable calculated according to the defined contribution plan is recognized as a liability and included in the current profit and loss or related asset costs.

(2) The accounting treatment of defined benefit plans usually includes the following steps:

Based on the expected cumulative benefit unit method, use unbiased and mutually consistent actuarial assumptions to estimate relevant demographic variables and financial variables, measure the obligations arising from the defined benefit plan, and determine the period to which the relevant obligations belong. At the same time, the obligations arising from the defined benefit plan are discounted to determine the present value of the defined benefit plan obligations and the current service cost;

81/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

If there are assets in the defined benefit plan, the deficit or surplus formed by deducting the present value of the defined benefit plan obligations from the fair value of the defined benefit plan assets is recognized as a net liability or net asset of the defined benefit plan. If a defined benefit plan has a surplus, the net assets of the defined benefit plan shall be measured at the lower of the surplus of the defined benefit plan and the asset upper limit;
At the end of the period, the employee compensation costs generated by the defined benefit plan are recognized as service costs, net interest on the net liabilities or net assets of the defined benefit plan, and changes caused by remeasurement of the net liabilities or net assets of the defined benefit plan. Among them, service costs and net liabilities or net assets of the defined benefit plan are The net interest is included in the current profit and loss or related asset costs, and the changes resulting from the remeasurement of the net liabilities or net assets of the defined benefit plan are included in other comprehensive income, and are not allowed to be transferred back to profit or loss in subsequent accounting periods, but these amounts recognized in other comprehensive income can be transferred within the scope of equity.

(3) Accounting treatment of dismissal benefits

√Applicable □Not applicable

For dismissal benefits provided to employees, the employee compensation liabilities arising from the dismissal benefits are recognized and included in the current profit and loss at the earliest of the following two situations: (1) when the company cannot unilaterally withdraw the dismissal benefits provided due to the termination of labor relations plan or layoff proposal; (2) when the company recognizes costs or expenses related to the restructuring involving the payment of dismissal benefits.

(4) Accounting treatment methods for other long-term employee benefits

√Applicable □Not applicable

Other long-term benefits provided to employees that meet the conditions of the defined contribution plan shall be accounted for in accordance with the relevant provisions of the defined contribution plan; other long-term benefits shall be accounted for in accordance with the relevant provisions of the defined benefit plan. In order to simplify the relevant accounting treatment, the employee compensation costs incurred are recognized as service costs, net interest on other long-term employee benefit net liabilities or net assets, and the total net amount of the changes resulting from the remeasurement of other long-term employee benefit net liabilities or net assets shall be included in the current profit and loss or related asset costs.

Estimated liabilities

√Applicable □Not applicable

Obligations resulting from contingencies such as external guarantees, litigation matters, product quality guarantees, loss-making contracts, etc., become current obligations borne by the company. When the performance of the obligation is likely to cause economic benefits to flow out of the company, and the amount of the obligation can be reliably measured, the company will recognize the obligation as an estimated liability.
The company initially measures estimated liabilities based on the best estimate of the expenditure required to fulfill relevant current obligations, and reviews the book value of estimated liabilities on the balance sheet date.
Share-based payment

√Applicable □Not applicable

Types of share-based payment

Including equity-settled share-based payments and cash-settled share-based payments.

Accounting treatments related to the implementation, modification, and termination of share-based payment plans

(1) Equity-settled share-based payment

Equity-settled share-based payments that become exercisable immediately after grant in exchange for employee services will be included in relevant costs or expenses based on the fair value of the equity instrument on the date of grant, and the capital reserve will be adjusted accordingly. For equity-settled share-based payments in exchange for employee services that are vested upon completion of services within the waiting period or upon meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the number of exercisable equity instruments and the fair value on the date of grant of the equity instrument, the services obtained in the current period are included in the relevant costs or expenses, and the capital reserve is adjusted accordingly.

For equity-settled share-based payments in exchange for services from other parties, if the fair value of the other party's services can be reliably measured, it will be measured based on the fair value of the other party's services on the date of acquisition; if the fair value of the other party's services cannot be reliably measured, but the fair value of the equity instrument can be measured reliably, it will be measured based on the fair value of the equity instrument on the date of service acquisition, and the relevant costs or expenses will be included, and the owner's equity will be increased accordingly.

(2) Cash-settled share-based payment

Cash-settled share-based payments that are exercisable immediately after grant in exchange for employee services will be included in relevant costs or expenses based on the fair value of the company's liabilities on the date of grant, with corresponding increases in liabilities. The right can only be vested after completing the services within the waiting period or meeting the specified performance conditions.

82/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

For cash-settled share-based payments in exchange for employee services, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation and the fair value of the liabilities borne by the company, the services obtained in the current period will be included in the relevant costs or expenses and corresponding liabilities.

(3) Modification and termination of share-based payment plan

If the modification increases the fair value of the equity instruments granted, the company will recognize the increase in the services obtained according to the increase in the fair value of the equity instruments; if the modification increases the number of equity instruments granted, the company will recognize the increased fair value of the equity instruments as an increase in the services obtained accordingly; if the company modifies the vesting conditions in a way that is beneficial to employees, the company will consider the modified vesting conditions when processing the vesting conditions.

If the modification reduces the fair value of the equity instruments granted, the company will continue to recognize the amount of services obtained based on the fair value of the equity instruments on the date of grant, regardless of the decrease in the fair value of the equity instruments; if the modification reduces the number of equity instruments granted, the company will treat the reduction as the cancellation of the equity instruments granted; if the vesting conditions are modified in a way that is unfavorable to employees, the modified vesting conditions will not be considered when processing the vesting conditions.

If the company cancels the granted equity instruments or settles the granted equity instruments during the waiting period (except for cancellation due to failure to meet vesting conditions), the cancellation or settlement will be treated as accelerated vesting, and the amount originally recognized during the remaining waiting period will be immediately recognized.

Preferred shares, perpetual bonds and other financial instruments

□Applicable √Not applicable

Income

(1) Disclose the accounting policies adopted for revenue recognition and measurement according to business type

√Applicable □Not applicable

Principles of revenue recognition

On the contract commencement date, the company evaluates the contract, identifies each individual performance obligation contained in the contract, and determines whether each individual performance obligation is to be performed within a certain period of time or at a certain point in time.

When one of the following conditions is met, the performance obligation is fulfilled within a certain period of time; otherwise, the performance obligation is fulfilled at a certain point in time: (1) The customer obtains and consumes the economic benefits brought by the company's performance while the company performs the contract; (2) The customer is able to control the goods under construction during the company's performance; (3) The goods produced during the company's performance have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period.

For performance obligations performed within a certain period of time, the company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred are expected to be compensated, revenue shall be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined. For performance obligations fulfilled at a certain point in time, revenue is recognized at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods, the company considers the following signs: (1) the company has a current right to receive payment for the goods, that is, the customer has a current payment obligation for the goods; (2) the company has transferred the legal ownership of the goods to the customer, that is, the customer already has legal ownership of the goods; (3) the company has physically transferred the goods to the customer, that is, the customer has physical possession of the goods; (4) The company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity; (5) the customer has accepted the commodity; (6) other indications that the customer has obtained control of the commodity.

Income measurement principles

(1) The company measures revenue based on the transaction price allocated to each individual performance obligation. The transaction price is the amount of consideration that the company expects to be entitled to receive for the transfer of goods or services to the customer, excluding amounts collected on behalf of third parties and amounts expected to be returned to the customer.

(2) If there is variable consideration in the contract, the company determines the best estimate of the variable consideration based on the expected value or the most likely amount, but the transaction price including the variable consideration shall not exceed the amount at which a significant reversal of the accumulated recognized revenue is unlikely to occur when the relevant uncertainty is eliminated.

(3) If there is a significant financing component in the contract, the company determines the transaction price based on the amount payable in cash when the customer obtains control of the goods or services. The difference between the transaction price and the contract consideration is amortized using the effective interest method during the contract period.

(4) If the contract contains two or more performance obligations, the company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods promised by each individual performance obligation on the contract commencement date.

Specific methods of revenue recognition

83/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

The company's basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, infection control and protection and other product sales business are performance obligations performed at a certain point in time. Domestic sales revenue is recognized when the company delivers the products to the delivery location agreed in the contract and the customer confirms acceptance, the price has been collected or the right to receive payment has been obtained, and the relevant economic benefits are likely to flow in. Export sales revenue is recognized when the company has declared the product to customs according to the contract, obtained the bill of lading, collected payment or obtained the right to receive payment, and the relevant economic benefits are likely to flow in.

(2) Similar businesses using different business models involve different revenue recognition methods and measurement methods

□Applicable √Not applicable

Contract costs

□Applicable √Not applicable

Government subsidies

√Applicable □Not applicable

Government subsidies are recognized when the following conditions are met at the same time: (1) the company can meet the conditions attached to the government subsidy; (2) the company can receive the government subsidy. If the government subsidy is a monetary asset, it shall be measured according to the amount received or receivable. If the government subsidy is a non-monetary asset, it shall be measured at fair value; if the fair value cannot be obtained reliably, it shall be measured at the nominal amount.
Judgment basis and accounting treatment method for government subsidies related to assets

Government documents stipulate that government subsidies used to purchase, construct or otherwise form long-term assets are classified as asset-related government subsidies. If the government documents are unclear, the judgment will be based on the basic conditions that must be met to obtain the subsidy. If the basic condition is the acquisition, construction or other means of forming long-term assets, it will be regarded as an asset-related government subsidy. Government subsidies related to assets are offset against the book value of the relevant assets or recognized as deferred income. If government subsidies related to assets are recognized as deferred income, they shall be included in profits and losses in installments according to a reasonable and systematic method within the useful life of the relevant assets. Government subsidies measured according to the nominal amount are directly included in the current profit and loss. If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful life, the undistributed balance of relevant deferred income will be transferred to the profit and loss of the current period of asset disposal.

Judgment basis and accounting treatment method for government subsidies related to income

Government subsidies other than asset-related government subsidies are classified as income-related government subsidies. For government subsidies that contain both asset-related parts and income-related parts, it is difficult to distinguish whether they are asset-related or income-related, and are generally classified as income-related government subsidies. If government subsidies related to income are used to compensate for relevant costs, expenses or losses in the future period, they are recognized as deferred income. During the period when the relevant costs, expenses or losses are recognized, they are included in the current profits and losses or offset the relevant costs; if they are used to compensate for the relevant costs, expenses or losses that have already occurred, they are directly included in the current profits and losses or offset the relevant costs.

Government subsidies related to the company's daily operating activities shall be included in other income or offset related costs and expenses according to the economic business essence. Government subsidies that are not related to the company's daily activities are included in non-operating income and expenses.
Accounting treatment method for policy preferential loan interest discounts

(1) The finance department allocates interest discount funds to the lending bank, and the lending bank provides loans to the company at policy-based preferential interest rates. The actual loan amount received is used as the entry value of the loan, and the relevant borrowing costs are calculated based on the loan principal and the policy-based preferential interest rate.

(2) If the finance department directly allocates interest discount funds to the company, the corresponding interest discount will be used to offset related borrowing costs.

Deferred income tax assets/deferred income tax liabilities

√Applicable □Not applicable

Based on the difference between the book value of assets and liabilities and their tax basis (if the tax basis of items not recognized as assets and liabilities can be determined in accordance with tax laws, the difference between the tax basis and their book amount), deferred income tax assets or deferred income tax liabilities are calculated and recognized according to the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled.
Deferred income tax assets are recognized to the extent that it is probable that the taxable income will be available to offset the deductible temporary differences. On the balance sheet date, if there is conclusive evidence that sufficient taxable income is likely to be obtained in the future period to offset the deductible temporary differences, deferred income tax assets that have not been recognized in previous accounting periods will be recognized.
On the balance sheet date, the book value of the deferred tax assets is reviewed. If it is likely that sufficient taxable income will not be available in the future period to offset the benefits of the deferred tax assets, the book value of the deferred tax assets will be written down. The amount of the write-down is reversed when it is probable that sufficient taxable income will be obtained.

84/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

The company's current income tax and deferred income tax are included in the current profit and loss as income tax expenses or income, but do not include income tax arising from the following situations: (1) business merger; (2) transactions or events directly recognized in owner's equity.
When the following conditions are met at the same time, the company will present the deferred income tax assets and deferred income tax liabilities as the net amount after offsetting: (1) It has the legal right to settle the current income tax assets and current income tax liabilities on a net basis; (2) Deferred income tax assets and deferred income tax liabilities are related to the income tax levied by the same tax collection and administration department on the same taxable entity or to different taxable entities. However, in each future period when important deferred income tax assets and deferred income tax liabilities are reversed, the taxable entity involved intends to settle the current income tax assets and current income tax liabilities with a net amount or to obtain assets and pay off debts at the same time.
Leasing

√Applicable □Not applicable

As a lessee, the judgment basis and accounting treatment method for simplified treatment of short-term leases and low-value asset leases

√Applicable □Not applicable

Company as lessee

On the start date of the lease period, the company identifies leases with a lease period of no more than 12 months and that do not include a purchase option as short-term leases; leases with a low value when a single leased asset is a new asset are identified as low-value asset leases. If a company subleases or anticipates subletting a leased asset, the original lease will not be deemed a low-value asset lease.

For all short-term leases and low-value asset leases, the company includes the lease payments into the relevant asset cost or current profit and loss on a straight-line basis throughout the lease term.

In addition to the above-mentioned short-term leases and low-value asset leases that adopt simplified treatment, the company recognizes right-of-use assets and lease liabilities for leases on the start date of the lease period.

(1) Right-of-use assets

The right-of-use assets are initially measured at cost, which includes: 1) the initial measurement amount of the lease liability; 2) the lease payment amount paid on or before the start date of the lease period, and if there is a lease incentive, the amount related to the lease incentive that has been enjoyed is deducted; 3) the initial direct costs incurred by the lessee; 4) the costs expected to be incurred by the lessee to dismantle and remove the leased asset, restore the site where the leased asset is located, or restore the leased asset to the state agreed upon in the lease terms.

The company depreciates right-of-use assets on a straight-line basis. If it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the company will accrue depreciation over the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the company will accrue depreciation during the shorter of the lease term and the remaining useful life of the leased asset.

(2) Lease liabilities

At the beginning of the lease period, the company recognizes the present value of the unpaid lease payments as lease liabilities. When calculating the present value of lease payments, the interest rate implicit in the lease is used as the discount rate. If the interest rate implicit in the lease cannot be determined, the company's incremental borrowing rate is used as the discount rate. The difference between the lease payment and its present value is regarded as an unrecognized financing expense, and interest expenses are recognized at the discount rate used to confirm the present value of the lease payment during each period of the lease term, and included in the current profit and loss. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss when they actually occur.

After the start date of the lease period, when the actual fixed payment amount changes, the estimated amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment amount changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, When a change occurs, the company remeasures the lease liability based on the present value of the changed lease payment, and adjusts the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the remaining amount will be included in the current profit and loss.

Lease classification standards and accounting treatment methods as a lessor

√Applicable □Not applicable

company as lessor

On the lease commencement date, the Company classifies leases that substantially transfer almost all risks and rewards related to the ownership of the leased assets as finance leases, and other leases as operating leases.

operating lease

The company recognizes the lease receipts as rental income according to the straight-line method in each period during the lease term. The initial direct expenses incurred are capitalized and amortized on the same basis as the rental income recognition, and included in the current profit and loss in installments. Variable lease payments obtained by the company related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur.

85/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other important accounting policies and accounting estimates

√Applicable □Not applicable

Accounting treatments related to repurchases of company shares

If the company's shares are acquired for reasons such as reducing registered capital or rewarding employees, the actual amount paid will be treated as treasury shares, and registration will be carried out at the same time. If the repurchased shares are cancelled, the difference between the total par value of the shares calculated based on the par value of the canceled shares and the number of canceled shares and the actual amount paid for the repurchase will be offset against the capital reserve. If the capital reserve is insufficient for offset, the retained earnings will be offset; if the repurchased shares are awarded to the company The employee is an equity-settled share-based payment. When the employee exercises his option to purchase the company's shares and receives the price, the cost of the treasury shares delivered to the employee and the accumulated amount of capital reserve (other capital reserve) during the waiting period are written off, and at the same time, the capital reserve (equity premium) is adjusted according to the difference.

Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

□Applicable √Not applicable

(2) Changes in important accounting estimates

□Applicable √Not applicable

(3) The first implementation of new accounting standards or standard interpretations from 2026 will involve adjustments to the financial statements at the beginning of the year of first implementation □ Applicable √ Not applicable

Others

□Applicable √Not applicable

6. Taxes

Main tax types and tax rates

Main tax types and tax rates

√Applicable □Not applicable

Type of tax Tax basis Tax rate Value-added tax Output tax is calculated based on income from sales of goods and taxable services calculated in accordance with tax laws [Note 1]

After deducting the input tax allowed to be deducted in the current period, the difference is the value-added tax payable.

If the real estate tax is levied on an ad valorem basis, it is calculated as 1.2% of the residual value after deducting 30% of the original value of the property;

If calculated and levied, it is calculated and paid at the rate of 12% of the rental income. 12% urban maintenance and construction tax. Actual turnover tax paid. 5%, 7% education surcharge. Actual turnover tax paid. 3% local education surcharge. Actual turnover tax paid. 2% corporate income tax. Taxable income. Note below.

Ming [Note 1] The sales revenue of the company and its domestic subsidiaries is calculated and paid at a tax rate of 13%; the products sold by the overseas subsidiaries are calculated and paid VAT at the relevant tax rate in the region where they operate; the company’s house rental income is subject to a 5% tax rate and paid VAT; the company and its domestic subsidiaries export goods enjoy the "exemption, credit, and refund" tax or "exemption and refund" tax policy, and the refund rates are 13% and 4%

If there are taxpayers with different corporate income tax rates, a description of the disclosure

√Applicable □Not applicable

Income tax tax payer name

Rate (%) Our company, Xuchang Zhengde Medical Products Co., Ltd., Zhejiang Stange Sports Medical Technology Co., Ltd., Shanghai

Ya'ao Medical Health Products Co., Ltd., Jiangsu Inbest Technology Development Co., Ltd., Anhui Lanxin Medical Technology Co., Ltd., Ningbo Shengyurui Medical Equipment Co., Ltd.

86/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Shaoxing Haoshide Medical Products Co., Ltd., Hangzhou Pujian Medical Equipment Co., Ltd., Ningbo Anmu Medical Technology Co., Ltd.

20% Co., Ltd.

Zhende Medical Supplies (Hong Kong) Co., Ltd., Hong Kong New Starting Point Investment Co., Ltd., ROCIALLE

HEALTHCARELIMITED, ZHENDEETHIOPIAMEDICALPLC, MIDMEDS

LIMITED, DENEHEALTHCARELIMITED, NEWBEGINNINGS(SINGAPORE)

PTELTD、FULLCARE(KENYA)MEDICALTECHNOLOGYEPZLTD、

[Note 2] BOSTONBGECAREINC, FULLCARE(KENYA)MEDICALSEZLIMITED,

MEDTECHMEDICALMEXICO,S.DER.L.DEC.V.,MEDTECHMEXICO

HEALTH,S.DER.L.DEC.V., Zhende Medical Japan Co., Ltd., PTINDONESIA

FULLCAREMEDICAL AND ZHENDEMIDDLEEASTCOMPANY

Other taxpayers other than the above 25% [Note 2] Calculated and paid according to the relevant tax rates in the regions where they operate.

Tax incentives

√Applicable □Not applicable

According to the "Announcement on the Registration of High-tech Enterprises Recognized and Reported by the Zhejiang Provincial Certification Agency in 2025" issued by the National High-tech Enterprise Certification Management Leading Group Office, the company passed the high-tech enterprise certification and obtained the high-tech enterprise certificate numbered GR202533006916. The certification is valid for 2025-2027, and the corporate income tax is calculated and paid at a reduced rate of 15% from January to June 2026.
According to the "Announcement on the Registration of the First Batch of High-tech Enterprises Certified and Reported by the Henan Provincial Certification Agency in 2023" issued by the Office of the National High-tech Enterprise Recognition Management Leading Group, the subsidiary Xuchang Zhengde Medical Supplies Co., Ltd. passed the high-tech enterprise certification , and obtained a high-tech enterprise certificate numbered GR202341001729. The certification is valid from 2023 to 2025. The high-tech enterprise certification is currently under review. From January to June 2026, the corporate income tax will be calculated and paid at a reduced rate of 15%.
According to the notice of the "Registration List of High-tech Enterprises Certified and Reported by the Zhejiang Provincial Certification Agency in 2024" issued by the Office of the National High-tech Enterprise Certification Management Leading Group, the subsidiary Zhejiang Stange Sports Medical Technology Co., Ltd. passed the high-tech enterprise certification and obtained the high-tech enterprise certificate numbered GR202433002428. The certification is valid for 2024-2026, and the corporate income tax is calculated and paid at a reduced rate of 15% from January to June 2026.
According to the "Announcement on the Registration of the First Batch of High-tech Enterprises Certified and Reported by the Shanghai Certification Agency in 2025" issued by the Office of the National High-tech Enterprise Recognition Management Leading Group, the subsidiary Shanghai Ya'ao Medical Health Products Co., Ltd. passed the high-tech enterprise certification and obtained the high-tech enterprise certificate numbered GR202531000637. The certification is valid for 2025-2027, and the corporate income tax is calculated and paid at a reduced rate of 15% from January to June 2026.
According to the "Announcement on the Registration of the First Batch of High-tech Enterprises Recognized and Registered by the Jiangsu Provincial Recognition Agency in 2023" issued by the Office of the National High-tech Enterprise Recognition Management Leading Group, the subsidiary Jiangsu Inbest Technology Development Co., Ltd. passed the high-tech enterprise certification Certificate, and obtained a high-tech enterprise certificate numbered GR202332002029. The certification is valid for 2023-2025. The high-tech enterprise certification is currently under review. From January to June 2026, the corporate income tax will be calculated and paid at a reduced rate of 15%.
According to the "Announcement on the Registration of the Second Batch of High-tech Enterprises Certified and Reported by the Anhui Provincial Certification Agency in 2024" issued by the Office of the National High-tech Enterprise Recognition Management Leading Group, the subsidiary Anhui Lanxin Medical Technology Co., Ltd. passed the high-tech enterprise certification and obtained the high-tech enterprise certificate numbered GR202434005867. The certification is valid for 2024-2026, and the corporate income tax is calculated and paid at a reduced rate of 15% from January to June 2026.
According to the "Announcement on the Recording of High-tech Enterprises Recognized and Reported by Ningbo Certification Agencies in 2025" issued by the Office of the National High-tech Enterprise Certification Management Leading Group, the subsidiary Ningbo Shengyurui Medical Equipment Co., Ltd. passed the high-tech enterprise certification and obtained the high-tech enterprise certificate numbered GR202533101324. The certification is valid for 2025-2027, and the corporate income tax is calculated and paid at a reduced rate of 15% from January to June 2026.
According to the relevant provisions of the "Announcement of the Ministry of Finance and the State Administration of Taxation on Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (Announcement No. 12 of the Ministry of Finance and the State Administration of Taxation of 2023), small and low-profit enterprises will be subject to a reduced rate of 25% to calculate taxable income and pay corporate income tax at a rate of 20%. This policy will continue to be implemented until December 31, 2027. The subsidiaries Shaoxing Haoshide Medical Products Co., Ltd., Hangzhou Pujian Medical Equipment Co., Ltd. and Ningbo Anmu Medical Technology Co., Ltd. are small and low-profit enterprises that meet the above conditions and enjoy the above preferential corporate income tax policies.
According to the relevant provisions of the "Announcement of the Ministry of Finance and the State Administration of Taxation on Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (Announcement No. 12 of the Ministry of Finance and the State Administration of Taxation 2023), from January 1, 2023 to December 31, 2027

87/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

On the same day, resource tax (excluding water resources tax), urban maintenance and construction tax, real estate tax, urban land use tax, stamp tax (excluding securities transaction stamp tax), cultivated land occupation tax, education surcharge, and local education surcharge are halved for small-scale VAT taxpayers, small low-profit enterprises, and individual industrial and commercial households. Subsidiaries Nantong Mattel Medical Supplies Co., Ltd., Shaoxing Haoshide Medical Supplies Co., Ltd., Hangzhou Pujian Medical Equipment Co., Ltd., Shaoxing Zhende Medical Technology Co., Ltd., Hangzhou Xindong Network Technology Co., Ltd., Shanghai Liande Medical Biomaterials Co., Ltd., Yanling County Mattel Medical Supplies Co., Ltd. and Ningbo Anmu Medical Technology Co., Ltd. are small and low-profit enterprises that meet the above conditions and enjoy the above preferential tax policies.

According to the "Notice of the Ministry of Finance and the State Administration of Taxation on Preferential Corporate Income Tax Policies Regarding the Employment of Disabled Personnel" (Caishui [2009] No. 70), when an enterprise places disabled persons, on the basis of actual deductions based on the wages paid to disabled employees, an additional deduction of 100% of the wages paid to disabled employees can be used when calculating taxable income. The company and its subsidiaries meet the conditions in this period and enjoy the preferential policy of 100% super deduction from the wages of disabled employees in this period.
According to the relevant regulations of the "Announcement of the Ministry of Finance and the State Administration of Taxation on the Additional Deduction Policy for Value-Added Tax for Advanced Manufacturing Enterprises" (Announcement No. 43 of the Ministry of Finance and the State Administration of Taxation of 2023), from January 1, 2023 to December 31, 2027, advanced manufacturing enterprises are allowed to deduct an additional 5% of the deductible input tax for the current period to offset the value-added tax payable. The company and its subsidiaries Xuchang Zhengde Medical Supplies Co., Ltd. and Zhejiang Stange Sports Medical Technology Co., Ltd. comply with the above regulations in this period and enjoy the additional deduction of input tax.
Others

□Applicable √Not applicable

7. Notes on Consolidated Financial Statement Items

Monetary funds

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Bank deposits 616,414,963.66 754,671,540.89 Other monetary funds 77,575,078.57 70,636,540.53 Total 693,990,042.23 825,308,081.42 Including: total amount deposited abroad 164,286,407.89 222,549,718.16Other instructions

At the end of the period, other monetary funds include available funds for futures of RMB 4,244,108.42, deposits of RMB 3,739,051.80 for the issuance of letters of guarantee, and interest balance of the L/C margin account of RMB 1,048. 08 yuan, frozen funds involved in the lawsuit of 59,832,076.38 yuan, and funds deposited on a third-party payment platform of 9,758,793.89 yuan (including a deposit of 1,128,586.03 yuan).

Trading financial assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Reason and basis for designation Measured at fair value with changes included in current profit and loss /

266,752,486.90 283,321,317.20

financial assets

Among them:

Investment in cash management products 266,752,486.90 283,321,317.20 /

Total 266,752,486.90 283,321,317.20 /Other instructions:

□Applicable √Not applicable

Derivative financial assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Closing balance Opening balance

88/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Commodity futures contract 249,500.00

Total 249,500.00Other instructions:

None

Notes receivable

(1) Classified presentation of notes receivable

□Applicable √Not applicable

(2) The company’s pledged notes receivable at the end of the period □ Applicable √ Not applicable

(3) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date □ Applicable √ Not applicable

(4) Classified disclosure based on bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

The basis for dividing each stage and the proportion of bad debt provisions not applicable

Explanation of significant changes in the book balance of notes receivable that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

(5) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(6) Notes receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of bills receivable: □ Applicable √ Not applicable

Instructions for writing off notes receivable:

89/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Accounts receivable

(1) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 790,346,019.93 736,413,074.81 Within 1 year 790,346,019.93 736,413,074.81 1 to 2 years 14,242,304.91 3,531,716.23 2 to 3 years 2,684,213.33 810,748.27 More than 3 years 12,682,455.25 11,877,565.08 Total 819,954,993.42 752,633,104.39

90/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Classified disclosure based on bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book Book proportion Provision proportion Proportion Provision proportion

Amount Amount Value Amount Amount Value

(%) (%) (%) (%)

Provision for bad debts on an individual basis 562,000.00 0.07 562,000.00 100.00 562,000.00 0.07 562,000.00 100.00

Among them:

Provision for bad debts on an individual basis 562,000.00 0.07 562,000.00 100.00 562,000.00 0.07 562,000.00 100.00

Provision for bad debts on a group basis 819,392,993.42 99.93 53,867,250.76 6.57 765,525,742.66 752,071,104.39 99.93 49,016,370.55 6.52 703,054,733.84 of which:

Provision for bad debts on a group basis 819,392,993.42 99.93 53,867,250.76 6.57 765,525,742.66 752,071,104.39 99.93 49,016,370.55 6.52 703,054,733.84Total 819,954,993.42 / 54,429,250.76 / 765,525,742.66 752,633,104.39 / 49,578,370.55 / 703,054,733.84

91/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Provision for bad debts is made individually:

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Reason for provision

Single provision 562,000.00 562,000.00 100 It is expected to be unrecoverable after independent testing

Total 562,000.00 562,000.00 100 /

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

√Applicable □Not applicable

Portfolio accrual items: aging portfolio

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Subtotal within 1 year 790,346,019.93 39,517,301.02 5.00 1 to 2 years 14,242,304.91 1,424,230.49 10.00 2 to 3 years 2,684,213.33 805,264.00 30.00 More than 3 years 12,120,455.25 12,120,455.25 100.00

Total 819,392,993.42 53,867,250.76 6.57 Instructions on the provision of bad debt provisions by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(3) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or approval Others Ending balance accrual

Reversal of sales change

Single provision for bad debts

562,000.00 562,000.00Preparation

Bad provision based on combination

49,016,370.55 4,892,178.42 41,298.21 53,867,250.76 Account preparation

Total 49,578,370.55 4,892,178.42 41,298.21 54,429,250.76 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

□Applicable √Not applicable

Other notes:

None

92/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(4) Accounts receivable actually written off in the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Write-off amount Accounts receivable actually written off 41,298.21 Among them, the write-off of important accounts receivable

□Applicable √Not applicable

Instructions for writing off accounts receivable:

□Applicable √Not applicable

(5) Accounts receivable and contract assets of the top five ending balances by debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB accounts receivable and contract assets

Accounts receivable at the end of the period Contract asset period Bad debt provision period Unit name Ending balance of the same assets Total ending balance Ending balance Ending balance Count ratio

(%) Customer one 62,153,271.02 62,153,271.02 7.58 3,107,663.55 Customer two 49,269,606.32 49,269,606.32 6.01 2,463,480.32 Customer three 42,221,917.76 42,221,917.76 5.15 2,111,095.89Customer four 19,162,303.52 19,162,303.52 2.34 958,115.18Customer five 14,404,556.71 14,404,556.71 1.76 720,227.84

Total 187,211,655.33 187,211,655.33 22.83 9,360,582.77Other instructions

None

Other notes:

□Applicable √Not applicable

Contract assets

(1) Contract assets

□Applicable √Not applicable

(2) Amount and reasons for significant changes in book value during the reporting period

□Applicable √Not applicable

(3) Classified disclosure based on bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

93/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

Not applicable

Explanation of significant changes in the book balance of contract assets that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

(4) Bad debt provisions for contract assets in the current period

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(5) Contract assets actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of contract assets

□Applicable √Not applicable

Instructions for write-off of contract assets:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Accounts receivable financing

(1) Classified presentation of financing receivables

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Bank acceptance bill 19,107,166.01 25,709,568.07 Total 19,107,166.01 25,709,568.07

94/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Financing of the company’s pledged receivables at the end of the period

□Applicable √Not applicable

(3) Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount derecognized at the end of the period Amount not derecognized at the end of the period Bank acceptance bill 39,445,866.71

Total 39,445,866.71

(4) Classified disclosure based on bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Provision Book Provision Book Ratio

Amount Amount Proportion Value Amount Proportion (%) Amount Proportion Value (%)

(%) (%)

Provision for bad debts on a group basis 19,107,166.01 100.00 19,107,166.01 25,709,568.07 100.00 25,709,568.07 Of which:

Bank acceptance bill 19,107,166.01 100.00 19,107,166.01 25,709,568.07 100.00 25,709,568.07

Total 19,107,166.01 / 19,107,166.01 / 25,709,568.07 / / 25,709,568.07 Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

95/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Provision for bad debts by group:

√Applicable □Not applicable

Combined accrual items: bank acceptance bill

Unit: Yuan Currency: RMB Closing balance name

Book balance Bad debt provision Provision ratio (%) Bank acceptance bill 19,107,166.01

Total 19,107,166.01Explanation of provision for bad debts by combination

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Explanation of significant changes in the book balance of accounts receivable financing that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

(5) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(6) Financing of receivables actually written off in the current period

□Applicable √Not applicable

Important financing write-offs of receivables

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

(7) Increases and decreases in receivables financing and changes in fair value during the period: □ Applicable √ Not applicable

(8) Other instructions:

□Applicable √Not applicable

Advance payment

(1) Prepayments are presented based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB Aging Closing balance Opening balance

96/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Amount Proportion (%) Amount Proportion (%) Within 1 year 80,706,765.72 88.83 58,861,293.00 80.50 1 to 2 years 10,146,895.21 11.17 14,259,862.91 19.50

Total 90,853,660.93 100.00 73,121,155.91 100.00 Explanation on the reasons why prepayments with an aging of more than 1 year and important amounts were not settled in time:

None

(2) Prepayments of the top five closing balances by prepayment objects

√Applicable □Not applicable

Unit: Yuan Currency: RMB accounted for the total closing balance of prepayments Unit name Closing balance

Proportion (%)

Supplier one 10,275,027.34 11.31 Supplier two 2,604,895.44 2.87 Supplier three 2,054,158.52 2.26 Supplier four 1,853,805.85 2.04 Supplier five 1,412,639.44 1.55

Total 18,200,526.59 20.03Other instructions:

None

Other instructions

□Applicable √Not applicable

Other receivables

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Other receivables 37,881,221.47 44,813,852.61

Total 37,881,221.47 44,813,852.61Other instructions:

□Applicable √Not applicable

interest receivable

(1) Classification of interest receivable

□Applicable √Not applicable

(2) Important overdue interest

□Applicable √Not applicable

(3) Classified disclosure based on bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

97/169

Zhende Medical Supplies Co., Ltd. 2026 Semi-Annual Report □Applicable √Not applicable

Provision for bad debts by combination: □ Applicable √ Not applicable

(4) Provision for bad debts is made based on the general expected credit loss model □Applicable √Not applicable

(5) Bad debt provision □Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(6) Interest receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of interest receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Dividends receivable

(7) Dividends receivable

□Applicable √Not applicable

(8) Important dividends receivable aged more than 1 year □ Applicable √ Not applicable

(9) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts on an individual basis: □ Applicable √ Not applicable

Explanation on the provision of bad debt provisions on an individual basis: □ Applicable √ Not applicable

Provision for bad debts by combination: □ Applicable √ Not applicable

98/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(10) Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

(11) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other notes:

None

(12) Dividends receivable actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of dividends receivable

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other receivables

(13) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 32,887,099.45 17,366,158.97 Within 1 year 32,887,099.45 17,366,158.97 1 to 2 years 5,290,633.07 30,701,031.03 2 to 3 years 923,890.79 14,715,344.82 More than 3 years 17,192,387.89 2,501,583.32

Total 56,294,011.20 65,284,118.14

(14) Classification by nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Long-term asset disposal receivables 1,365,443.04 31,366,880.38 Temporary payments receivable 14,341,452.21 14,416,916.13 Deposits and security deposits 12,841,618.48 10,886,828.20 Value-added tax refunds receivable 23,787,733.43 7,658,402.47 Others 3,957,764.04 955,090.96 Total 56,294,011.20 65,284,118.14

99/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(15) Bad debt provision accrual

√Applicable □Not applicable

Unit: Yuan Currency: RMB Phase 1 Phase 2 Phase 3 Expected throughout the duration Expected bad debt provisions throughout the duration Expected total credit losses in the next 12 months (credit losses not incurred (credit losses incurred)

Credit impairment) Balance on January 1, 2026 485,387.82 3,070,103.10 16,914,774.61 20,470,265.53 Balance on January 1, 2026

This issue

--Transfer to the second stage -264,531.65 264,531.65

--Transfer to the third stage -92,389.08 92,389.08 --Transfer to the second stage

--Return to the first stage

Provision in this period 193,315.13 -2,713,182.37 462,391.44 -2,057,475.80 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on June 30, 2026 414,171.30 529,063.30 17,469,555.13 18,412,789.73 Basis for division of each stage and proportion of provision for bad debts

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Explanation of significant changes in the book balance of other receivables that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

The amount of bad debt provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly: □ Applicable √ Not applicable

(16) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or other Ending balance accrual

Reversal, write-off, change in individual provision for bad debts 15,083,696.92 15,083,696.92 Provision for bad debts on a group basis

5,386,568.61 -2,057,475.80 3,329,092.81 prepared

Total 20,470,265.53 -2,057,475.80 18,412,789.73 Among them, the amount of bad debt provision reversed or recovered in the current period is important:

□Applicable √Not applicable

Other instructions

None

(17) Other receivables actually written off in the current period

□Applicable √Not applicable

Important write-offs of other receivables:

100/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

□Applicable √Not applicable

Instructions for writing off other receivables:

□Applicable √Not applicable

(18) Other receivables with top five closing balances based on debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Percentage of the closing balance of other receivables Name of bad debt provision unit Closing balance Aging

Proportion of total amount (%) Pledge Closing balance State Administration of Taxation Shaoxing Added value receivable

21,126,758.02 37.53 Within 1 year

Shiyuecheng District Taxation Bureau Tax Refund

Shenzhen Duracell Precision Electrical Receivables Temporary Payment

9,620,104.00 17.09 More than 3 years 9,620,104.00 Subsidiary Co., Ltd.

Shao, People's Republic of China Deposit and guarantee within 1 year,

6,909,946.17 12.27 535,724.82 Xingguan Customs Certificate 1-2 years

Chongqing Xinle Medical Care Receivables and Temporary Payments

4,123,592.92 7.33 More than 3 years 4,123,592.92 Products Co., Ltd.

State Administration of Taxation Shanghai Value Added Receivable

1,341,416.82 2.38 Within 1 year

Pudong New Area Taxation Bureau Tax Refund

Total 43,121,817.93 76.60 / / 14,279,421.74

(19) Presented in other receivables due to centralized management of funds

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Inventory

(1) Inventory classification

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Inventories are accurate for price decreases Inventories are accurate for decreases in price

Project preparation/contract performance preparation/contract performance

Book balance Book value Book balance Book value Cost impairment allowance Cost impairment allowance

Be prepared

Raw materials 557,727,414.69 32,145,666.34 525,581,748.35 448,112,573.99 28,952,826.70 419,159,747.29 Work in progress 16,985,478.55 16,985,478.55 16,107,145.93 16,107,145.93 Stockist

380,156,232.13 35,556,785.80 344,599,446.33 365,868,681.96 69,135,883.88 296,732,798.08 products

Issuer

11,337,967.22 11,337,967.22 22,660,771.97 529,981.07 22,130,790.90 products

Total 966,207,092.59 67,702,452.14 898,504,640.45 852,749,173.85 98,618,691.65 754,130,482.20

(2) Data resources confirmed as inventory

□Applicable √Not applicable

101/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(3) Provision for inventory depreciation and provision for impairment of contract performance costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 28,952,826.70 11,576,816.40 8,383,976.76 32,145,666.34 Goods in stock 69,135,883.88 10,012,121.90 43,591,219.98 35,556,785.80 Goods shipped 529,981.07 529,981.07

Total 98,618,691.65 21,588,938.30 52,505,177.81 67,702,452.14

Reasons for the reversal or write-off of inventory depreciation provisions in the current period

√Applicable □Not applicable

Reversal of inventory depreciation provisions. Write-off of inventory depreciation provisions. Specific basis for determining net realizable value.

the reason the reason

The estimated selling price of relevant finished goods minus the estimated completion price will be. Provisions for inventories in previous periods have been made. In this period, the cost of raw materials to be incurred, estimated sales expenses and corresponding inventory provision for inventory depreciation have been accrued at the beginning of the period.

The net realizable value is determined as the amount after taxes and fees. The increase in net realizable value is divided into inventory consumption. The estimated selling price of related finished goods is less the estimated sales expenses. Inventories have been accrued in previous periods. The current period has determined the net realizable value from the amount accrued at the beginning of the period, issuance and relevant taxes.

Provision for inventory decline in value on a group basis

□Applicable √Not applicable

Standards for accruing inventory depreciation provisions on a group basis

□Applicable √Not applicable

(4) The capitalized amount of borrowing costs included in the closing balance of inventories and its calculation standards and basis

□Applicable √Not applicable

(5) Explanation of the amortization amount of contract performance costs for the current period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Assets held for sale

□Applicable √Not applicable

Non-current assets due within one year

□Applicable √Not applicable

Debt investments due within one year

□Applicable √Not applicable

Other debt investments due within one year

□Applicable √Not applicable

Other instructions for non-current assets due within one year

None

102/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other current assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance to be deducted VAT input tax 120,120,187.00 133,683,187.52 Prepaid corporate income tax 11,651,547.77 15,905,928.43

Total 131,771,734.77 149,589,115.95 Information related to compensatory assets

□Applicable √Not applicable

Other notes:

None

Debt investment

(1) Debt investment situation

□Applicable √Not applicable

Changes in provision for impairment of debt investments during the current period

□Applicable √Not applicable

(2) Important debt investments at the end of the period

□Applicable √Not applicable

(3) Provision for impairment losses

□Applicable √Not applicable

Basis for dividing each stage and proportion of impairment provision: Not applicable

Explanation of significant changes in the book balance of debt investments that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

The amount of impairment provision for the current period and the basis for assessing whether the credit risk of financial instruments has significantly increased: □ Applicable √ Not applicable

(4) Actual write-off debt investments in the current period □ Applicable √ Not applicable

Among them, the write-off of important debt investments □Applicable √Not applicable

Instructions for writing off debt investments:

□Applicable √Not applicable

Other notes:

None

Other debt investments

(1) Other debt investments

□Applicable √Not applicable

Changes in impairment provisions for other debt investments during the period □ Applicable √ Not applicable

103/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Important other debt investments at the end of the period □ Applicable √ Not applicable

(3) Provision for impairment losses

□Applicable √Not applicable

(4) Other debt investments actually written off in the current period □ Applicable √ Not applicable

Among them, the write-off situation of other important debt investments □Applicable √Not applicable

Instructions for writing off other debt investments: □ Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

Long-term receivables

(1) Long-term receivables

□Applicable √Not applicable

(2) Classified disclosure according to bad debt accrual method □ Applicable √ Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions on an individual basis: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

(3) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(4) Long-term receivables actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of long-term receivables □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

104/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Long-term equity investment

(1) Long-term equity investment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in the current period

At the beginning of the period, the impairment allowance is catch-up. At the end of the period, the impairment allowance is other comprehensive. Others are declared to be released and accrued.

The balance of the invested unit (book price at the beginning of the provision period plus less) is recognized under the equity method. Its balance (book price at the end of the provision period), combined income, equity, cash dividends, impairment

Value) Balance Investment gains and losses (other value) Balance adjustment changes or profit reserves

capital

1. Joint ventures

2. Joint ventures

Hunan Sijetek Medical Department

17,961,309.36 -293,124.55 17,668,184.81 Technology Co., Ltd.

Hangzhou Public Health Intellectual Property Service

48,374.85 1,455.99 49,830.84 Service Center Co., Ltd.

Shaoxing Guochuang Zhende Medical Products

Phase I Equity Investment Partnership 100,445,910.11 -487,923.86 99,957,986.25 Enterprise (Limited Partnership)

Subtotal 118,455,594.32 -779,592.42 117,676,001.90

Total 118,455,594.32 -779,592.42 117,676,001.90

(2) Impairment testing of long-term equity investments

□Applicable √Not applicable

Other instructions

None

105/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Investment in other equity instruments

(1) Investment in other equity instruments

□Applicable √Not applicable

(2) Explanation of termination of recognition in this period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other non-current financial assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance classified as financial assets at fair value through profit or loss 16,252,163.09 71,927,026.58 Including: equity instrument investment 16,252,163.09 71,927,026.58

Total 16,252,163.09 71,927,026.58Other instructions:

book balance

Investee

This issue

Beginning amount Decrease in the current period Ending amount

increase

Baoma Medical Technology (Wuxi) Co., Ltd. 49,500,000.00 49,500,000.00

Shanghai Hongsheng Yide Private Equity Investment Fund Partnership

20,000,000.00 5,909,090.91 14,090,909.09 (limited partnership)

CHINTORONTOBUSINESS

2,427,026.58 265,772.58 2,161,254.00 DEVELOPMENTLTD[Note]

Subtotal 71,927,026.58 55,674,863.49 16,252,163.09 [Note] The decrease in this period is due to the impact of conversion of exchange rate changes

Investment real estate

Investment real estate measurement model

Not applicable

Fixed assets

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Fixed assets 3,090,329,389.35 3,007,931,714.46

Total 3,090,329,389.35 3,007,931,714.46Other instructions:

None

106/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

fixed assets

(1) Fixed assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Houses and buildings Machinery and equipment Transportation Other equipment Land ownership Total

1. Original book value:

Opening balance 2,343,015,446.35 1,529,470,543.02 22,220,534.08 244,143,979.32 20,503,190.72 4,159,353,693.49 2. Increase in the current period 126,575,764.63 110,602,568.25 813,910.38 16,524,973.89 254,517,217.15 (1) Purchase 1,546,387.63 813,910.38 347,882.41 2,708,180.42

(2) Transfer of construction in progress 126,575,764.63 109,056,180.62 16,177,091.48 251,809,036.73 3. Decrease amount in the current period 9,173,939.05 32,086,294.58 490,724.37 2,393,315.11 10,517.69 44,154,790.80 (1) Disposal or scrapping 26,164,167.70 329,233.41 1,377,707.79 27,871,108.90 (2) Transfer to construction in progress 1,565,869.54 1,565,869.54

(3) Exchange rate changes 9,173,939.05 4,356,257.34 161,490.96 1,015,607.32 10,517.69 14,717,812.36 4. Closing balance 2,460,417,271.93 1,607,986,816.69 22,543,720.09 258,275,638.10 20,492,673.03 4,369,716,119.84

2. Accumulated depreciation

Opening balance 441,323,242.27 531,285,394.65 14,396,426.16 148,686,962.79 1,135,692,025.87 2. Increase in the current period 56,211,504.72 71,406,964.61 1,146,962.15 17,326,254.31 146,091,685.79

(1) Provision 56,211,504.72 71,406,964.61 1,146,962.15 17,326,254.31 146,091,685.79 3. Decrease amount in the current period 532,523.06 14,290,496.50 308,603.36 1,389,484.20 16,521,107.12 (1) Disposal or scrapping 12,704,239.22 230,004.04 731,690.23 13,665,933.49 (2) Transfer to construction in progress 697,339.12 697,339.12

(3) Exchange rate changes 532,523.06 888,918.16 78,599.32 657,793.97 2,157,834.51 4. Closing balance 497,002,223.93 588,401,862.76 15,234,784.95 164,623,732.90 1,265,262,604.54

3. Impairment provision

Opening balance 15,400,100.24 329,852.92 15,729,953.16 2. Increase in the current period
Decrease amount in this period 1,575,048.90 - 30,778.31 1,605,827.21

(1) Disposal or scrapping 1,575,048.90 - 30,778.31 1,605,827.21 4. Closing balance 13,825,051.34 299,074.61 14,124,125.95

4. Book value

Book value at the end of the period 1,963,415,048.00 1,005,759,902.59 7,308,935.14 93,352,830.59 20,492,673.03 3,090,329,389.35 2. Book value at the beginning of the period 1,901,692,204.08 982,785,048.13 7,824,107.92 95,127,163.61 20,503,190.72 3,007,931,714.46

107/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Temporarily idle fixed assets

□Applicable √Not applicable

(3) Fixed assets leased through operating leases

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing book value

Houses and buildings 157,416,620.00 Subtotal 157,416,620.00

(4) Fixed assets for which title certificates have not been obtained

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Book value Reasons for not completing the property ownership certificate Houses and buildings 255,624,051.57 Processing in progress

(5) Impairment testing of fixed assets

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Fixed asset liquidation

□Applicable √Not applicable

Projects under construction

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Construction in progress 338,964,255.07 468,589,159.87

Total 338,964,255.07 468,589,159.87Other instructions:

None

108/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Construction in progress

(1) Situation of projects under construction

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Wound dressing and surgical infection control investment and construction project 138,856,947.45 138,856,947.45 270,391,399.56 270,391,399.56 Annual output of 200 million mattresses project 58,622,976.89 58,622,976.89 51,725,281.04 51,725,281.04 High-performance medical device production base with an annual output of 42.4 million pieces

29,806,032.21 29,806,032.21 and Medical Biological New Materials Research Institute Construction Project

Surgical gloves new line production capacity doubling project 19,988,096.28 19,988,096.28 18,475,655.15 18,475,655.15 Medical solvent glue production project 13,916,293.76 13,916,293.76 Technical transformation project to produce 530 million pieces of high-end medical dressings per year 8,639,121.32 8,639,121.32 8,509,722.28 8,509,722.28 Human-machine integrated equipment introduction project 4,177,297.42 4,177,297.42 6,298,667.87 6,298,667.87 Compression stockings production line capacity expansion and upgrade project 2,802,952.00 2,802,952.00 2,423,058.41 2,423,058.41 Nasal oxygen tube production project 830,345.64 830,345.64 7,593,469.04 7,593,469.04 Medical sterilized rubber surgical gloves project phase I 22,320,069.03 22,320,069.03 7,231,960.82 7,231,960.82 Medical supplies production capacity expansion project 3,594,724.66 3,594,724.66 3,203,722.72 3,203,722.72 Increase in production capacity of surgical infection control products 4,031,878.24 4,031,878.24 565,574.93 565,574.93 Sporadic projects 75,099,846.14 75,099,846.14 48,448,322.08 48,448,322.08

Total 338,964,255.07 338,964,255.07 468,589,159.87 468,589,159.87

(2) Changes in important projects under construction during the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB Accumulated interest capital for other projects in the current period Including: This period Interest budget amount This period Increase in this period Name of fund transferred to fixed capital in this period Beginning balance Decrease Ending balance Budget ratio Progress Accumulated interest capitalization Capitalization rate (10,000 yuan) Amount Amount Source Amount Example (%) (%) Amount Amount (%)

109/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Annual output of 42.4 million high-performance medical devices

Owned machine production base and new medical biological materials 61,000.00 29,806,032.21 13,562,876.27 43,368,908.48 61.80 100

Funding Research Institute Construction Project

Investment and construction of factories for wound dressing and surgical infection control Self-owned 40,000.00 270,391,399.56 8,011,984.16 139,546,436.27 138,856,947.45 106.32 95

Project Fund 27.15 million Self-owned annual production of 200 million mattresses project 51,725,281.04 6,897,695.85 58,622,976.89 66.87 95

USD Capital Annual production of 530 million pieces of high-end medical dressings Own 6,000.00 8,509,722.28 1,636,366.39 1,506,967.35 8,639,121.32 63.27 70

Technical transformation project Self-funded medical solvent glue production project 6,763.00 13,916,293.76 13,916,293.76 103.78 100

Self-funded man-machine integrated equipment introduction project 3,768.00 6,298,667.87 3,096,895.71 5,218,266.16 4,177,297.42 109.67 78

Self-funded project to double the production capacity of new surgical glove lines 4,000.00 18,475,655.15 3,217,067.64 1,704,626.51 19,988,096.28 127.91 97

Funds Medical Sterilized Rubber Surgical Gloves Project 1 Owned 7,000.00 7,231,960.82 32,191,712.19 17,103,603.98 22,320,069.03 58.59 90

Total funds for the period 406,355,012.69 68,614,598.21 222,365,102.51 252,604,508.39 / / / /

(3) Provision for impairment of projects under construction in the current period

□Applicable √Not applicable

(4) Impairment testing of projects under construction

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Engineering supplies

□Applicable √Not applicable

110/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Productive biological assets

(1) Productive biological assets using cost measurement model

□Applicable√Not applicable

(2) Impairment testing of productive biological assets using the cost measurement model

□Applicable √Not applicable

(3) Productive biological assets using fair value measurement model

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Oil and gas assets

(1) Oil and gas assets

□Applicable √Not applicable

(2) Impairment testing of oil and gas assets

□Applicable √Not applicable

Other notes:

None

Right-of-use assets

(1) Right-of-use assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Project Houses and Buildings Total

1. Original book value

Balance at the beginning of the period 37,653,644.63 37,653,644.63 2. Increase in the current period 31,952,780.56 31,952,780.56

(1) Lease 31,952,780.56 31,952,780.56 3. Decrease amount in the current period 2,207,366.27 2,207,366.27 (1) Disposal 374,685.17 374,685.17

(2) Exchange rate changes 1,832,681.10 1,832,681.10 4. Closing balance 67,399,058.92 67,399,058.92

2. Accumulated depreciation

Opening balance 7,863,075.29 7,863,075.29 2. Increase in current period 7,072,721.07 7,072,721.07 (1) Provision 7,063,339.22 7,063,339.22

(2) Exchange rate changes 9,381.85 9,381.85 3. Decrease amount in the current period 610,468.89 610,468.89 (1) Disposal 374,685.17 374,685.17

(2) Exchange rate changes 235,783.72 235,783.72 4. Closing balance 14,325,327.47 14,325,327.47

3. Impairment provision

4. Book value

Book value at the end of the period 53,073,731.45 53,073,731.45

111/169

Zhende Medical Products Co., Ltd. 2026 Semi-annual Report 2. Beginning book value 29,790,569.34 29,790,569.34

(2) Impairment testing of right-of-use assets

□Applicable √Not applicable

Other notes:

None

112/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Intangible assets

(1) Intangible assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB Patent rights and non-

Project Land use rights Information system Management software Franchise rights Emission rights Total

Patented technology

1. Original book value

Opening balance 688,612,093.64 14,688,771.61 35,804,669.17 16,470,452.95 108,114,545.27 683,815.00 864,374,347.64 2. Increase in the current period 556,200.00 1,184,404.75 1,740,604.75

(1) Purchase 556,200.00 1,184,404.75 1,740,604.75 3. Decrease amount in the current period 4,542,265.77 169,119.57 733,389.57 5,444,774.91 (1) Disposal

(2) Exchange rate changes 4,542,265.77 169,119.57 733,389.57 5,444,774.91 4. Closing balance 684,626,027.87 14,688,771.61 36,819,954.35 15,737,063.38 108,114,545.27 683,815.00 860,670,177.48

2. Accumulated amortization

Opening balance 75,690,702.39 8,429,596.64 17,364,613.23 3,294,090.59 36,820,020.52 96,024.14 141,695,047.51 2. Increase in the current period 6,991,788.57 734,138.57 1,685,758.76 786,853.17 5,506,626.55 23,612.55 15,728,778.17

(1) Provision 6,991,788.57 734,138.57 1,685,758.76 786,853.17 5,506,626.55 23,612.55 15,728,778.17 3. Decrease amount in the current period 100,124.23 148,871.27 146,677.91 395,673.41 (1) Disposal

(2) Exchange rate changes 100,124.23 148,871.27 146,677.91 395,673.41 4. Closing balance 82,582,366.73 9,163,735.21 18,901,500.72 3,934,265.85 42,326,647.07 119,636.69 157,028,152.27

3. Impairment provision

4. Book value

Book value at the end of the period 602,043,661.14 5,525,036.40 17,918,453.63 11,802,797.53 65,787,898.20 564,178.31 703,642,025.21 2. Book value at the beginning of the period 612,921,391.25 6,259,174.97 18,440,055.94 13,176,362.36 71,294,524.75 587,790.86 722,679,300.13

The proportion of intangible assets formed through the company's internal research and development at the end of the current period to the balance of intangible assets is 0%

113/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Data resources recognized as intangible assets

□Applicable √Not applicable

(3) Land use rights for which property rights certificates have not been obtained

□Applicable √Not applicable

(4) Impairment testing of intangible assets

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Goodwill

(1) Original book value of goodwill

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Increase in this period Decrease in this period

Name of invested unit or enterprise joint venture

Beginning balance Others Events that resulted in goodwill in the closing balance Other

He set

Suzhou Medis Medical Transportation

57,656,115.43 57,656,115.43 Moving Supplies Co., Ltd.

Hangzhou Pujian Medical Equipment

17,008,378.22 17,008,378.22 Co., Ltd.

Shaoxing Tomei Medical Supplies

11,594,396.30 11,594,396.30 Co., Ltd.

Shaoxing Haoshide Medical Supplies

3,356,816.41 3,356,816.41 Co., Ltd.

Zhejiang Stange Sports Medicine

43,312,473.87 43,312,473.87 Medical Technology Co., Ltd.

Hangzhou Xindong Network Technology

1,388,129.05 1,388,129.05 Co., Ltd.

Shanghai Yaao Medical Healthcare

190,348,990.26 190,348,990.26 Products Co., Ltd.

Nantong Mattel Medical Supplies

60,923,570.35 60,923,570.35 Co., Ltd.

Anhui Lanxin Medical Technology

16,825,315.33 16,825,315.33 Co., Ltd.

MIDMEDS LIMITED

82,950,980.22 3,693,607.23 79,257,372.99 BOSTON BGECARE INC

6,130,845.35 190,062.48 5,940,782.87 DENE HEALTHCARE

144,879,643.77 6,451,141.37 138,428,502.40 LIMITED

Jiangsu Inbest Technology Co., Ltd.

167,117,920.04 167,117,920.04 Exhibition Co., Ltd.

Ningbo Shengyurui Medical Devices

226,175,125.60 226,175,125.60 Machinery Co., Ltd.

Ningbo Anmu Medical Technology

13,257,748.86 13,257,748.86 Co., Ltd.

114/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Total 1,042,926,449.06 10,334,811.08 1,032,591,637.98 [Note] Other changes in goodwill resulting from the acquisition of equity interests in MIDMEDSLIMITED, BOSTONBGECAREINC and DENEHEALTHCARELIMITED are the impact of exchange rate changes and translation

(2) Goodwill impairment provision

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase in the current period Decrease in the name of the invested unit or formation of goodwill in the current period Beginning balance Ending balance

Provision for disposal of Hangzhou Xindong Network Technology Co., Ltd.

1,212,876.18 1,212,876.18 Shanghai Yaao Medical Health Products Co., Ltd.

4,345,484.89 4,345,484.89 Nantong Mattel Medical Supplies Co., Ltd. 480,002.39 480,002.39 Anhui Lanxin Medical Technology Co., Ltd. 112,141.25 112,141.25 Jiangsu Inbest Technology Development Co., Ltd.

53,729.39 53,729.39

Total 6,204,234.10 6,204,234.10

(3) Relevant information about the asset group or asset group combination where the goodwill is located

□Applicable √Not applicable

Changes in asset group or asset group combination

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(4) Specific determination method of recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable √Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable √Not applicable

Reasons for the obvious inconsistency between the above information and the information used in impairment testing in previous years or external information □ Applicable √ Not applicable

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

□Applicable √Not applicable

(5) Performance commitments and corresponding goodwill impairment

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Long-term deferred expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

115/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Increase in current period Amortization in current period Other decreases

Item Beginning balance Closing balance

amount amount amount

Operating leased fixed assets

5,403,960.09 6,598,443.50 3,312,600.74 8,689,802.85 Good expenses

Total 5,403,960.09 6,598,443.50 3,312,600.74 8,689,802.85Other instructions:

None

Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Items Deductible temporary differences Deferred income tax Deductible temporary differences Deferred income taxes

Different assets Different assets Asset impairment provision 118,602,099.83 19,215,037.51 134,942,065.84 23,083,246.15 Unrealized profits from internal transactions 27,684,320.43 4,210,974.12 14,827,194.24 2,754,994.40 Deferred income 215,190,710.81 42,150,550.37 215,236,541.61 41,996,828.53 Measured at fair value and its changes

249,157.06 37,373.56

Financial liabilities included in current profits and losses

Caused by different tax rates for joint ventures

42,013.75 6,302.06

temporary difference

Uncovered losses 100,736,396.44 10,073,639.64 77,956,989.56 7,795,698.96 Lease liabilities 27,377,837.28 4,168,959.58 3,385,204.46 590,185.88

Total 489,882,535.60 79,862,836.83 446,347,995.71 76,220,953.92

(2) Deferred income tax liabilities without offset

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Taxable temporary difference Deferred income tax Taxable temporary difference Deferred income tax

Different liabilities Different liabilities Assets consolidated by enterprises not under common control

129,738,940.20 20,440,019.98 136,140,790.26 21,454,054.51 Appraisal value added

Measured at fair value and changes in

2,345,826.76 376,824.01 321,317.20 48,197.58 Financial assets included in current profits and losses

Fixed assets are allowed to be recorded in one lump sum

112,385,578.67 13,368,006.21 94,539,233.40 11,798,707.66 Current costs and expenses

Right-of-use assets 30,724,046.85 4,728,131.25 2,677,591.09 485,028.94 Due to different tax rates of joint ventures

445,910.11 66,886.52 Temporary differences

Total 275,194,392.48 38,912,981.45 234,124,842.06 33,852,875.21

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Closing balance Opening balance

116/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Deferred income tax assets are deferred after offsetting. Deferred income tax assets are offset against deferred assets and liabilities after offsetting. Taxable assets or liabilities are offset against each other. Taxable assets or liabilities are offset against each other.

Amount Debt balance Amount Debt balance Deferred income tax assets 16,296,023.26 63,566,813.58 10,510,832.82 65,710,121.10 Deferred income tax liabilities 16,296,023.26 22,616,958.19 10,510,832.82 23,342,042.39

(4) Details of deferred income tax assets not recognized

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Deductible temporary differences 37,129,726.42 49,455,215.05 Deductible losses 231,645,028.95 209,431,311.31

Total 268,774,755.37 258,886,526.36

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Year Ending amount Beginning amount Remarks

2026 9,466,297.96 20,194,273.14

2027 31,475,685.51 36,822,279.99

2028 38,704,901.09 38,704,901.09

2029 64,054,410.70 64,054,410.70

2030 49,655,446.39 49,655,446.39

2031 38,288,287.30

Total 231,645,028.95 209,431,311.31 /

Other notes:

□Applicable √Not applicable

Other non-current assets

□Applicable √Not applicable

Assets with restricted ownership or use rights

√Applicable □Not applicable

Unit: Yuan Currency: RMB End of Period Beginning of Period

Item Book balance Book price Restricted category Restricted situation Book balance Book price Restricted Restricted situation Amount Value Type Amount Value Type

Letter of guarantee guarantee Others Letter of guarantee deposit, gold, letter of credit Letter of credit guarantee

Margin interest, monetary capital involved in the lawsuit 64,700, 64,700, interest, frozen funds involved in the lawsuit 64,318,3 64,318, frozen funds, No.

Others

Deposit 762.29 762.29 settled funds, 98.23 398.23 third-party payment platform and e-commerce store platform and e-commerce store deposit deposit

Total 64,700, 64,700, / / 64,318,3 64,318, / / 762.29 762.29 98.23 398.23

117/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other notes:

None

Short-term borrowings

(1) Classification of short-term loans

√Applicable □Not applicable

Unit: Yuan Currency: RMB items Closing balance Opening balance Credit borrowings 407,500,468.61 767,002,817.30 Discounted and unexpired bank acceptance bills 498,951,393.51

Total 906,451,862.12 767,002,817.30 Description of short-term loan classification:

None

(2) Overdue short-term borrowings that have not been repaid

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Trading financial liabilities

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Derivative financial liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Ending balance Beginning balance Commodity futures contract 214,000.00

Total 214,000.00

Other notes:

None

Notes payable

√Applicable □Not applicable

Unit: Yuan Currency: Type of RMB Closing balance Opening balance Bank acceptance bill 10,381,930.51 16,450,317.87 Total 10,381,930.51 16,450,317.87 The total amount of notes payable that has expired and not been paid at the end of this period is 0 yuan. The reason for not paying when due is none

Accounts payable

(1) Presentation of accounts payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

118/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Item Closing balance Opening balance Payable for materials and merchandise purchases 336,928,706.71 419,255,405.20 Payable for long-term asset purchases 139,595,037.58 137,327,481.55

Total 476,523,744.29 556,582,886.75

(2) Important accounts payable that are aged more than 1 year or are overdue

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Advance payments

(1) Presentation of accounts received in advance

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Rent received in advance 3,458,689.43 191,276.41

Total 3,458,689.43 191,276.41

(2) Important advances from customers aged more than 1 year

□Applicable √Not applicable

(3) Amount and reasons for significant changes in book value during the reporting period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Contract liabilities

(1) Contract liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Payment for goods 28,823,533.49 21,597,685.23

Total 28,823,533.49 21,597,685.23

(2) Important contract liabilities aged more than 1 year

□Applicable √Not applicable

(3) Amount and reasons for significant changes in book value during the reporting period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

119/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Payable to employees

(1) Presentation of employee benefits payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Short-term salary 120,585,883.07 474,102,386.53 488,836,612.28 105,851,657.32

2. Post-employment benefits-set bonus

2,473,716.30 33,916,796.00 33,261,880.43 3,128,631.87 Savings plan

Total 123,059,599.37 508,019,182.53 522,098,492.71 108,980,289.20

(2) Presentation of short-term remuneration

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Salaries, bonuses, allowances and

116,793,557.43 433,720,914.80 449,144,849.66 101,369,622.57 Subsidy

2. Employee welfare fees 13,172,792.27 13,172,792.27

Social insurance premiums 3,228,366.57 16,206,758.66 15,951,188.44 3,483,936.79 Including: medical insurance premiums 3,137,485.37 14,632,752.29 14,402,585.82 3,367,651.84 Work-related injury insurance premium 87,114.61 1,510,713.19 1,486,658.27 111,169.53

Maternity insurance premium 3,766.59 63,293.18 61,944.35 5,115.42

Housing provident fund 445,066.27 8,881,967.09 8,705,585.53 621,447.83

5. Trade union funds and employee education

118,892.80 2,119,953.71 1,862,196.38 376,650.13 Funding

Total 120,585,883.07 474,102,386.53 488,836,612.28 105,851,657.32

(3) Display of defined contribution plan

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Basic pension insurance 2,398,486.02 32,885,428.38 32,252,337.00 3,031,577.40
Unemployment insurance premium 75,230.28 1,031,367.62 1,009,543.43 97,054.47

Total 2,473,716.30 33,916,796.00 33,261,880.43 3,128,631.87Other instructions:

□Applicable √Not applicable

Taxes payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Value-added tax 18,142,391.06 18,457,973.08Corporate income tax 12,779,951.90 11,104,291.79Urban maintenance and construction tax 910,940.03 668,465.62Personal income tax withheld 2,353,436.10 3,160,363.66 Real estate tax 2,472,850.16 4,781,722.88 Land use tax 1,133,447.91 1,681,023.02 Stamp tax 949,979.01 920,277.94 Education fee surcharge 459,320.88 346,231.64

120/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Local education surcharge 306,213.96 230,821.14 Local water conservancy construction fund 28,042.31 28,284.01 Resource tax 198,881.93 Disability security fund 33,241.45 33,241.45

Total 39,569,814.77 41,611,578.16Other instructions:

None

Other payables

(1) Project list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Other payables 152,991,601.22 149,514,610.48 Total 152,991,601.22 149,514,610.48

(2) Interest payable

□Applicable √Not applicable

(3) Dividends payable

□Applicable √Not applicable

(4) Other payables

Present other payables according to nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Deposit guarantee 52,266,068.08 48,512,239.66 Unpaid operating expenses 74,859,709.35 39,335,840.90 Equity transfer payable 22,140,000.00

Employee stock ownership plan repurchase obligation 40,440,082.80 Loans payable to minority shareholders of subsidiaries 17,782,280.00 Others 3,725,823.79 3,444,167.12

Total 152,991,601.22 149,514,610.48 Important other payables aged more than 1 year or overdue

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Liabilities held for sale

□Applicable √Not applicable

Non-current liabilities due within one year

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Long-term borrowings due within one year 2,001,305.56 100,311,733.80

121/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Lease liabilities due within one year 7,481,829.72 5,228,560.88

Total 9,483,135.28 105,540,294.68Other instructions:

None

Other current liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Advance payment for equity transfer 25,000,000.00 Advance payment for long-term asset disposal 12,500,000.00

Output tax to be transferred 1,623,270.15 1,603,512.85

Total 14,123,270.15 26,603,512.85 Increase or decrease in short-term bonds payable:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Long-term borrowing

(1) Classification of long-term loans

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Credit loan 381,833,847.77 383,096,181.74

Total 381,833,847.77 383,096,181.74 Description of long-term loan classification:

None

Other instructions

□Applicable √Not applicable

Bonds payable

(1) Bonds payable

□Applicable √Not applicable

(2) Details of bonds payable: (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities) □ Applicable √ Not applicable

(3) Description of convertible corporate bonds

□Applicable √Not applicable

Accounting treatment and judgment basis for equity transfer

□Applicable √Not applicable

122/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(4) Description of other financial instruments classified as financial liabilities

Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

□Applicable √Not applicable

Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

□Applicable √Not applicable

Explanation of the basis for classifying other financial instruments as financial liabilities

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Lease liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Lease payment 32,728,455.88 9,616,375.61 Less: Unrecognized financing costs 2,268,070.11 819,458.35

Total 30,460,385.77 8,796,917.26Other instructions:

None

Long-term accounts payable

Item list

□Applicable √Not applicable

long-term payables

□Applicable √Not applicable

Special payables

□Applicable √Not applicable

Long-term employee benefits payable

□Applicable √Not applicable

Estimated liabilities

□Applicable √Not applicable

Deferred income

Deferred income

√Applicable □Not applicable

Unit: Yuan Currency: RMB items Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation

Government subsidies related to assets 215,236,541.61 10,788,510.00 10,834,340.80 215,190,710.81 Government subsidies

123/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Total 215,236,541.61 10,788,510.00 10,834,340.80 215,190,710.81 /

Other notes:

□Applicable √Not applicable

Other non-current liabilities

□Applicable √Not applicable

Share capital

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in this change (+, one)

Beginning balance Closing balance

Issuance of new shares Bonus shares Conversion of provident funds Others Subtotal

Total number of shares 265,835,535 -1,959,310 -1,959,310 263,876,225Other instructions:

For details of the changes in share capital during the current period, please refer to Section 8 of this report. 7. Notes to Items in Consolidated Financial Statements 55. Explanation of Capital Reserves

Other equity instruments

(1) Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

□Applicable √Not applicable

(2) Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

□Applicable √Not applicable

Changes in other equity instruments during the current period, explanations of the reasons for the changes, and the basis for relevant accounting treatments:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Capital reserve

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Capital premium (equity premium) 1,772,090,902.96 73,259,335.59 1,698,831,567.37

Total 1,772,090,902.96 73,259,335.59 1,698,831,567.37 Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

Equity premium decreased by 73,259,335.59 in this period Yuan, including ① The company repurchased and canceled the 1,829,868 shares that have expired and not been unlocked under the employee stock ownership plan and the remaining 129,442 shares that have been repurchased and unused in the special repurchase account, totaling 1,959,310 shares, and paid employees The original capital contribution plus the bank deposit interest rate for the same period and the calculated interest totaled 44,549,546.52 yuan, correspondingly reducing the capital reserve share premium by 44,549,546.52 yuan; ② According to the "Hu Dongying and Zhende Medical Use" signed between the company and Hu Dongying According to the Equity Transfer Agreement of Ningbo Shengyurui Medical Equipment Co., Ltd. of Ningbo Shengyurui Medical Equipment Co., Ltd., the company transferred 10% equity of Ningbo Shengyurui Medical Equipment Co., Ltd., a subsidiary held by Hu Dongying, for RMB 39,600,000.00, the price for purchasing the equity. The difference of RMB 28,709,789.07 higher than the share of identifiable net assets of Ningbo Shengyurui Medical Devices Co., Ltd. calculated based on the newly increased shareholding ratio calculated continuously from the date of purchase shall be offset against the capital reserve (equity premium) in the consolidated financial statements.

Treasury stocks

√Applicable □Not applicable

124/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Unlocked restricted stocks 40,440,082.80 40,440,082.80

Repurchase of public shares 6,103,008.09 6,103,008.09

Total 46,543,090.89 46,543,090.89

Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

According to the company's holding of the sixth meeting of the fourth board of directors and the second extraordinary shareholders' meeting of 2026 on January 23 and February 9, 2026 respectively, the "Proposal on the Company's Second Employee Stock Ownership Plan (Revised Draft) and its Summary", the "Proposal on the Management Measures for the Company's Second Employee Stock Ownership Plan (Revised Draft)", and " Proposal on Repurchasing Unlocked Shares of the Company's Second Phase Employee Stock Ownership Plan", "Proposal on Changing the Purpose of Repurchased Shares and Cancellation" and "Proposal on Changing the Company's Registered Capital, Amending the Articles of Association and Handling Industrial and Commercial Change Registration", including ① agreeing to repurchase and cancel 1,829,868 company shares that have not been unlocked under the employee stock ownership plan. As of June 30, 2026, the company has canceled the aforementioned shares, the grant price is 22.10 yuan/share, and the treasury shares have been reduced by 40,440,082.80 yuan; ② It is agreed to transfer the shares already in the company’s special securities account for repurchase The purpose of the repurchased and unused 129,442 company shares was changed from "used to implement the employee stock ownership plan" to "cancellation and reduction of the company's registered capital" and was cancelled, reducing treasury shares by RMB 6,103,008.09.

125/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other comprehensive income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount incurred in the current period

Less: Included in the previous period

Other comprehensive income for the current period

Beginning of the period Less: Included in the previous period Less: All items at the end of the period before income tax transferred to retained earnings after tax attributable to the parent After tax attributable to less than the balance of other comprehensive income in the current period Taxes and fees Balance incurred Company Several shareholders

For transfer to profit and loss

1. Cannot be re-divided

Similar to profit and loss

Other comprehensive income

2. Reclassify

Others entering profit and loss -3,141,814.03 -57,189,920.69 -46,354,738.06 -10,835,182.63 -49,496,552.09Comprehensive income

Foreign currency financial statements

-3,141,814.03 -57,189,920.69 -46,354,738.06 -10,835,182.63 -49,496,552.09Table conversion difference

other comprehensive income

-3,141,814.03 -57,189,920.69 -46,354,738.06 -10,835,182.63 -49,496,552.09Total

Other explanations include adjustments to the initial recognition amount of the effective portion of cash flow hedging gains and losses converted into hedged items:

None

Special reserves

□Applicable √Not applicable

126/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Surplus reserve

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 239,372,019.36 239,372,019.36

Total 239,372,019.36 239,372,019.36 Description of surplus reserve, including changes in increases and decreases in the current period and explanation of reasons for changes:

None

Undistributed profits

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Current period Last year Undistributed profits at the end of the previous period before adjustment 3,459,120,894.80 3,377,815,618.11 Total undistributed profits at the beginning of the adjustment period (increase +, decrease -)

Undistributed profit at the beginning of the adjusted period 3,459,120,894.80 3,377,815,618.11 Plus: Net profit attributable to owners of the parent company for the period 143,778,780.32 260,817,281.43 Less: Appropriation of statutory surplus reserve 14,806,585.95

Dividends payable on ordinary shares 79,162,867.49 164,705,418.79 Undistributed profits at the end of the period 3,523,736,807.63 3,459,120,894.80 Details of adjustments to undistributed profits at the beginning of the period:

Due to the retrospective adjustment of the "Accounting Standards for Business Enterprises" and its related new regulations, the undistributed profit at the beginning of the period was affected by RMB 0.
Due to changes in accounting policies, the undistributed profit at the beginning of the period was affected by RMB 0.
Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected by RMB 0.
The change in the scope of consolidation due to the same control affects the undistributed profit at the beginning of the period of 0 yuan.
The total impact of other adjustments on the undistributed profit at the beginning of the period is 0 yuan.
Operating income and operating costs

(1) Operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Main business 2,202,203,673.52 1,445,623,979.80 2,088,086,041.91 1,370,625,097.79 Other businesses 21,856,961.02 9,119,403.09 12,111,284.40 11,505,720.18

Total 2,224,060,634.54 1,454,743,382.89 2,100,197,326.31 1,382,130,817.97

(2) Breakdown information of operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Medical Supplies Total

Contract classification

Operating income Operating cost Operating income Operating cost Product type

Basic nursing 444,310,251.94 322,719,108.47 444,310,251.94 322,719,108.47 Surgical infection control 993,888,735.93 682,771,351.63 993,888,735.93 682,771,351.63 Pressure therapy and solidification 244,823,720.55 142,761,291.50

244,823,720.55 142,761,291.50 fixed

127/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Ostomy and modern injuries 359,624,341.72 179,468,750.66

359,624,341.72 179,468,750.66 Oral care

Infection control and protection 159,556,623.36 117,903,477.54 159,556,623.36 117,903,477.54

Others 21,856,961.02 9,119,403.09 21,856,961.02 9,119,403.09 Classified by operating area

Domestic 865,365,502.78 500,836,275.63 865,365,502.78 500,836,275.63 Overseas 1,358,695,131.76 953,907,107.26 1,358,695,131.76 953,907,107.26

Total 2,224,060,634.54 1,454,743,382.89 2,224,060,634.54 1,454,743,382.89Other instructions

√Applicable □Not applicable

The income recognized in the current period and included in the opening book value of contract liabilities was RMB 21,597,685.23.

(3) Description of performance obligations

□Applicable √Not applicable

(4) Description of allocation to remaining performance obligations

□Applicable √Not applicable

(5) Major contract changes or major transaction price adjustments

□Applicable √Not applicable

Other notes:

None

Taxes and surcharges

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Urban maintenance and construction tax 6,626,553.06 6,221,506.66 Education fee surcharge 3,241,042.59 3,102,448.19 Resource tax 23,248.74 367,155.50 Property tax 9,541,886.98 8,024,207.63 Land use tax 4,084,547.12 3,309,585.41 Vehicle and vessel tax 4,728.91 4,083.12 Stamp duty 1,783,206.13 3,631,636.07 Local education surcharge 2,160,694.99 2,068,298.79 Local water conservancy construction fund 56,972.79 52,355.57

Total 27,522,881.31 26,781,276.94Other instructions:

None

Sales expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Employee compensation 98,817,183.66 91,816,583.36 E-commerce platform service fee 33,775,660.76 33,396,659.16 Office and travel expenses 22,854,074.52 20,813,334.88

128/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Publicity and promotion fee 11,357,070.78 11,679,627.28 Sales commission and service fee 10,052,859.64 10,284,190.11 Others 8,620,501.81 10,401,637.62

Total 185,477,351.18 178,392,032.41Other instructions:

None

Management expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Employee compensation 149,970,285.50 142,590,073.26 Depreciation and amortization expenses 73,289,317.24 61,589,647.30 Office and travel expenses 35,946,694.60 39,779,895.06 Intermediary service expenses 24,043,743.34 25,129,340.61 Lease fee 3,056,999.00 1,365,189.90 Others 18,655,992.25 16,555,596.53

Total 304,963,031.93 287,009,742.65Other instructions:

None

Research and development expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Salaries of R&D personnel 27,025,658.07 28,036,622.59 Inventories used for R&D 28,088,599.73 30,647,468.57 Fuel and power expenses 408,975.43 677,140.16 Depreciation and amortization expenses 2,351,553.27 2,176,007.79 Design, testing and equipment commissioning fees 5,435,926.81 1,690,247.53 Others 1,577,907.61 508,355.77

Total 64,888,620.92 63,735,842.41Other instructions:

None

Financial expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Interest expense 15,709,188.11 13,228,489.81 Less: Interest income 2,539,094.22 4,765,356.05 Exchange gains and losses 14,054,926.99 3,681,409.63 Bank fees and others 3,091,165.00 2,397,804.26

Total 30,316,185.87 14,542,347.65Other instructions:

None

129/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Other income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Classification by nature Amount incurred in the current period Amount incurred in the previous period

Government subsidies related to assets 10,834,340.80 10,088,314.80 Government subsidies related to income 4,085,969.96 3,889,864.20 Refund of withholding personal income tax fees 864,029.18 376,799.39 Additional value-added tax deduction 2,534,273.41 4,636,733.61

Total 18,318,613.35 18,991,712.00Other instructions:

None

Investment income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Long-term equity investment income calculated by equity method -779,592.42 -1,542,790.73 Investment income from the disposal of trading financial assets 3,102,127.69 3,174,125.96 Investment income from the disposal of derivative financial assets 4,266,803.47

Interest income accrued accordingly on return receivables 1,396,226.42

Investment income from disposal of other non-current financial assets 14,960,610.41

Total 22,946,175.57 1,631,335.23

Other notes:

None

Net exposure hedging income

□Applicable √Not applicable

Income from changes in fair value

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Sources of income from changes in fair value Amount for the current period Amount for the previous period Trading financial assets 10,690,009.70 2,037,383.51 Among them: financial assets classified as measured at fair value with changes included in current profits and losses

2,061,169.70 2,037,383.51 Income from changes in fair value of property

Gains and losses from changes in fair value of derivative financial instruments 8,628,840.00

Trading financial liabilities 2,758,277.37 Including: financial liabilities classified as measured at fair value and changes included in current profits and losses

2,758,277.37 Gains from changes in fair value of bonds

Total 10,690,009.70 4,795,660.88Other instructions:

None

Credit impairment losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Amount for the current period Amount for the previous period

130/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Bad debt losses on accounts receivable -4,892,178.42 25,107.21 Bad debt losses on other receivables 2,057,475.80 -4,049,575.60

Total -2,834,702.62 -4,024,468.39Other instructions:

None

Asset impairment losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Inventory depreciation losses and contract performance cost impairment losses -21,588,938.29 -15,307,976.39 Prepayment impairment losses 3,860,608.39

Total -21,588,938.29 -11,447,368.00Other instructions:

None

Income from asset disposal

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Income from disposal of fixed assets -8,313,935.18 238,610.64 Income from disposal of right-of-use assets 101,570.79

Total -8,313,935.18 340,181.43Other instructions:

□Applicable √Not applicable

Non-operating income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Included in non-recurring losses for the current period Amount incurred in the current period Amount incurred in the previous period

amount of profit

No payment required 20,042.46

Penalties and liquidated damages gains 75,064.00 614,082.09 75,064.00 Others 152.88 18,650.52 152.88

Total 75,216.88 652,775.07 75,216.88Other instructions:

□Applicable √Not applicable

Non-operating expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Amount included in non-recurring gains and losses for the current period Total losses from damage and scrapping of non-current assets 169,008.24 237,474.98 169,008.24 Among them: losses from damage and scrapping of fixed assets 169,008.24 237,474.98 169,008.24 External donations 777,882.12 736,877.19 777,882.12 Fines and late payment fees 920,021.29 63,500.69 920,021.29 Abnormal inventory losses 222,926.17

131/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Compensation expenses 760,923.50 760,923.50 Others 115,872.63 225,384.32 115,872.63

Total 2,743,707.78 1,486,163.35 2,743,707.78Other instructions:

None

Income tax expenses

(1) Income tax expense schedule

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Current income tax expense 20,228,937.23 23,635,958.75 Deferred income tax expense 1,418,223.31 2,769,295.90

Total 21,647,160.54 26,405,254.65

(2) Adjustment process of accounting profits and income tax expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Total profits for the current period 172,697,912.07 Income tax expenses calculated according to statutory/applicable tax rates 25,904,686.81 Impact of different tax rates applicable to subsidiaries 1,466,380.52 Impact of adjusting income taxes in previous periods

Effect of non-taxable income -116,938.86 Effect of non-deductible costs, expenses and losses 950,479.28 Effect of using deductible losses of unrecognized deferred income tax assets in the previous period -4,032,913.75 Effect of deductible temporary differences or deductible losses of unrecognized deferred income tax assets in the current period 6,946,011.82 Effect of additional deduction of research and development expenses -9,241,882.83 Super deduction from wages for persons with disabilities -228,662.45 Income tax expense 21,647,160.54 Other notes:

□Applicable √Not applicable

Other comprehensive income

√Applicable □Not applicable

See notes for details

Cash flow statement items

(1) Cash related to operating activities

Other cash received related to operating activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Received deposits such as bills and letters of guarantee related to operating activities 1,581,903.66 Received government subsidies and refund of personal tax fees 15,738,509.14 11,460,963.59 Received (recovered) deposits and security deposits 4,777,849.60 8,611.41 Lease income 14,694,614.00 42,150.00

132/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Interest income 2,539,094.22 4,765,356.05 Others 252,996.76 1,275,745.49

Total 38,003,063.72 19,134,730.20 Description of other cash received related to operating activities:

None

Other cash paid related to operating activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Payment of deposits and guarantees 2,974,559.81 7,664,081.78 Payment of bills and guarantees related to operating activities 382,363.80 334,383.20 Cash payment fees 138,769,198.63 148,229,694.53 Litigation-related freezing 59,832,076.38 Others 111,961.74 1,418,610.26

Total 142,238,083.98 217,478,846.15 Description of other cash paid related to operating activities:

None

(2) Cash related to investing activities

Cash received in connection with significant investing activities

□Applicable √Not applicable

Cash payments related to significant investment activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Purchase of cash management products 240,370,000.00 432,166,258.40 Payment of delivery losses on forward foreign exchange settlement and sales contracts 1,743,000.00 Payment of futures margin 11,063,367.60

Total 251,433,367.60 433,909,258.40 Description of cash paid for important investment activities

None

Other cash received related to investing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Interest income accrued accordingly on return receivables 1,396,226.42

Total 1,396,226.42

Description of other cash received related to investing activities:

None

Other cash paid related to investing activities

□Applicable √Not applicable

(3) Cash related to financing activities

Other cash received related to financing activities

133/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

□Applicable √Not applicable

Other cash payments related to financing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Repay minority shareholders' capital loan 16,529,580.00 8,374,101.92 Rent and interest paid in the current period 8,129,482.60 2,045,377.02 Payment for the repurchase of unlocked shares under the employee stock ownership plan 40,440,082.80

Transfer money for purchasing minority shareholders’ equity 14,760,000.00

Total 79,859,145.40 10,419,478.94 Description of other cash paid related to financing activities:

None

134/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Changes in various liabilities arising from financing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase in this period Decrease in this period

Item Beginning balance Closing balance

Cash changes Non-cash changes Cash changes Non-cash changes

Short-term borrowings 767,002,817.30 886,000,000.00 9,537,872.58 756,088,827.76 906,451,862.12 Dividends payable 81,362,867.49 81,362,867.49

Long-term borrowings (including long-term borrowings due within one year) 483,407,915.54 6,202,998.41 105,775,760.62 383,835,153.33 Lease liabilities (including lease liabilities due within one year) 14,025,478.14 32,046,219.95 8,129,482.60 37,942,215.49 Other payables (borrowings from subsidiary minority shareholders) 17,782,280.00 16,529,580.00 1,252,700.00

Other payables (minority shareholder equity transfer amount) 36,900,000.00 14,760,000.00 22,140,000.00 Other payables (employee stock ownership plan repurchase obligations) 40,440,082.80 40,440,082.80

Total 1,322,658,573.78 886,000,000.00 166,049,958.43 1,023,086,601.27 1,252,700.00 1,350,369,230.94

(4) Explanation on presenting cash flows in net amount

□Applicable √Not applicable

(5) Major activities and financial impacts that do not involve current cash receipts and payments but affect the company's financial status or may affect the company's cash flow in the future

□Applicable √Not applicable

135/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Supplementary information for cash flow statement

(1) Supplementary information for cash flow statement

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Supplementary information Amount for the current period Amount for the previous period 1. Reconcile net profit to cash flow from operating activities:

Net profit 151,050,751.53 130,653,676.50 plus: asset impairment provision 21,588,938.29 11,447,368.00 Credit impairment loss 2,834,702.62 4,024,468.39 Depreciation of fixed assets, depreciation of oil and gas assets, depreciation of productive biological assets 146,091,685.79 127,831,052.16 Amortization of right-of-use assets 7,063,339.22 1,582,831.73 Amortization of intangible assets 15,728,778.17 13,635,360.85 Amortization of long-term prepaid expenses 1,205,174.82 170,364.04 Loss (gain) from disposal of fixed assets, intangible assets and other long-term assets

8,313,935.18 -340,181.43 (please fill in with "-")

Losses from scrapping of fixed assets (income is listed with "-") 169,008.24 237,474.98 Loss from changes in fair value (income is listed with "-") -10,690,009.70 -4,795,660.88 Financial expenses (income is listed with "-") 29,764,115.09 16,909,899.44 Investment losses (income is shown with "-") -22,946,175.57 -1,631,335.23 Decrease in deferred income tax assets (increases are shown with "-") 2,143,307.52 4,051,668.21 Increase in deferred income tax liabilities (decreases are shown with "-") -725,084.20 -1,282,372.30 Decrease in inventory (increases are indicated by "-") -165,963,096.55 -4,623,387.07 Decrease in operating receivables (increases are indicated by "-") -63,464,359.98 28,596,482.59 Increase in operating payables (decreases are listed with "-") -77,267,455.04 -165,759,229.41 Others

Net cash flow generated from operating activities 44,897,555.43 160,708,480.57 2. Major investing and financing activities that do not involve cash receipts and payments:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

3． Net changes in cash and cash equivalents:

Closing balance of cash 629,289,279.94 857,133,471.65 Less: Opening balance of cash 760,989,683.19 589,333,115.00 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents -131,700,403.25 267,800,356.65

(2) Net cash paid in the current period to acquire subsidiaries

□Applicable √Not applicable

(3) Net cash received from disposal of subsidiaries in the current period

□Applicable √Not applicable

(4) Composition of cash and cash equivalents

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Closing balance Opening balance

136/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Cash 629,289,279.94 760,989,683.19 Including: cash on hand

Bank deposits that can be used for payment at any time 616,414,963.66 754,671,540.89 Other monetary funds that can be used for payment at any time 12,874,316.28 6,318,142.30

2. Cash equivalents

Balance of cash and cash equivalents at the end of the period 629,289,279.94 760,989,683.19 Including: Restricted use of cash and cash equivalents by the parent company or subsidiaries within the group

thing

(5) Situations where the scope of use is limited but still presented as cash and cash equivalents

□Applicable √Not applicable

(6) Monetary funds other than cash and cash equivalents

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Ending balance Beginning balance Reason

Letter of guarantee deposit, letter of credit deposit

Interest, third-party payment platform and other monetary funds 64,700,762.29 64,318,398.23

Store deposits, frozen capital involved in litigation

gold

Total 64,700,762.29 64,318,398.23 /

Other notes:

□Applicable √Not applicable

Notes on items in the statement of changes in owners’ equity

Explain the names of "other" items that were adjusted to the closing balance of the previous year and the amount of adjustment, etc.:

□Applicable √Not applicable

Foreign currency monetary items

(1) Foreign currency monetary items

√Applicable □Not applicable

Unit: yuan Conversion of RMB items at the end of the period Foreign currency balance at the end of the period Conversion exchange rate

balance

Monetary funds 292,693,323.42 including: US dollars 30,035,140.50 6.8109 204,566,338.43 Euros 1,967,839.02 7.7671 15,284,402.45 British pounds 7,345,441.32 9.0145 66,215,480.78 Hong Kong dollars 462,571.85 0.8686 401,766.78 Singapore dollars 91,123.20 5.2605 479,353.59 birr 211,334.00 0.0428 9,036.64 Mexican pesos 2,031,183.71 0.3897 791,511.67 yen 6,303,913.00 0.0420 265,048.02 rials 822,855.78 1.8104 1,489,681.65 rupiah 1,618,794,879.00 0.0004 613,571.82 Kenyan shillings 49,116,287.09 0.0525 2,577,131.58 Accounts receivable 197,306,058.96

137/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Including: USD 27,897,434.58 6.8109 190,006,637.18

Euro 939,787.28 7.7671 7,299,421.78 Accounts payable 4,233,897.05 Including: USD 410,996.61 6.8109 2,799,256.81 Euro 183,962.21 7.7671 1,428,852.88

Ringgit 3,458.40 1.6734 5,787.36 Other receivables 1,149,453.46 Including: USD 168,766.75 6.8109 1,149,453.46 Other payables 7,545,047.79 Including: USD 1,095,895.71 6.8109 7,464,036.09

Singapore Dollar 15,400.00 5.2605 81,011.70Other instructions:

None

(2) The nature of the currency’s lack of convertibility and its financial impact, the spot exchange rate used and its estimation process, and the company’s

Risks from lack of convertibility

□Applicable √Not applicable

(3) Description of overseas operating entities, including for important overseas operating entities, their main overseas operating place and accounting standard currency should be disclosed.

and the basis for selection. If the accounting standard currency changes, the reasons should also be disclosed.

√Applicable □Not applicable

Company name Main place of business Accounting standard currency Basis for selection

Zhende Medical Supplies (Hong Kong) Co., Ltd. Hong Kong USD The company operates a universal settlement currency Hong Kong New Starting Point Investment Co., Ltd. Hong Kong USD The company operates a universal settlement currency ROCIALLEHEALTHCARELIMITED British Pounds The company operates a universal settlement currency ZHENDEETHIOPIAMEDICALPLC Ethiopia USD The company operates a universal settlement currency MIDMEDSLIMITED British Pounds The company operates a common settlement currency DENEHEALTHCARELIMITED British Pounds The company operates a common settlement currency NEWBEGINNINGS(SINGAPORE)PTE

Singapore USD Company operating common settlement currency LTD

FULLCARE(KENYA)MEDICAL

Kenyan Shilling The company operates a common settlement currency TECHNOLOGYEPZLTD

FULLCARE(KENYA)MEDICALSEZ

Kenyan Shilling Company operates in Common Settlement Currency LTD

BOSTONBGECAREINC United States United States Dollar The company operates the universal settlement currency MEDTECHMEDICALMEXICOS.DE

Mexico Mexican Peso The company operates the universal settlement currency R.L.DEC.V

MEDTECHMEXICOHEALTH,S.DE

Mexico Mexican Peso The company operates the universal settlement currency R.L.DEC.V.

Zhende Medical Japan Co., Ltd. Japan Japanese Yen The company operates a common settlement currency PTINDONESIAFULLCAREMEDICAL Indonesia Indonesian rupiah The company operates a common settlement currency ZHENDEMIDDLEEASTCOMPANY Saudi Arabia Saudi Riyal The company operates a common settlement currency

(4) Lack of convertibility between the accounting functional currency of overseas operations and the enterprise’s presentation currency

□Applicable √Not applicable

Leasing

(1) As a lessee

√Applicable □Not applicable

138/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Variable lease payments not included in the measurement of lease liabilities

□Applicable √Not applicable

Simplified treatment of short-term leases or lease payments for low-value assets

√Applicable □Not applicable

Item Amount for the current period Amount for the same period last year

Short-term rental expenses 3,056,999.00 1,365,189.90 Total 3,056,999.00 1,365,189.90

Sale and leaseback transactions and basis for judgment

□Applicable √Not applicable

The total cash outflow related to leasing is 11,190,266.62 (unit: yuan, currency: RMB)

(2) As a lessor

Operating lease as lessor

√Applicable □Not applicable

Unit: Yuan Currency: RMB Including: Available items not included in lease receipts Lease income

Income related to variable lease payments Fixed asset lease 13,672,029.07 281,993.36

Total 13,672,029.07 281,993.36 Finance lease as lessor

□Applicable √Not applicable

Reconciliation of undiscounted lease receipts and net lease investment

□Applicable √Not applicable

Undiscounted lease receipts over the next five years

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Annual undiscounted lease payments

Project

Ending amount Beginning amount

First year 27,466,543.78 11,721,779.23 One to three years 55,908,083.57 17,101,314.04 More than three years 7,232,457.36 15,875,247.68 Total 90,607,084.71 44,698,340.95

(3) Recognizing financial lease sales profits and losses as a manufacturer or distributor

□Applicable √Not applicable

Other instructions

None

Data resources

□Applicable √Not applicable

139/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Others

□Applicable √Not applicable

8. R&D expenditures

List according to nature of expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Salaries of R&D personnel 27,025,658.07 28,036,622.59 Inventories used for R&D 28,088,599.73 30,647,468.57 Fuel and power expenses 408,975.43 677,140.16 Depreciation and amortization expenses 2,351,553.27 2,176,007.79 Design, testing and equipment commissioning fees 9,132,365.39 4,694,239.94 Others 1,577,907.61 508,355.77

Total 68,585,059.50 66,739,834.82 Including: expensed R&D expenditures 64,888,620.92 63,735,842.41

Capitalized R&D expenditures 3,696,438.58 3,003,992.41Other explanations:

None

Development expenditures on R&D projects that meet capitalization conditions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase amount in this period Decrease amount in this period

Items at the beginning of the period and at the end of the period: Internal development expenses are recognized as intangible assets and transferred to the current period's losses.

Balance Balance

Produce other profits

XWY 2,678,590.77 518,890.69 3,197,481.46 NFL 1,062,363.17 1,062,363.17 TMQ 1,124,926.87 271,698.11 1,396,624.98 YPMC 6,274,789.36 2,642,104.85 8,916,894.21 SSD 275,167.94 10,400.00 285,567.94 CHG 1,421,046.86 91,095.68 1,512,142.54 YZSY 1,546,876.20 162,249.25 1,709,125.45 IID 246,043.44 246,043.44Total 14,629,804.61 3,696,438.58 18,326,243.19 Important capitalized R&D projects

□Applicable √Not applicable

Impairment provision for development expenditures

□Applicable √Not applicable

Other instructions

None

Important outsourced research projects

□Applicable √Not applicable

140/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

9. Changes in consolidation scope

Merger of enterprises not under common control

□Applicable √Not applicable

Merger of enterprises under common control

□Applicable √Not applicable

Reverse purchase

□Applicable √Not applicable

Disposal of subsidiaries

Are there any transactions or events that result in the loss of control of subsidiaries during this period?

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period?

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related situations: □ Applicable √ Not applicable

Others

□Applicable √Not applicable

10. Interests in other entities

Interests in subsidiaries

(1) Composition of enterprise groups

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Major shareholding ratio

Subsidiary business (%) Obtained operating registered capital Place of registration

name, quality, time, manner

Connect to Henan 330 million people Xuchang Zhende Medical Dressing Co., Ltd. under common control Xuchang, Henan Manufacturing 100

Xuchang coin business merger

23.193 million people Non-common control Shanghai Yaao Medical and Health Products Co., Ltd. Shanghai Shanghai Manufacturing 100

Currency Business merger under Jiangsu 33.887 million people Not under common control Nantong Mattel Medical Products Co., Ltd. Nantong, Jiangsu Manufacturing 100 Nantong currency Business merger under Henan 160 million people Xuchang Zhengde Medical Products Co., Ltd. under common control Xuchang, Henan Manufacturing 100

Xuchang coin enterprise merger Henan 30 million people

Henan Zhende Medical Supplies Co., Ltd. Xuchang, Henan Manufacturing 100 Establishment of Xuchang Coin

141/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Anhui 120 million people Anhui Medis Medical Products Co., Ltd. under common control Huainan, Anhui Manufacturing 100

Huainan Coin Business merger Zhejiang 10 million people Non-common control Shaoxing Haoshide Medical Products Co., Ltd. Shaoxing, Zhejiang Manufacturing 100

Shaoxing Currency under enterprise merger Zhejiang 27.3 million people Non-common control Shaoxing Tuomei Medical Supplies Co., Ltd. Zhejiang Shaoxing Commercial 100

Shaoxing currency merged with Shanghai Liande Medical Biomaterials Co., Ltd.

Shanghai 5 million RMB Shanghai Business 100 Establishment

Division

Zhejiang

Hangzhou Lingtu Technology Co., Ltd. 5 million RMB Hangzhou, Zhejiang Commercial 90 Established

Hangzhou

Zhejiang 2.488 million people Non-common control Hangzhou Pujian Medical Equipment Co., Ltd. Hangzhou, Zhejiang Commercial 100

Hangzhou currency enterprise merger Zhejiang 154.1353 million people

Shaoxing Zhende Medical Products Co., Ltd. Shaoxing, Zhejiang Business 6.5 93.5 Established

Shaoxing RMB

Suzhou Medis Medical Sports Goods Co., Ltd. Jiangsu 10 million people Not under common control

Suzhou, Jiangsu Business 100

Company Suzhou Coin Under Business Merger China

Zhende Medical Supplies (Hong Kong) Co., Ltd. 1 million RMB Hong Kong, China Commercial 100 Established

Hong Kong

China USD 500,000

Hong Kong New Starting Point Investment Co., Ltd. Hong Kong, China Business 100 Established

Hong Kong +£6 million

ROCIALLEHEALTHCARE Not under common control UK £100 UK Manufacturing 55

LIMITED under business merger Ethiopia

ZHENDEETHIOPIA 6.4 million Ethiopian Ethiopian

Russia-Belgium Manufacturing 100 Establishment

MEDICALPLC BIABILIA

Asia

Not under common control MIDMEDSLIMITED UK £200 UK Business 55

NextBusiness MergerNEW

new addition

BEGINNINGS(SINGAPORE) US$1 million Singapore Business 100 Establishment

slope

PTELTD

FULLCARE(KENYA)

Kenya 3.9 billion

MEDICALTECHNOLOGY Kenya Manufacturing 100 Established

Asia shilling

EPZLIMITED

Non-common control BOSTONBGECAREINC United States US$100,000 Boston Business 100

Under Business Combination DENEHEALTHCARE Not under common control UK £300 UK Business 55

LIMITED under business combination FULLCARE (KENYA) Kenya 3.25 billion Kenya

Kenya Manufacturing 100 established

MEDICALSEZLIMITED Asian shillings

MEDTECHMEDICAL Mexico 445,761,380

Mexico Business 100 Establishment

MEXICO,S.DER.L.DEC.V. Mexican Peso

Zhejiang Stange Sports Medical Technology Co., Ltd. Zhejiang 13.15 million people Not under common control

Yiwu, Zhejiang Manufacturing 60

Company Yiwu Currency Business merger under Zhejiang Non-common control Hangzhou Xindong Network Technology Co., Ltd. 3 million RMB Hangzhou, Zhejiang Commercial 100

Hangzhou merged with Zhejiang Zhende Health Technology Co., Ltd. Zhejiang 10 million people

Hangzhou, Zhejiang Business 100 Established

Division Hangzhou Coin

Anhui 6.175 million people Non-common control Anhui Lanxin Medical Technology Co., Ltd. Chuzhou, Anhui Manufacturing 60

Chuzhou currency enterprise merger Zhejiang 10 million people

Shaoxing Zhende Medical Technology Co., Ltd. Shaoxing, Zhejiang Manufacturing 60 Established

Shaoxing Coin

Anhui 20 million people

Huainan Mattel Medical Products Co., Ltd. Huainan, Anhui Manufacturing 100 Established

Huainan coin

Henan 10 million people

Yanling County Mattel Medical Products Co., Ltd. Xuchang, Henan Manufacturing 100 Established

Xuchang coin

Jiangsu 60 million people Non-common control Jiangsu Inbest Technology Development Co., Ltd. Huaian, Jiangsu Manufacturing 100

Business merger under Huaian Coin

142/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

MEDTECHMEXICO Mexico 8.88114 million ink

Mexico Manufacturing 100 Establishment of HEALTH,S.DER.L.DEC.V. Colombia Mexican Peso

Zhende Medical Japan Co., Ltd. Japan 30.94 million yen Japan Business 100 Established

Henan 60 million people

Xuchang Huitong Textile Co., Ltd. Xuchang, Henan Province Business 100 Establishment of Xuchang Coin

Anhui 35 million people

Huainan Meian Textile Co., Ltd. Huainan, Anhui Business 100 Establishment Huainan Coin

Jiangxi

Jing'an Yude Medical Technology Co., Ltd. 1 million yuan Yichun, Jiangxi Commercial 100 Established

Yichun

ZHENDEMIDDLEEAST 18.75 million Saudi Arabia

Saudi Arabia Manufacturing 80 Establishment COMPANY Riyals

India

PTINDONESIAFULLCARE 113.9964 billion Indonesia

Nigeria Manufacturing 100 Establishment of MEDICAL Nigeria Asia

Asia

Zhejiang 23 million people Non-common control Ningbo Shengyurui Medical Equipment Co., Ltd. Ningbo, Zhejiang Manufacturing Industry Merger under 100 Ningbo currency

Zhejiang Ningbo Anmu Medical Technology Co., Ltd. not under common control RMB 1 million Ningbo, Zhejiang Commercial 100

Explanation on the difference between the shareholding ratio of subsidiaries in Ningbo's corporate merger and the voting rights ratio:

Not applicable

Basis for holding half or less of the voting rights but still controlling the invested unit, and holding more than half of the voting rights but not controlling the invested unit:

Not applicable

For important structured entities included in the scope of consolidation, the basis for control is:

Not applicable

Basis for determining whether a company is agent or principal:

Not applicable

Other notes:

None

(2) Important non-wholly owned subsidiaries

□Applicable √Not applicable

(3) Main financial information of important non-wholly owned subsidiaries

□Applicable √Not applicable

(4) Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts:

□Applicable √Not applicable

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements: □Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Transactions in which the ownership share of the subsidiary changes and the subsidiary is still controlled

√Applicable □Not applicable

143/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(1) Description of changes in owner’s equity share of subsidiaries

√Applicable □Not applicable

Subsidiary name Time of change Shareholding ratio before change Shareholding ratio after change Ningbo Shengyurui Medical Equipment Co., Ltd. June 25, 2026 90% 100%

(2) The impact of the transaction on minority shareholders’ equity and owner’s equity attributable to the parent company

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Purchase cost/disposal consideration of Ningbo Shengyurui Medical Devices Co., Ltd.

--Cash 36,900,000.00 Total purchase cost/disposal consideration 36,900,000.00 Less: Share of net assets of subsidiaries calculated based on the proportion of equity acquired/disposed 8,190,210.93 Difference 28,709,789.07 Including: Adjusted capital reserve 28,709,789.07 Other notes

□Applicable √Not applicable

Interests in joint ventures or associated enterprises

√Applicable □Not applicable

(1) Important joint ventures or associates

□Applicable √Not applicable

(2) Main financial information of important joint ventures

□Applicable √Not applicable

(3) Main financial information of important associates

□Applicable √Not applicable

(4) Summary financial information of immaterial joint ventures and associates

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Closing balance/Amount incurred in the current period Opening balance/Amount incurred in the previous period Associates:

Total book value of investments 117,676,001.90 118,455,594.32 Total of the following items calculated based on shareholding ratio

--Net profit -779,592.42 -1,542,790.73 --Other comprehensive income

--Total comprehensive income -779,592.42 -1,542,790.73Other explanations

None

(5) Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company

□Applicable √Not applicable

(6) Excess losses incurred by joint ventures or associates

□Applicable √Not applicable

144/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(7) Unconfirmed commitments related to investments in joint ventures

□Applicable √Not applicable

(8) Contingent liabilities related to investments in joint ventures or associates

□Applicable √Not applicable

Important joint operations

□Applicable √Not applicable

Interests in structured entities not included in the scope of consolidated financial statements

Relevant instructions for structured entities not included in the scope of consolidated financial statements:

□Applicable √Not applicable

Others

□Applicable √Not applicable

11. Government subsidies

Government subsidies recognized according to the amount receivable at the end of the reporting period

□Applicable √Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

□Applicable √Not applicable

Liability items involving government subsidies

√Applicable □Not applicable

Unit: Yuan Currency: RMB for this period

credited

Financial Current Period and Assets

Newly added business in this period will be transferred to it in this period

Statement Beginning Balance Others Closing Balance/Income

Subsidy amount, external income, other income

Project changes related deposits

Deferred and assets

215,236,541.61 10,788,510.00 10,834,340.80 215,190,710.81 Income related total 215,236,541.61 10,788,510.00 10,834,340.80 215,190,710.81/

Government subsidies included in current profits and losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB Type Amount for the current period Amount for the previous period

Related to income 4,085,969.96 3,889,864.20 Related to assets 10,834,340.80 10,088,314.80

Total 14,920,310.76 13,978,179.00Other instructions:

None

145/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

12. Risks related to financial instruments

Risks of financial instruments

√Applicable □Not applicable

The company's goal in risk management is to strike a balance between risks and returns, minimize the negative impact of risks on the company's operating performance, and maximize the interests of shareholders and other equity investors. Based on this risk management objective, the company's basic risk management strategy is to confirm and analyze the various risks faced by the company, establish an appropriate risk tolerance bottom line and conduct risk management, and supervise various risks in a timely and reliable manner to control risks within a limited range.

The Company faces various risks related to financial instruments in its daily activities, mainly including credit risk, liquidity risk and market risk. Management has reviewed and approved policies for managing these risks, which are summarized below.

(1) Credit risk

Credit risk refers to the risk that one party to a financial instrument cannot fulfill its obligations, causing financial losses to the other party.

Credit risk management practices

(1) Credit risk evaluation methods

The Company assesses at each balance sheet date whether the credit risk of relevant financial instruments has increased significantly since initial recognition. When determining whether credit risk has increased significantly since initial recognition, the Company considers reasonable and evidence-based information that is available without unnecessary additional cost or effort, including qualitative and quantitative analysis based on historical data, external credit risk ratings, and forward-looking information. Based on a single financial instrument or a combination of financial instruments with similar credit risk characteristics, the company determines the changes in default risk during the expected duration of the financial instrument by comparing the risk of default of the financial instrument on the balance sheet date with the risk of default on the initial recognition date.

When one or more of the following quantitative and qualitative criteria are triggered, the company believes that the credit risk of financial instruments has increased significantly:

The quantitative standard is mainly that the default probability of the remaining duration on the balance sheet date has increased by more than a certain percentage compared with the initial recognition;
Qualitative standards mainly include major adverse changes in the debtor's operating or financial conditions, existing or expected changes in technology, market, economic or legal environment, which will have a major adverse impact on the debtor's ability to repay the company, etc.

(2) Definition of defaulted and credit-impaired assets

When a financial instrument meets one or more of the following conditions, the company defines the financial asset as having defaulted, and its standards are consistent with the definition of credit impairment:

The debtor encounters major financial difficulties;
The debtor violates the binding clauses on the debtor in the contract;
The debtor is likely to go bankrupt or undergo other financial reorganization;
The creditor grants concessions to the debtor that the debtor would not have made under any other circumstances due to economic or contractual considerations related to the debtor's financial difficulty.

Measurement of expected credit losses

Key parameters for measuring expected credit losses include probability of default, loss given default rate and exposure to default risk. The company considers quantitative analysis and forward-looking information of historical statistical data (such as counterparty ratings, guarantee methods and collateral types, repayment methods, etc.) to establish default probability, default loss rate and default risk exposure models.

For details of the reconciliation statement between the opening balance and the closing balance of financial instrument loss provisions, please refer to Section 8 of this report. 7. Consolidated Financial Statement Items Notes

(1) Explanation of 2, 3, 4, 5, and 7.

Credit risk exposure and credit risk concentration

The company's credit risk mainly comes from monetary funds and accounts receivable. In order to control the above-mentioned related risks, the Company has taken the following measures.

(1) Monetary funds

The Company places bank deposits and other monetary funds in financial institutions with higher credit ratings, so its credit risk is lower.

(2) Accounts receivable

The company regularly conducts credit assessments on customers who trade on credit. Based on the credit assessment results, the Company chooses to conduct transactions with approved customers with good credit and monitors their receivable balances to ensure that the Company does not face significant bad debt risks.

As the Company only trades with accredited and creditworthy third parties, no collateral is required. Credit risk is managed centrally by customer. As of June 30, 2026, the Company has certain credit concentration risks, and the Company’s accounts receivable

146/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

22.83% (December 31, 2025: 17.13%) comes from the top five customers with balance. The Company does not hold any collateral or other credit enhancements on the accounts receivable balance.

The Company's maximum exposure to credit risk is the carrying value of each financial asset on the balance sheet.

(2) Liquidity risk

Liquidity risk refers to the risk of a shortage of funds when the company fulfills its obligations to settle by delivering cash or other financial assets. Liquidity risk may arise from the inability to sell financial assets at fair value as quickly as possible; or from the counterparty's inability to repay its contractual debts; or from debts that mature prematurely; or from the inability to generate expected cash flows. In order to control this risk, the Company comprehensively uses various financing methods such as bill settlement and bank borrowing, and adopts an appropriate combination of long-term and short-term financing methods to optimize the financing structure and maintain a balance between financing continuity and flexibility. The Company has obtained bank credit lines from a number of commercial banks to meet its working capital requirements and capital expenditures.

Financial liabilities are classified by remaining maturity

Closing amount

Project

Book value Undiscounted contract amount Within 1 year 1-3 years Short-term loan over 3 years

906,451,862.12 914,135,418.63 914,135,418.63

Derivatives

214,000.00 214,000.00 214,000.00 Financing liabilities

Invoices payable

10,381,930.51 10,381,930.51 10,381,930.51According to

Accounts payable

476,523,744.29 476,523,744.29 476,523,744.29

Other should

152,991,601.22 152,991,601.22 152,991,601.22 Payment

within one year

due

9,483,135.28 9,504,170.82 9,504,170.82 Non-current

Liabilities

long term loan

381,833,847.77 431,902,841.53 99,882,200.00 332,020,641.53

Lease negative

30,460,385.77 32,728,455.88 29,831,846.72 2,896,609.16 Debt

Subtotal 1,968,340,506.96 2,028,382,162.88 1,563,750,865.47 129,714,046.72 334,917,250.69

(Continued from above table)

End of last year

Project

Book value Undiscounted contract amount Within 1 year 1-3 years Short-term loan over 3 years

767,002,817.30 772,448,104.00 772,448,104.00

Invoices payable

16,450,317.87 16,450,317.87 16,450,317.87According to

Accounts payable

556,582,886.75 556,582,886.75 556,582,886.75 models

Other should

149,514,610.48 149,514,610.48 149,514,610.48 Payment

within one year

due

105,540,294.68 105,880,852.88 105,880,852.88 non-current

Liabilities

147/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

End of last year

Project

Book value Undiscounted contract amount Within 1 year 1-3 years Long-term loan over 3 years

383,096,181.74 440,622,019.20 11,240,394.00 119,705,823.60 309,675,801.60

Lease negative

8,796,917.26 9,616,375.62 6,410,917.08 3,205,458.54 Debt

Subtotal 1,986,984,026.08 2,051,115,166.80 1,612,117,165.98 126,116,740.68 312,881,260.14

(3) Market risk

Market risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market prices. Market risks mainly include interest rate risk and foreign exchange risk.

Interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Fixed-rate interest-bearing financial instruments expose the Company to fair value interest rate risk, while floating-rate interest-bearing financial instruments expose the Company to cash flow interest rate risk. The Company determines the proportion of fixed-rate and floating-rate financial instruments based on market conditions, and maintains an appropriate portfolio of financial instruments through regular review and monitoring.

Foreign exchange risk

Foreign exchange risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. The risk of exchange rate changes faced by the Company is mainly related to the Company's foreign currency monetary assets and liabilities. For foreign currency assets and liabilities, if short-term imbalances occur, the Company will buy and sell foreign currencies at market exchange rates when necessary to ensure that the net risk exposure is maintained at an acceptable level.

For details of the Company’s foreign currency monetary assets and liabilities at the end of the period, please refer to Note 81 of Chapter 7, Consolidated Financial Statement Items in Section 8 of this report.

Hedging

(1) The company carries out hedging business for risk management

√Applicable □Not applicable

expected wind

Corresponding risk management

Item Determination of the hedged risk The hedged item and related hedging activities The corresponding hedging activities have an impact on the management strategy objectives

Objectives and quantitative information Economic relationships between instruments Impact of risk exposures and objective achievement

situation

Locked company, hedged item and hedging instrument

Exchange rate changes lead to

There is an economic relationship with the foreign exchange held by the foreign exchange. The economic risk is expected to

The foreign currency assets held by the company purchase hedging instruments to manage the hedging instruments and the hedged risks.

Assets and foreign currency liabilities Reduce exchange rate risk exposure Foreign currency liabilities The value of projects facing the same objectives may vary

resulting in corresponding exchange losses.

The exchange rate risk is hedged and the risk occurs in the opposite direction.

benefit

dangerous changes

Business between the hedged item and the hedging instrument

There is an economic relationship between polypropylene, polyethylene, buying or selling corresponding products. The economic risk is expected to

Locking the company's commodity futures contract system for natural rubber and other raw materials enables hedging tools and hedged risk management

Commodity price fluctuations lead to contract material price fluctuations, which can be used to hedge the value of projects facing the same goals.

The company's operating costs are the risk of the company's spot business. There are risks in the spot business. The direction of the occurrence is related to the hedging risk to achieve

exposure to fluctuations in

Other instructions

□Applicable √Not applicable

148/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) The company carries out qualified hedging business and applies hedging accounting

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(3) The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting

√Applicable □Not applicable

Item Reasons for not applying hedging accounting Impact on financial statements The company uses foreign exchange forwards, foreign exchange options and other derivative financial instruments to hedge foreign exchange risk exposures, and strictly controls the amount of foreign exchange locked in forward contracts not to exceed the corresponding foreign exchange risk exposure. In view of the fact that forward contracts and foreign exchange exposures cannot match the changing profits and losses and investment allocations in terms of term, amount and delivery time, the applicable conditions for hedging accounting are not met. In the income account, the company uses polypropylene, polyethylene, and derivative financial instruments based on inventory, procurement, sales demand and price trends.

Futures contracts such as natural rubber are used to hedge commodity risk exposure, and futures positions are strictly controlled so that current profits are directly included in the fair price.

within the purchase quantity range. Profit and loss and investment risks arise due to changes in term, amount and delivery time between contract delivery and spot storage.

Unable to match one by one and does not meet the applicable conditions for hedge accounting. In the income account

Other instructions

□Applicable √Not applicable

Transfer of financial assets

(1) Classification of transfer methods

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Transferred Financial Financing Termination Confirmation Information

Transfer method Nature of transferred financial assets Derecognition is judged based on the amount of assets

Has transferred substantially all of its note endorsements Receivables financing 39,445,866.71 Derecognized

Risks and Rewards

Total / 39,445,866.71 / /

(2) Financial assets derecognized due to transfer

√Applicable □Not applicable

Unit: Yuan Currency: RMB

The party to transfer the financial assets. The amount of the financial assets derecognized. Gains or losses related to the derecognition.

formula amount loss

Receivables financing endorsement 39,445,866.71

Total / 39,445,866.71

(3) Transferred financial assets with continued involvement

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

13. Disclosure of fair value

Closing fair value of assets and liabilities measured at fair value

√Applicable □Not applicable

149/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Unit: Yuan Currency: RMB Closing fair value

Project First level fairness Second level fairness Third level fairness

total

Fair value measurement Value measurement Value measurement

1. Continuous fair value measurement

(1) Trading financial assets 266,752,486.90 266,752,486.90

(2) Derivative financial assets 249,500.00 249,500.00

(3) Financing of accounts receivable 19,107,166.01 19,107,166.01

(4) Other non-current financial assets 16,252,163.09 16,252,163.09 Total assets continuously measured at fair value 249,500.00 266,752,486.90 35,359,329.10302,361,316.00

(5) Derivative financial liabilities 214,000.00 214,000.00 Total liabilities continuously measured at fair value 214,000.00 214,000.00

Basis for determining the market price of continuous and non-continuous first-level fair value measurement items

√Applicable □Not applicable

The Company holds derivative financial assets measured at the first level of fair value of RMB 249,500.00 and derivative financial liabilities.

The RMB 214,000.00 is a futures contract, and its fair value is determined using open market quotations.

Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters √ Applicable □ Not applicable

The second-level fair value measurement trading financial assets held by the Company amounting to RMB 266,752,486.90 are financial products, and the market value provided by financial institutions is used to determine their fair value.

Continuous and non-continuous third-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters √ Applicable □ Not applicable
The company holds financing receivables of RMB 19,107,166.01, which are bills receivable that the company and its subsidiaries expect to use for endorsement or discounting. Considering the short term of the bills, the company uses the face amount to confirm its fair value.
For the equity investment in unlisted companies held by the company, if there is a transaction by the investee during the reporting period, the latest transaction price will be used as the fair value; if there is no transaction, and there is no significant change in the operating conditions and financial status of the investee, the investment cost will be used as a reasonable estimate of the fair value.
For ongoing third-level fair value measurement items, the reconciliation information and unobservable parameters between the opening and closing book values are sensitive

sexual analysis

□Applicable √Not applicable

For ongoing fair value measurement items, if there is a conversion between levels during the current period, the reasons for the conversion and the policy for determining the time of conversion.

policy

□Applicable √Not applicable

Valuation technology changes and reasons for changes during the period

□Applicable √Not applicable

Fair value of financial assets and financial liabilities not measured at fair value

□Applicable √Not applicable

Others

□Applicable √Not applicable

150/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

14. Related parties and related transactions

Information about the parent company of this enterprise

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB

Parent company to this enterprise Parent company to this enterprise Parent company name Place of registration Nature of business Registered capital

Shareholding ratio (%) Voting rights ratio (%)

Zhejiang Zhende Holdings Zhejiang Shaoxing Industrial Investment 5,000 49.72 49.72 Co., Ltd.

Description of the parent company of this enterprise

Zhejiang Zhende Holding Co., Ltd. directly holds 49.7168% of the company's shares. Zhejiang Zhende Holdings Co., Ltd. was funded and established by 10 natural persons including Lu Jianguo and Shen Zhendong. It currently holds a business license with a unified social credit code of 91330602755933132U issued by the Shaoxing Yuecheng District Market Supervision Administration. After several capital increases and equity transfers, the existing registered capital is 50 million yuan, of which Lu Jianguo contributed 43.5776 million yuan, accounting for 87.1552% of the registered capital; Shen Zhendong and other nine natural persons contributed 6.4224 million yuan, accounting for 12.8448% of the registered capital.

The ultimate controlling parties of this enterprise are Lu Jianguo and Shen Zhenfang.

Other notes:

Lu Jianguo directly holds 1.4873% of the company's shares and indirectly holds 43.3308% of the company's shares through Zhejiang Zhende Holding Co., Ltd. Shen Zhenfang, the wife of Lu Jianguo, directly holds 3.5282% of the company's shares and indirectly holds 0.9943% of the company's shares through Zhejiang Zhende Holding Co., Ltd. Lu Jianguo and Shen Zhenfang collectively control 49.3406% of the company's shares, so the actual controllers of the company are Lu Jianguo and Shen Zhenfang.

Information about the company’s subsidiaries

Please refer to the notes for details of the company’s subsidiaries.

√Applicable □Not applicable

For details, please refer to Section 8 of this report 10. Description of interests in other entities

Information about the company’s joint ventures and associated enterprises

Please refer to the notes for details of important joint ventures or associates of this company.

√Applicable □Not applicable

For details, please refer to Section 8 of this report 10. Description of interests in other entities

The details of other joint ventures or associates that have related party transactions with the company in the current period, or have balances from related party transactions with the company in previous periods are as follows:

□Applicable √Not applicable

Other related parties

√Applicable □Not applicable

Names of other related parties Relationship between other related parties and the company

Yanling Zhende Biomass Energy Thermal Power Co., Ltd. Same controlling shareholder

Yanling Xiangfa Packaging and Printing Co., Ltd. is controlled by the close family members of the actual controller of the company. Shaoxing Gangfeng Medical Products Co., Ltd. is controlled by the close family members of the actual controller of the company. Shaoxing Yuantong Information Technology Co., Ltd. is controlled by the close family members of the directors of the company.

MULTIGATEMEDICALPRODUCTSUK [Note 1]

LIMITED

MULTIGATEMEDICALPRODUCTSPTY [Note 2]

LTD

Other instructions

[Note 1] MULTIGATE MEDICAL PRODUCTSUK LIMITED holds 45.00% of the shares of the company’s holding subsidiary ROCIALLE HEALTHCARELIMITED

151/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

[Note 2] MULTIGATEMEDICALPRODUCTSPTYLTD is the controlling shareholder of MULTIGATEMEDICALPRODUCTS UKLIMITED

Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Whether it exceeds the approved transaction amount within the cross-linked transaction

Related parties Amount incurred in the current period Transaction limit (such as the amount incurred in the previous period (if applicable)

Applicable) Yanling Xiangfa packaging printing

Purchase of goods 8,467,252.97 25,000,000 No 8,046,958.62 Co., Ltd.

Yanling Zhende Biomass Energy

Steam, electricity 22,972,096.51 60,000,000 No 21,740,510.66Yuan Thermal Power Co., Ltd.

Shaoxing Yuantong Information Technology

Accepting labor services 17,821.78 20,000 No limited company

Subtotal 31,457,171.26 29,787,469.28

List of goods sold/services provided

√Applicable □Not applicable

Unit: Yuan Currency: RMB Related parties Related party transaction content Amount of the current period Amount of the previous period MULTIGATEMEDICAL

Sales of goods 33,624,882.98 48,743,890.56 PRODUCTSPTYLTD

Subtotal 33,624,882.98 48,743,890.56

Description of related transactions for purchasing and selling goods, providing and receiving services

□Applicable √Not applicable

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

The company's entrusted management/contracting status table:

□Applicable √Not applicable

Description of associated hosting/contracting situations

□Applicable √Not applicable

The company’s entrusted management/outsourcing status table:

□Applicable √Not applicable

Description of association management/outsourcing situation

□Applicable √Not applicable

(3) Related lease situation

As a lessor, our company:

□Applicable √Not applicable

As a lessee, our company:

□Applicable √Not applicable

152/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Description of related leasing situation

□Applicable √Not applicable

(4) Related guarantees

The company acts as a guarantor

□Applicable √Not applicable

The company as the guaranteed party

□Applicable √Not applicable

Description of related guarantees

□Applicable √Not applicable

(5) Fund lending from related parties

□Applicable √Not applicable

(6) Asset transfer and debt restructuring of related parties

□Applicable √Not applicable

(7) Remuneration of key management personnel

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Remuneration of key management personnel 702.49 516.89

(8) Other related transactions

□Applicable √Not applicable

Unsettled items such as receivables and payables to related parties

(1) Items receivable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Ending balance Beginning balance

Project name Related parties

Book balance Bad debt provision Book balance Bad debt provision Accounts receivable

MULTIGATEMEDICAL

10,397,237.50 519,861.88 17,896,002.30 894,800.12 PRODUCTSPTYLTD

Shaoxing Gangfeng Medical Products Co., Ltd. 14,108.64 705.43 Subtotal 10,397,237.50 519,861.88 17,910,110.94 895,505.55

(2) Items payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB Project name Related parties Book balance at the end of the period Book balance at the beginning of the period Accounts payable

Yanling Xiangfa Packaging and Printing Co., Ltd. 4,741,483.83 5,114,475.46

Yanling Zhende Biomass Energy Thermal Power Co., Ltd. 1,250,983.40 1,406,147.58 Subtotal 5,992,467.23 6,520,623.04

153/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Project name Related party Book balance at the end of the period Book balance at the beginning of the period Other payables

MULTIGATEMEDICALPRODUCTSUKLIMITED 16,982,280.00 Subtotal 16,982,280.00

(3) Other items

□Applicable √Not applicable

Related party commitments

□Applicable √Not applicable

Others

□Applicable √Not applicable

15. Share-based payment

Various equity instruments

(1) Details

√Applicable □Not applicable

Quantity unit: shares Amount unit: Yuan Currency: RMB Grant object Granted in this period Exercise in this period Unlocked in this period Expired in this period

Category Quantity Amount Quantity Amount Quantity Amount Quantity Amount Management staff 292,400 6,482,508.00 Sales staff 1,537,468 34,085,665.56

Total 1,829,868 40,568,173.56

(2) Stock options or other equity instruments outstanding at the end of the period

□Applicable √Not applicable

Equity-settled share-based payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Equity-settled share-based payment objects Company directors (excluding independent directors), supervisors, senior managers, middle managers and core technology (industry)

service) key personnel

Method for determining the fair value of equity instruments on the grant date. The fair value of restricted stocks is based on the company’s listed and tradable shares.

The market price on the day the ticket is awarded is determined

Important parameters for the fair value of equity instruments on the date of grant. The fair value of stock options is based on the Black-Scholes period.

The right pricing model is calculated and determined.

The basis for determining the number of exercisable equity instruments. The reason for the significant difference between the estimate for this period and the estimate for the previous period is determined based on the expected number of exercisable employees and other information. Not applicable

The cumulative amount of equity-settled share-based payments included in capital reserves 39,355,641.14 Other notes

None

Share-based payment settled in cash

□Applicable √Not applicable

154/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Share-based payment expenses for this period □ Applicable √ Not applicable
Modification and termination of share-based payment □Applicable √Not applicable
Others

□Applicable √Not applicable

Commitments and contingencies
Important commitments

□Applicable √Not applicable

Contingencies

(1) Important contingencies existing on the balance sheet date □Applicable √Not applicable

(2) If the company has no important contingencies that need to be disclosed, it should also be explained: √Applicable □Not applicable

As of the balance sheet date, the Company has no important contingencies that need to be disclosed.

Others

□Applicable √Not applicable

Events after the balance sheet date
Important non-adjustment matters □Applicable √Not applicable
Profit distribution

□Applicable √Not applicable

Sales returns

□Applicable √Not applicable

Description of other post-balance sheet events □Applicable √Not applicable
Other important matters
Correction of previous accounting errors

(1) Retrospective restatement method

□Applicable √Not applicable

(2) Prospective applicable law

□Applicable √Not applicable

155/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Important debt restructuring

□Applicable √Not applicable

Asset replacement

(1) Non-monetary asset exchange

□Applicable √Not applicable

(2) Other asset swaps

□Applicable √Not applicable

Annuity plan

□Applicable √Not applicable

Termination of operations

□Applicable √Not applicable

Branch information

(1) Determination basis and accounting policies of reportable segments

√Applicable □Not applicable

The company's main business is the production and sales of basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control and protection products. The company regards this business as a whole to implement management and evaluate operating results. Therefore, the Company is not required to disclose segment information. For detailed information on the company's revenue breakdown, please refer to Section 8 of this report. 7. Notes to Items in Consolidated Financial Statements 61 Description of operating income and operating costs.

(2) Financial information of reportable segments

□Applicable √Not applicable

(3) If the company has no reportable segments, or cannot disclose the total assets and total liabilities of each reportable segment, the reasons should be stated □Applicable √Not applicable

(4) Other instructions

□Applicable √Not applicable

Other important transactions and matters that have an impact on investors’ decision-making □Applicable √Not applicable
Others

□Applicable √Not applicable

19. Notes on main items of the parent company’s financial statements

Accounts receivable

(1) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 285,312,862.16 398,088,787.08

156/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Within 1 year 285,312,862.16 398,088,787.08 1 to 2 years 11,185,685.41 2,450,910.58 2 to 3 years 1,063,555.73 465,365.16 More than 3 years 639,613.01 174,247.85 Total 298,201,716.31 401,179,310.67

157/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(2) Classified disclosure based on bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book Book proportion Provision proportion Proportion Provision proportion

Amount Amount Value Amount Amount Value

(%) (%) (%) (%)

Provision for bad debts on an individual basis 562,000.00 0.19 562,000.00 100 562,000.00 0.14 562,000.00 100.00

Among them:

Provision for bad debts on an individual basis 562,000.00 0.19 562,000.00 100 562,000.00 0.14 562,000.00 100.00

Provision for bad debts on a group basis 297,639,716.31 99.81 14,501,807.60 4.87 283,137,908.71 400,617,310.67 99.86 14,072,777.48 3.51 386,544,533.19 of which:

Provision for bad debts on a group basis 297,639,716.31 99.81 14,501,807.60 4.87 283,137,908.71 400,617,310.67 99.86 14,072,777.48 3.51 386,544,533.19

Total 298,201,716.31 / 15,063,807.60 / 283,137,908.71 401,179,310.67 / 14,634,777.48 / 386,544,533.19

Provision for bad debts is made individually:

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Reason for provision Individual provision 562,000.00 562,000.00 100.00 It is expected to be unrecoverable after independent testing

Total 562,000.00 562,000.00 100.00 /

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

158/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Provision for bad debts by group:

√Applicable □Not applicable

Group accrual items: Bad debt provisions are accrued on a group basis

Unit: Yuan Currency: RMB Closing Balance Name

Book balance Bad debt provision Provision ratio (%) Aging combination 272,058,040.72 15,063,807.60 5.54 Receivables combination within the scope of consolidated financial statements 25,581,675.59

Total 297,639,716.31 15,063,807.60 5.06 Instructions on the provision of bad debt provisions by group:

√Applicable □Not applicable

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

Not applicable

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(3) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

take back

Category Opening balance Write-off or verification Others Closing balance Provision or transfer

sales change

return

Individual provision for bad debts 562,000.00 562,000.00 Provision for bad debts on a group basis 14,072,777.48 454,763.72 25,733.60 14,501,807.60

Total 14,634,777.48 454,763.72 25,733.60 15,063,807.60 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

□Applicable √Not applicable

Other instructions

None

(4) Accounts receivable actually written off in the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Write-off amount Accounts receivable actually written off 25,733.60 Among them, the write-off of important accounts receivable

□Applicable √Not applicable

Instructions for writing off accounts receivable:

□Applicable √Not applicable

159/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(5) Accounts receivable and contract assets of the top five ending balances by debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB in accounts receivable

Accounts receivable and contract assets

Accounts receivable period Contract asset period Bad debt provision period Unit name Contract asset period Total ending balance

Ending Balance Ending Balance Ending Balance Ending Balance Count Ratio

(%)

Customer 1 24,893,931.89 24,893,931.89 8.35

Customer two 23,643,347.36 23,643,347.36 7.93 1,182,167.37 Customer three 13,745,225.55 13,745,225.55 4.61 687,261.28 Customer four 8,782,021.80 8,782,021.80 2.94 439,101.09Customer 5 5,615,498.71 5,615,498.71 1.88 280,774.94

Total 76,680,025.31 76,680,025.31 25.71 2,589,304.67Other instructions

None

Other notes:

□Applicable √Not applicable

Other receivables

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Other receivables 676,412,787.79 930,300,832.94

Total 676,412,787.79 930,300,832.94Other instructions:

□Applicable √Not applicable

interest receivable

(1) Classification of interest receivable

□Applicable √Not applicable

(2) Important overdue interest

□Applicable √Not applicable

(3) Classified disclosure based on bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

160/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(4) Provision for bad debts is made based on the general expected credit loss model □Applicable √Not applicable

(5) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(6) Interest receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of interest receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Dividends receivable

(7) Dividends receivable

□Applicable √Not applicable

(8) Important dividends receivable aged more than 1 year □ Applicable √ Not applicable

(9) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions on an individual basis: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

(10) Provision for bad debts based on the general expected credit loss model □Applicable √Not applicable

(11) Bad debt provisions

□Applicable √Not applicable

161/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other notes:

None

(12) Dividends receivable actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of dividends receivable

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other receivables

(13) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 386,107,508.84 712,340,129.10 Within 1 year 386,107,508.84 712,340,129.10 1 to 2 years 263,453,083.99 218,070,353.21 2 to 3 years 25,540,319.13 13,141,717.16 More than 3 years 13,837,186.93 1,819,414.50

Total 688,938,098.89 945,371,613.97

(14) Classification by nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Current accounts within the scope of the consolidated financial statements 670,548,736.69 902,819,550.18 Value-added tax refund receivable 5,008,302.63

Long-term asset disposal receivables 29,780,588.20 Temporary payments receivable 10,160,104.00 10,251,480.83 Deposits and guarantees 2,713,641.50 2,441,864.75 Others 507,314.07 78,130.01

Total 688,938,098.89 945,371,613.97

(15) Bad debt provision accrual

√Applicable □Not applicable

Unit: Yuan Currency: RMB Phase 1 Phase 2 Phase 3

Expected total bad debt provisions for the next 12 months Expected for the entire duration Expected for the entire duration

period credit losses

Credit losses (unissued credit losses (already

162/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Credit impairment occurs) Credit impairment occurs)

Balance on January 1, 2026 10,094.87 3,015,013.35 12,045,672.81 15,070,781.03 Balance on January 1, 2026 in the current period

--Transfer to the second stage -850.76 850.76

--Transfer to the third stage -54,031.91 54,031.91 --Transfer to the second stage

--Return to the first stage

Provision in this period 15,082.81 -2,960,130.68 399,577.95 -2,545,469.93 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance as of June 30, 2026 24,326.92 1,701.51 12,499,282.67 12,525,311.10 Basis for division of each stage and provision ratio for bad debts

For details, please refer to Section 8 of this report 5. Important Accounting Policies and Accounting Estimates 11. Financial Instruments.

Explanation of significant changes in the book balance of other receivables that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

The amount of bad debt provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly: □ Applicable √ Not applicable

(16) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or other Ending balance accrual

Reversal, write-off, change in individual provision for bad debts 10,960,104.00 10,960,104.00 Provision for bad debts on a group basis

4,110,677.03 -2,545,469.93 1,565,207.10

Total 15,070,781.03 -2,545,469.93 12,525,311.10 Among them, the amount of bad debt provision reversed or recovered in the current period is important:

□Applicable √Not applicable

Other instructions

None

(17) Other receivables actually written off in the current period

□Applicable √Not applicable

Important write-offs of other receivables:

□Applicable √Not applicable

Instructions for writing off other receivables:

□Applicable √Not applicable

(18) Other receivables with top five closing balances based on debtors

√Applicable □Not applicable

163/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Unit: Yuan Currency: RMB Bad debts account for other receivables period

Name of preparation unit Closing balance Nature of payment in total closing balance Aging period closing balance ratio (%)

uh NEWBEGINNINGS

Consolidated financial statement scope Within 1 year, (SINGAPORE) PTE 225,466,583.71 32.73

Current funds within the scope 1-2 years LTD

NEWBEGINNINGS Consolidated Financial Statements

153,278,320.00 22.25 INVESTMENT within 1 year

Zhejiang Zhende Health Technology Consolidated financial statement scope Within 1 year,

89,542,686.68 13.00

Limited liability company Current accounts within the scope 1-2 years Huainan Mattel Medical Supplies Consolidated financial statements scope Within 1 year,

66,711,053.52 9.68

Co., Ltd. Current accounts within the scope 1-2 years Zhejiang Stange Sports Medicine Consolidated financial statements scope Within 1 year,

50,500,000.00 7.33

Medical Technology Co., Ltd. Internal current funds 1-2 years

Total 585,498,643.91 84.99 / /

(19) Presented in other receivables due to centralized management of funds

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

164/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Long-term equity investment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Beginning balance items

Book balance Impairment provision Book value Book balance Impairment provision Book value Investment in subsidiaries 1,658,019,061.54 1,658,019,061.54 1,621,119,061.54 1,621,119,061.54 Investment in associates and joint ventures 117,676,001.90 117,676,001.90 118,455,594.32 118,455,594.32

Total 1,775,695,063.44 1,775,695,063.44 1,739,574,655.86 1,739,574,655.86

(1) Investment in subsidiaries

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB Increase or decrease in the current period

Balance at the beginning of the period (account) Impairment provision period Ending balance (book price Impairment provision at the end of the period Invested unit Additional investment Decrease investment Provision for impairment Others

face value) initial balance value) balance

prepare him

Xuchang Zhende Medical Dressing Co., Ltd. 32,967.16 32,967.16 Xuchang Zhengde Medical Supplies Co., Ltd. 18,165.08 18,165.08 Henan Zhende Medical Supplies Co., Ltd. 3,063.02 3,063.02 Shaoxing Tuomei Medical Supplies Co., Ltd. 2,059.23 2,059.23 Anhui Medis Medical Supplies Co., Ltd. 10,401.84 10,401.84 Shaoxing Haoshide Medical Products Co., Ltd. 20.41 20.41 Shanghai Liande Medical Biomaterials Co., Ltd. 677.28 677.28 Hangzhou Pujian Medical Devices Co., Ltd. 2,175.25 2,175.25 Hangzhou Lingtu Technology Co., Ltd. 450.00 450.00 Shaoxing Zhende Medical Products Co., Ltd. 1,499.89 1,499.89 Suzhou Medis Medical Sports Products Co., Ltd. 16,115.88 16,115.88 Hong Kong New Starting Point Investment Co., Ltd. 4,255.93 4,255.93 Zhende Medical Products (Hong Kong) Co., Ltd. 100.00 100.00 Zhejiang Stange Sports Medical Technology Co., Ltd. 7,500.00 7,500.00 Hangzhou Xindong Network Technology Co., Ltd. 225.25 225.25

165/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Zhejiang Zhende Health Technology Co., Ltd. 1,115.69 1,115.69 Anhui Lanxin Medical Technology Co., Ltd. 2,520.00 2,520.00 Shaoxing Zhende Medical Technology Co., Ltd. 250.00 250.00 Huainan Mattel Medical Supplies Co., Ltd. 2,000.00 2,000.00 Yanling County Mattel Medical Supplies Co., Ltd. 1,000.00 1,000.00 Jiangsu Inbest Technology Development Co., Ltd. 24,330.00 24,330.00 Ningbo Shengyurui Medical Equipment Co., Ltd. 29,720.00 3,690.00 33,410.00 Ningbo Anmu Medical Technology Co., Ltd. 1,500.00 1,500.00

Total 162,111.91 3,690.00 165,801.91

(2) Investment in associates and joint ventures

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in the current period

Beginning of the period Impairment quasi-investment declared Impairment quasi-investment recognized under the equity method Other comprehensive Other provisions Closing balance (book value)

Balance (book value at the beginning of the provision period, additional reduction, cash release, investment loss and combined income, equity, impairment, value) recognized by the unit at the end of the provision period, value) balance investment investment dividend or other balance profit adjustment change provision

profit

1. Joint ventures

2. Joint ventures

Hunan Sijetek Medical Department

17,961,309.36 -293,124.55 17,668,184.81 Technology Co., Ltd.

Hangzhou Public Health Intellectual Property Service

48,374.85 1,455.99 49,830.84 Service Center Co., Ltd.

Shaoxing Guochuang Zhende Medical Products

Phase I Equity Investment Partnership 100,445,910.11 -487,923.86 99,957,986.25 Enterprise (Limited Partnership)

Total 118,455,594.32 -779,592.42 117,676,001.90

166/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

(3) Impairment testing of long-term equity investments

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Operating income and operating costs

(1) Operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount for the current period Amount for the previous period

Project

Revenue Cost Revenue Cost Main business 911,591,622.78 647,373,859.50 899,006,360.26 663,252,201.03 Other business 19,881,159.26 17,219,167.94 4,501,091.05 5,596,125.28

Total 931,472,782.04 664,593,027.44 903,507,451.31 668,848,326.31

(2) Breakdown information of operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Medical Supplies Total

Contract classification

Operating income Operating cost Operating income Operating cost Product type

Basic nursing 254,900,442.79 201,264,637.70 254,900,442.79 201,264,637.70 Surgical infection control 307,746,878.20 216,338,002.69 307,746,878.20 216,338,002.69 Pressure treatment and fixation 79,148,864.84 46,169,044.06 79,148,864.84 46,169,044.06 Ostomy and modern wounds

154,254,312.20 76,480,241.77 154,254,312.20 76,480,241.77Nursing

Infection control and protection 115,541,124.75 107,121,933.28 115,541,124.75 107,121,933.28 Others 19,881,159.26 17,219,167.94 19,881,159.26 17,219,167.94Classified by operating area

Domestic 784,718,958.93 553,388,063.59 784,718,958.93 553,388,063.59 Overseas 146,753,823.11 111,204,963.85 146,753,823.11 111,204,963.85

Total 931,472,782.04 664,593,027.44 931,472,782.04 664,593,027.44Other instructions

√Applicable □Not applicable

The income recognized in the current period and included in the opening book value of contract liabilities was RMB 9,488,720.77.

(3) Description of performance obligations

□Applicable √Not applicable

(4) Description of allocation to remaining performance obligations

□Applicable √Not applicable

(5) Major contract changes or major transaction price adjustments

□Applicable √Not applicable

Other notes:

167/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

None

Investment income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Long-term equity investment income calculated by cost method 30,800,000.00 10,000,000.00 Long-term equity investment income calculated by equity method -779,592.42 -1,542,790.73 Investment income generated from the disposal of derivative financial assets 185,000.00

Interest income collected corresponding to return receivables 1,396,226.42

Investment income from the disposal of trading financial assets 2,994,550.10 1,076,119.51 Investment income from the disposal of other non-current financial assets 14,960,610.41

Total 49,556,794.51 9,533,328.78Other instructions:

None

Others

□Applicable √Not applicable

20. Supplementary information

Detailed statement of non-recurring profits and losses for the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Amount

Profit and loss from the disposal of non-current assets, including the write-off of asset impairment provisions 6,477,666.99 Government subsidies included in the current profit and loss, but closely related to the company’s normal operating business and in compliance with the national

Except for government subsidies 4,085,969.96 that are stipulated by policies, enjoyed according to determined standards, and have a lasting impact on the company's profits and losses.

In addition to effective hedging business related to the company's normal business operations, non-financial enterprises hold financial

Gains and losses from changes in fair value of financial assets and financial liabilities and gains and losses from the disposal of financial assets and financial liabilities 18,058,940.86

Fund occupation fees charged to non-financial enterprises included in current profits and losses 1,396,226.42 Gains and losses from entrusting others to invest or manage assets

Profit and loss from external entrusted loans

Loss of various assets due to force majeure factors, such as natural disasters

Reversal of impairment provision for accounts receivable that has been individually tested for impairment

The investment cost of the enterprise in acquiring subsidiaries, associates and joint ventures is less than the entitlement to the investment when acquiring the investment.

Income generated from the fair value of the investee’s identifiable net assets

Net profit and loss for the current period from the beginning of the period to the date of merger of subsidiaries resulting from business combinations under common control

Gains and losses on non-monetary asset exchanges

Debt restructuring gains and losses

One-time expenses incurred by the enterprise because the relevant business activities are no longer sustainable, such as expenses for relocating employees

Wait

One-time impact on current profits and losses due to adjustments to tax, accounting and other laws and regulations

One-time confirmation of share-based payment expenses due to cancellation or modification of equity incentive plan

For cash-settled share-based payment, the fair value of employee compensation payable after the vesting date

Profit and loss arising from changes

168/169

Zhende Medical Products Co., Ltd. 2026 Semi-Annual Report

Say the item amount

Loss arising from changes in the fair value of investment properties that are subsequently measured using the fair value model.

benefit

Gains from transactions where the transaction price appears to be unfair

Profit and loss arising from contingencies unrelated to the company's normal business operations

Custody fee income from entrusted operations

Other non-operating income and expenses other than the above items -2,499,482.66 Other profit and loss items that meet the definition of non-recurring gains and losses

Less: Impact on income tax 2,781,372.29 Impact on minority shareholders’ equity (after tax) 9,707.25

Total 24,728,242.03 For companies that identify items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and are significant in amount, and define the non-recurring gain and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Return on net assets and earnings per share

√Applicable □Not applicable

Earnings per share weighted average return on equity

Profit for the reporting period Basic per share Diluted per share (%)

Income Income Net profit attributable to the company’s ordinary shareholders

2.51 0.54 0.54 belongs to the company’s ordinary shares after deducting non-recurring gains and losses.

2.08 0.45 0.45Shareholders’ net profit

Differences in accounting data under domestic and foreign accounting standards

□Applicable √Not applicable

Others

□Applicable √Not applicable

Legal representative: Lu Jianguo

Board approval submission date: August 27, 2026

Revision information

□Applicable √Not applicable

169/169

Semi-annual Report for 2026

2. All directors of the company shall attend the board meeting.

3. This semi-annual report has not been audited.

6. Risk Statement for Forward-Looking Statements

7. Whether there is any non-operating use of funds by controlling shareholders and other related parties

8. Whether there is any violation of the prescribed decision-making procedures in providing external guarantees

10. Major Risk Warning

11. Others

Section 1 Interpretation......................................................................................................................................................4

Section 2 Company Profile and Main Financial Indicators......................................................................................................4

Section 3 Management Discussion and Analysis................................................................................................................7

Section 4 Corporate Governance, Environment and Society......................................................................................................31

Section 5 Important Matters......................................................................................................................................33

Section 6 Changes in Shares and Status of Shareholders................................................................................................45

Section 7 Bond-related situations......................................................................................................................49

Section 8 Financial Report......................................................................................................................................50

1. Company information

2. Contact person and contact information

3. Introduction to changes in basic situation

4. Brief introduction to changes in information disclosure and storage location

5. Brief introduction of company stocks

6. Other relevant information

7. The company’s main accounting data and financial indicators

8. Differences in accounting data under domestic and foreign accounting standards

9. Non-recurring profit and loss items and amounts

11. Others

1. Description of the company’s industry and main business during the reporting period

2. Discussion and analysis of operating conditions

3. Analysis of core competitiveness during the reporting period

4. Main operating conditions during the reporting period

5. Other disclosure matters

1. Changes in directors and senior managers of the company

2. Profit distribution or capital reserve conversion plan

3. The situation and impact of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

1. Fulfillment of commitments

2. Non-operating capital occupation by controlling shareholders and other related parties during the reporting period

3. Illegal guarantee situation

4. Audit status of semi-annual report

5. Changes and handling of matters involved in non-standard audit opinions in last year’s annual report

6. Matters related to bankruptcy and reorganization

7. Major litigation and arbitration matters

9. Explanation of the integrity status of the company, its controlling shareholders and actual controllers during the reporting period

10. Major related transactions

12. Instructions on the use of raised funds

13. Description of other major matters

1. Changes in share capital

1. Shares with sales restrictions

2. Shareholder situation

3. Directors and senior managers

5. Relevant information on preference shares

2. Convertible corporate bonds

1. Audit report

2. Financial statements

8. Earnings per share:

5. Net amount of other comprehensive income after tax

7. Earnings per share:

1. Cash flow generated from operating activities:

2. Cash flow generated from investing activities:

3. Cash flow generated from financing activities:

4. The impact of exchange rate changes on cash and cash equivalents

1. Cash flow generated from operating activities:

2. Cash flow generated from investing activities:

3. Cash flow generated from financing activities:

1. Previous year period

2. Current year

3. Added in this issue

4. This issue

1. Previous year period

2. Current year

3. Added in this issue

4. This issue

3. Increase or decrease of change funds in this period

3. Increases and decreases in this period

3. Basic situation of the company

4. Basis for preparation of financial statements

5. Important accounting policies and accounting estimates

6. Taxes

7. Notes on Consolidated Financial Statement Items

1. Joint ventures

2. Joint ventures